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ABSTRACT 
Previous studies in our lab have reported that CB1 and CB2 cannabinoid receptors are 
expressed by islet -cells where they regulate insulin secretion. A novel cannabinoid receptor, 
GPR55, is also activated by cannabinoids, but its physiological role in islets of Langerhans has 
not been established: this was investigated in this thesis, which described the expression and 
function of this novel receptor in islets. 
Initial studies of this PhD project demonstrated that GPR55 is expressed at both mRNA and 
protein levels in isolated mouse and human islets. Pharmacological activation of GPR55 using 
either a pharmacological agonist (O-1602) or the putative endogenous agonist 




]i) in Fura-2-loaded 
mouse and human islet cells. In addition, both agonists also stimulated insulin secretion from 
perifused mouse and human islets at a sub-stimulatory glucose concentration (2mM) and 
potentiated glucose-stimulated insulin secretion. The stimulatory effects of O-1602 were 
abolished in islets isolated from GPR55 knockout mice, while the LPI-induced effects on 
[Ca
2+
]i and insulin secretion were maintained following GPR55 deletion. 
The second phase of this PhD project demonstrated that cannabidiol (CBD), which competes 
with agonists at GPR55 receptors and is commonly used as a GPR55 antagonist, unexpectedly 
increased [Ca
2+
]i in mouse islet cells. Stimulatory effects in response to CBD were also 
observed in perifusion experiments using isolated mouse and human islets, with observations 
of both initiation of insulin secretion at 2mM glucose and potentiation of glucose-stimulated 
insulin secretion. The effects of CBD on insulin secretion were also observed in experiments 
using islets isolated from GPR55 knockout mice.   
The effects of pharmacological regulation of GPR55 on islet apoptosis were also investigated. 
Exposure of mouse islets to O-1602 and LPI reduced basal apoptosis and these agents also 
promoted islet survival in the presence of cytokines, and the GPR55 ‘antagonist’ CBD also 
reduced apoptosis in the absence and presence of cytokines. In addition, islets from GPR55 
knockout mice showed elevations in basal and cytokine-induced apoptosis compared to 
wildtype mouse islets. 
In conclusion, the studies carried out during this PhD project indicate that GPR55 is expressed 
by islets and its activation stimulates increases in intracellular Ca
2+
 and insulin secretion, and 
promotes islet survival. Studies using islets isolated from GPR55 knockout mice have shown 
that the effect of O-1602 is dependent on the presence of GPR55, but LPI and CBD exert 
GPR55-independent effects in islets. These results suggest that GPR55 plays an important role 
in the regulation of islet physiology, and that it may contribute to the peripheral regulation of 
energy balance and glucose homeostasis by cannabinoids. 
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CHAPTER 1 INTRODUCTION 
1.1 Islets of Langerhans 
The pancreas is an important mammalian organ located in the posterior abdominal wall. It is 
structurally and functionally divided into two parts, the exocrine and the endocrine pancreas. 
The exocrine pancreas forms the main part of the pancreas and consists of clusters of cells 
known as acini, which are responsible for secreting digestive enzymes such as amylase, trypsin, 
and chymotrypsin into the gut. The endocrine pancreas is scattered throughout the exocrine 
tissues in the form of aggregates of endocrine cells known as islets of Langerhans, named after 
the German anatomist Paul Langerhans who discovered them . Islets make up 1-2% of the 
pancreatic mass and are responsible for regulating plasma glucose concentrations. 
 
Each islet contains four main types of cells and they are classified according to their function: 
the α-cells secrete glucagon, a hormone involved in carbohydrate metabolism; the β-cells 
secrete insulin that plays a vital role in regulating glucose homeostasis by decreasing plasma 
glucose levels; the δ-cells secrete somatostatin to regulate α- and β-cells; and the γ-cells 
produce pancreatic polypeptide that is suggested to regulate food intake and gastric emptying 
(Katsuura et al., 2002). Another cell type, the ε-cell, has also been identified in islets and is 
found to secrete ghrelin (Wierup et al., 2002) and amylin (Kruger et al., 2007). However, the 
exact functions of these islet-derived hormones are still uncertain. Islets are highly 
vascularised and receive 10 times the amount of blood than cells in the exocrine tissues in 
order to allow for greater nutrient and hormone exchange (Jansson and Hellerstrom, 1983). In 
addition, it is reported that there is interspecies variability in cell composition and islet 
structure (Wieczorek et al., 1998). Thus, it has been shown that rodent islets are comprised of 
approximately 77% β-cells and 18% α-cells (Orci and Unger, 1975), while human islets 
contain fewer β-cells (55%) and more α-cells (38%) (Cabrera et al., 2006). δ-cells and γ-cells 
constitute minority cell types in islets from all species, making up 8-10% and 3-5% of the islet 
mass, respectively, in rodents and human (Cabrera et al., 2006). Furthermore, cells in mouse 
Chapter 1 Introduction 
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islets are clearly segregated as β-cells clustered at the core surrounded by a ring of α- and δ-
cells. In contrast, different cell types are found integrated together in human and monkey islets 
(Figure 1.1.1) (Cabrera et al., 2006). The variability in islet topography allows unique cell-to-
cell interactions, for example via gap junctions or paracrine signalling, resulting in different 
islet functions. For example, oscillations in membrane potential are coordinated in rodent β-
cells because they are clustered, while they are not synchronised in human β-cells since they 
are segregated. This may explain some of the differences in changes in intracellular calcium 
levels and insulin secretory profiles between rodent and human islets (Cabrera et al., 2006). 
These species differences in islet cell composition and topography may reflect evolutionary 
adaptation to different dietary habits or other environmental factors.  
 
Chapter 1 Introduction 




Figure 1.1.1 Interspecies variability in cell composition and islet structure.  
Islets from four sources (human, A; monkey, B; mouse, C; pig, D) were analysed using 
confocal microscopy and multiple immunofluorescent labelling. Insulin- (red), glucagon- 
(green) and somatostatin-expressing cells (blue) are seen in all islets, with insulin-containing 
cells being the most abundant. In mouse islets, insulin-containing cells are seen clustered at the 
core, with few glucagon- and somatostatin-expressing cells surrounding them. In contrast, 
insulin-, glucagon- and somatostatin-expressing cells distribute throughout the human and 
monkey islets. Pig islets are made up of several smaller subunits that have similar architecture 
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1.1.1 Regulation of glucose storage by insulin 
Plasma glucose levels are closely regulated and maintained within a range of 3 to 5 mM in 
healthy individuals despite their ever-changing feeding and fasting patterns. This tight control 
is managed by the central nervous system (CNS) and peripheral tissues including liver, skeletal 
muscle, gastrointestinal tract, adipose tissue and endocrine pancreas. Elevated plasma glucose 
levels, neuronal signals from the parasympathetic nervous system, and non-nutrient 
secretagogues stimulate insulin release from islet β-cells. Insulin serves as the primary 
regulator of blood glucose in the body by increasing glucose uptake into muscle and adipose 
tissue, promoting glucose storage in muscle, liver and adipose tissues, and by inhibiting 
glucose production in the liver.  
 
Insulin exerts its action via heterotetrameric insulin receptors of the receptor tyrosine kinase 
family on insulin-sensitive tissues. Binding of insulin induces a conformational change in the 
extracellular α subunits of the insulin receptors leading to the activation of the intracellular β-
subunits by phosphorylation on multiple tyrosine residues. This allows recruitment and 
tyrosine phosphorylation of the insulin receptor substrates (IRS) (Schlessinger, 2000). There 
are four main members of the IRS protein family (Burks and White, 2001): IRS-1 and -2 are 
ubiquitously expressed (Sun et al., 1991; Sun et al., 1995), while IRS-3 is believed to be 
preferentially expressed in adipocytes (Lavan et al., 1997) and IRS-4 is primarily found in the 
CNS (Fantin et al., 1999). Tyrosine phosphorylated IRS proteins recruit downstream effectors, 
for example , IRS-1and IRS-2 becomes a docking site for the regulatory subunit p85 of class 
IA phosphatidylinositol 3-kinase (PI3K). the IRS-p85 complex then recruits and activates the 
catalytic subunit p110α of PI3K, which catalyses the conversion of phosphatidylinositol-4,5-
bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3) in the plasma membrane. 
Increased PIP3 levels leads to the accumulation of signalling proteins containing pleckstrin 
homology (PH) domain at the cell surface (Cantley, 2002). Association with PIP3 activates 
phosphoinositide-dependent kinase 1 (PDK1) to phosphorylate the serine-threonine kinase 
Chapter 1 Introduction 
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Akt/PKB, another signalling protein recruited via its PH domain. Together with 
phosphorylation by transducer of regulated CREB activity 2 (TORC2), PDK1 stimulates the 
catalytic activity of Akt/PKB, which phosphorylates a wide range of downstream proteins, 
such as Akt substrate 160 (ASK160), glycogen synthase kinase 3 (GSK3) and mammalian 
target of rapamycin complex 1 (mTORC1), leading to the cellular responses to insulin 
(Manning and Cantley, 2007). 
 
Glucose uptake 
One of the main insulin-mediated cellular responses is the stimulation of GLUT4 translocation 
to the cell surface of adipose and muscle cells for glucose uptake. Adipose and muscle cell-
specific glucose transporter GLUT4 is one of the 13 glucose transporter proteins encoded in 
the human genome. It catalyses transport of hexoses across the cell membrane in an energy-
independent manner (Huang and Czech, 2007). Akt/PKB-induced AS160 phosphorylation 
directly regulates the translocation of GLUT4 from the cytoplasm to the plasma membrane 
where it facilitates the entry of extracellular glucose to reduce plasma glucose concentrations 
(Leney and Tavare, 2009).  
 
Glucose storage 
In addition to promoting glucose uptake, insulin stimulates glycogen accumulation via 
Akt/PKB-induced GSK3 inhibition and consequent glycogen synthase activation in muscle 
and liver (Cohen and Frame, 2001). Insulin also profoundly inhibits the production and release 
of glucose in the liver by blocking gluconeogenesis and glycogenolysis via regulating the 
activities of a set of metabolic enzymes, such as phosphoenolpyruvate carboxykinase, glucose-
6-phosphatase and glycogen phosphorylase, by transcriptional and nontranscriptional 
mechanisms (Barthel and Schmoll, 2003; Hartmann et al., 1987). In adipocytes, insulin 
promotes glucose storage in the form of triacylglycerol by increasing activation of lipid 
Chapter 1 Introduction 
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synthetic enzymes. Furthermore, insulin inhibits lipolysis, primarily through inactivation of the 
insulin-sensitive lipases (Saltiel and Kahn, 2001).  
 
1.1.2 Regulation of insulin secretion 
In order to maintain constant blood glucose levels, islet β-cells need to secrete the appropriate 
amount of insulin in response to nutrient and non-nutrient stimulations. Indeed, β-cells are 
well-equipped with different tools to sense the external factors and to tune their insulin 
secretion levels. Healthy and functional β-cells are essential for the secretion of this hormone 
to ensure the precise regulation of glucose homeostasis. 
 
This insulin gene in the β-cells encodes for a 110-amino acid precursor molecule known as 
preproinsulin. This polypeptide is translocated across the rough endoplasmic reticulum (ER) 
membrane into the lumen, where it is post-translationally modified to yield proinsulin. 
Proinsulin consists of the A and B chains of insulin (21 and 30 amino acid residues, 
respectively) joined by a 31-amino acid C-peptide, which blocks the active site of proinsulin 
whose biological activity is only about 5% of insulin. Aided by ER chaperone proteins, 
proinsulin undergoes folding and formation of two disulphide bonds between A and B chains 
of insulin and one intra-chain bond of A chain for a matured three dimensional conformation. 
The folded proinsulin is transported from the ER to the Golgi apparatus, where proinsulin 
enters immature secretory vesicles. The conversion from proinsulin to insulin by proteolytic 
cleavage of C-peptide is initiated by a decrease in pH from the trans-Golgi network to the 
secretory vesicles (Davidson et al., 1988). C-peptide is removed via the Ca
2+
-dependent actions 
of endopeptidases, prohormone convertases 2 and 3, and carboxypeptidase H (Hutton, 1994). 
Insulin and C-peptide are then stored in these vesicles, where insulin is bound to Zn
2+
 to form 
stable crystalline insulin hexamers (Howell et al., 1969). Other β-cell secretory products, such 
as islet amyloid polypeptide (Nishi et al., 1990), are stored together and released 
simultaneously with insulin during exocytosis in response to stimulation.  
Chapter 1 Introduction 
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1.1.2.1 Glucose-induced insulin secretion 
β-cells respond to many nutrients, but the primarily respond to glucose in the blood due to their 
highly responsive coupling mechanisms. Oral intake of 75g of glucose by human subjects 
initiates an increase in plasma insulin concentration from 20-30 pM to 250-300 pM in 30 
minutes (Chang and Goldberg, 1978). Islet β-cells do not have membrane-bound glucose 
receptors, but are equipped with insulin-independent glucose transporters to take up glucose 
(GLUT-2 in rodents; GLUT-1, 2 and 3 in humans) (De Vos et al., 1995; Richardson et al., 
2007). Upon entering β-cells, glucose triggers a series of metabolic events to induce insulin 
secretion. In brief, glucose is phosphorylated by the rate-limiting enzyme glucokinase and 
phosphorylated glucose undergoes glycolysis to produce the end product pyruvate, which is 
fed into the tricarboxylic acid (TCA) cycle in mitochondria. The resulting increase in the 
cytosolic ATP/ADP ratio leads to the closure of ATP-sensitive K
+
 channels (KATP-channels) by 
binding to the Kir6.2 subunits. This results in decreased K
+
 efflux and plasma membrane 
depolarisation, followed by the opening of voltage-gated Ca
2+
 channels (VGCCs). An influx of 
Ca
2+
 activates exocytosis of secretion-ready insulin-containing vesicles (readily releasable pool, 
RRP) docked in close proximity to the VGCCs. Exocytosis in β-cells takes place in a similar 
mechanism to the soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
(SNARE)-regulated synaptic vesicle release. The fusion process between the insulin vesicles 
and the plasma membrane requires the assembly of SNARE protein complex including the 
plasma membrane proteins syntaxin and synaptosomal-associated protein of 25kDa (SNAP-
25), and vesicle-associated membrane protein 2 (VAMP-2) on the vesicle membrane (Rorsman 
and Renstrom, 2003). This allows the insulin vesicles to dock to the Ca
2+
-channels and fuse 
membranes after localised elevation in [Ca
2+
]i. Synaptotagmin proteins V or VII of the SNARE 
complex are responsible for sensing Ca
2+
 (Gut et al., 2001). A small GTP-binding protein 
Rab3A and its interaction partner Rab3-interacting molecule (Rim) on the insulin vesicles 
helps the SNARE complex to associate with synaptotagmin, as well as the Ca
2+
 channels 
(Rorsman and Renstrom, 2003). In addition, a study has shown that calpain-10, a Ca
2+
-
Chapter 1 Introduction 
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dependent protease, binds to the SNARE complex and triggers SNAP-25 proteolysis, a process 
which leads to exocytosis in β-cells (Marshall et al., 2005). The cellular signalling pathway for 
insulin secretion summarised above is conventionally known as the KATP channel-dependent 
pathway (Figure 1.1.2). It has also been reported that a subset of hypothalamic neurons use the 
same mechanisms as β-cells to sense and response to change in extracellular glucose 
concentrations (Squires et al., 2005).  
 
 
Figure 1.1.2 Schematic representation of the KATP channel-dependent pathway of 
glucose-induced insulin secretion. 
Glucose is taken up by β-cells via GLUT2 transporters and phosphorylated by glucokinase 
after entering the cell. Phosphorylated glucose is then processed through glycolysis to pyruvate, 
which is converted to ATP via the tricarboxylic acid (TCA) cycle in mitochondria. The 
elevated ATP/ADP ratio results in the closing of KATP channels via binding to their Kir6.2 
subunits. This leads to decreased K
+
 efflux, membrane depolarisation (Ψ) and the opening of 
voltage-gated Ca
2+
 channels (VGCCs). Influx of Ca
2+





 molecules interact with Ca
2+
 sensing proteins within SNARE complexes 
(synaptotagmins and calpain-10, not shown), which facilitates the fusion process between the 
plasma membrane and insulin containing vesicles. 
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Insulin secretion in response to elevated glucose exhibits a characteristic biphasic pattern that 
consists of a rapid but transient insulin release (first phase), that is followed by a sustained 
output (second phase). Experiments to date suggest that insulin vesicles exist in distinct 
functional pools and orderly release of these pools results in the observed biphasic insulin 
secretory profile. It is believed that the first phase involves rapid release of a small number of 
docked vesicles in the RRP (1-5% of all vesicles) straight after stimulation. When the RRP is 
depleted, vesicles from the reserve pool (95-99%) mobilise to the RRP, but they have to 
undergo a series of ATP-, Ca
2+
, time- and temperature-dependent reactions known as priming 
(Rorsman and Renstrom, 2003). This subsequent supply of new vesicles for release is 
responsible for the sustained second phase of insulin secretion. In addition to the KATP-
dependent pathway, various cellular signalling pathways involving different second 
messengers and their coupling enzymes have also been implicated in the biphasic nature of 
insulin secretion.  
 
In addition to nutrients, islet β-cells are also subject to regulation by hormones, which are 
delivered to the cells via the circulation or released by adjacent cells within the islets, resulting 
in a paracrine modulation of insulin secretion. Thus, islet hormones such as glucagon and 
somatostatin can regulate insulin output from β-cells, with stimulatory and inhibitory effects, 
respectively, and insulin secretion may also be modified by neurotransmitters and 
gastrointestinal incretins (Jones and Persaud, 2010). Many of these agents regulate insulin 
secretion through the signalling cascades described below following interaction with their 
target receptors on β-cells. 
 
1.1.2.1.1 Role of CaMKs in the regulation of insulin secretion 
In addition to the SNARE complex, β-cells express a variety of Ca2+-sensitive enzymes that 
may be involved in sensing and responding to changes in [Ca
2+
]i. It is well-established that 
Ca
2+
/calmodulin-dependent protein kinases (CaMKs) are activated in the presence of Ca
2+
 and 
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-binding protein calmodulin (CaM). CaM detects increases in [Ca
2+
]i and binds to free 
Ca
2+
 to form Ca
2+
/CaM complexes, which mediate downstream Ca
2+
-initiated responses by 
regulating the functions of CaMKs. CaMKs modulate their downstream effects by 
phosphorylating endogenous substrates on serine/threonine residues. A number of subtypes of 
CaMKs are expressed by β-cells: myosin light chain kinase (MLCK) and multifunctional 
CaMK II, III and IV (Ban et al., 2000; Jones and Persaud, 1998). Most investigations of 
CaMKs in β-cells have focused on CaMK II and data from a number of groups suggests that 
CaMK II is involved in glucose-induced insulin secretion (Figure 1.1.3) (Jones and Persaud, 
1998). Identified substrates of CaMK II in β-cells include synapsin-1 and microtubule-
associated protein-2 (MAP-2) (Easom, 1999), which are involved in vesicle trafficking and 
docking, and ryanodine receptor 2 (RyR2) (Okamoto and Takasawa, 2002), which is important 
to maintain sustained Ca
2+
 oscillations via Ca
2+
 release from the ER. 
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Figure 1.1.3 Schematic representation of CaMK signalling in insulin secretion. 
The KATP channel-dependent pathway in β-cells leads to elevations in [Ca
2+
]i which activates 
Ca
2+
/calmodulin-dependent protein kinases (CaMKs) via binding to calmodulin (CaM). 
CaMKs, such as CaMK II, phosphorylate ryanodine receptor 2 (RyR2) resulting in sustained 
Ca
2+
 release from the ER. CaMK II further phosphorylates synapsin-1 and microtubule-




1.1.2.1.2 Role of the PLC/PKC pathways in the regulation of insulin secretion 
Glucose also activates Ca
2+
-dependent phospholipase C (PLC) in β-cells (Biden et al., 1987). 
PLC breaks down membrane-bound phosphatidylinositol-4,5-bisphosphate (PIP2) into 
cytosolic inositol 1,4,5-trisphosphate (IP3) and membrane-bound diacylglycerol (DAG). 
Increased intracellular IP3 activates IP3 receptors located on the ER to allow Ca
2+
 release which 
has been implicated in contributing to glucose-induced [Ca
2+
]i elevation and both phases of 
insulin release (Dufer et al., 2007; Wiederkehr and Wollheim, 2008). On the other hand, DAG 
recruits and activates of protein kinase C (PKC), which is a serine-theronine family of 
enzymes that has three main classes: the conventional PKCs, which include isoforms α, β and 
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γ, are activated by Ca2+ and DAG; the novel PKCs, consisting of isoforms δ, ε, η and θ, are 
regulated by DAG but not Ca
2+
; and the atypical PKCs, isoforms ζ, ι and μ, are considered to 
be Ca
2+
- and DAG-independent (Idris et al., 2001). It has been shown that glucose is able to 
induce PKC translocation to the plasma membrane of β-cells (Persaud et al., 1989). The 
secretory response to glucose can also be enhanced by pharmacologically suppressing DAG 
breakdown (Zawalich et al., 1989). Moreover, exposure of islets to glucose results in the 
activation of an established downstream substrate of PKC, the myristoylated alanine-rich C 
kinase substrate (MARCKS) (Calle et al., 1992). Various proteins important to the secretory 
response in β-cells have also been identified as substrates of activated PKC, including the 
sulphonylurea receptor-1 (SUR1) subunit of the KATP channel (Inagaki et al., 1995), VGCCs 
(Seino, 1995), cytosolic phospholipase A2 (Dunlop and Clark, 1995) and other G protein-
dependent signalling cascades (Persaud et al., 1993). On the other hand, it was found that PKC 
depletion from β-cells did not affect glucose-induced insulin secretion, suggesting that 
activated PKCs are not necessary for nutrient-induced insulin secretion. Importantly, the Ca
2+
- 
and DAG-dependent PKCs are essential mediators in ligand-induced insulin secretion through 
the activation of G protein-coupled receptors (GPCRs) and the Gq/PLC signalling pathway, 
such as the response to the cholinergic neurotransmitter acetylcholine (Ach) (Persaud et al., 
1993). Furthermore, in addition to its role of activating PKC, DAG is also a precursor of other 
intracellular messengers including arachidonic acid (AA) and the endocannabinoid 2-
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Figure 1.1.4 Schematic representation of PLC/PKC signalling in insulin secretion. 




-dependent phospholipase C (PLC), which 
breaks down phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) 
and diacylglycerol (DAG). IP3 diffuses through the cytoplasm and activates IP3 receptors (IP3R) 
on the ER to increase [Ca
2+
]i and insulin secretion. DAG activates Ca
2+
-dependent protein 
kinase C (PKC) isoforms, which phosphorylate and activate a set of substrates, such as the 
SUR1 subunit of KATP channel and VGCCs, to potentiate insulin secretion. A range of 
secretagogues such as acetylcholine potentiate glucose-induced insulin secretion via G protein-




1.1.2.1.3 Role of cAMP/PKA/Epacs pathways in the regulation of insulin secretion 
Cyclic AMP (cAMP) is a universal second messenger regulating a range of cellular responses 
including insulin vesicle exocytosis in β-cells. Adenylate cyclases (ACs) hydrolyse ATP into 
cAMP, which is degraded by cyclic nucleotide phosphodiesterases (PDEs). Eight of the nine 
known membrane-bound AC isoforms are expressed in islets and β-cell lines (Delmeire et al., 
2003; Landa et al., 2005; Leech et al., 1999). For cAMP degradation, 25 PDE genes have been 
identified that encode a superfamily of more than 50 different PDE proteins, with PDE1C, 
PDE3B, PDE4A, PDE4D, PDE8A and PDE10A being expressed by islets (Szaszak et al., 
2008). The activities of ACs and PDEs are regulated by numerous signalling pathways to 
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govern intracellular cAMP levels. It is well established that cAMP is not considered as an 
essential messenger mediating the insulinotropic effect of glucose, but it is believed that cAMP 
can modulate the action of glucose in β-cells (Malaisse and Malaisse-Lagae, 1984; Prentki and 
Matschinsky, 1987a). Thus, cAMP alone does not stimulate insulin secretion at low glucose 
(1-2.8mM) (Charles et al., 1973; Charles et al., 1975), although it does enhance both phases of 
glucose-induced insulin secretion (Takahashi et al., 2002; Wiedenkeller and Sharp, 1983). 
Studies using PDE inhibitors and manipulation of the PDE genes demonstrated that PDE plays 
a negative role in both phases of glucose-induced insulin secretion, confirming the importance 
of cAMP in β-cell functions (Han et al., 1999; Walz et al., 2007). It was also shown that cAMP 
increases the size of the RRP and promotes insulin vesicle mobilisation (Hisatomi et al., 1996; 
Renstrom et al., 1997).  
 
cAMP exerts its physiological effects via both protein kinase A (PKA)-dependent and PKA-
independent pathways. The PKA family, consisting of type I and II isoforms, are downstream 
effectors activated by cAMP. Once activated, PKA phosphorylates its substrates on serine/ 
threonine residues to trigger cellular effects with the help from a scaffolding protein, A-kinase 
anchor protein (AKAP). cAMP-dependent PKA activation has been shown to trigger an 
increase in the activities of L-type VGCCs by phosphorylating the ion channels (Ammala et al., 
1993; Yada et al., 1993) and PKA phosphorylation primes the ryanodine receptor Ca
2+
 
channels (RyR) on the ER membrane, so the channels are ready to be activated by Ca
2+
 influx 
(Islam, 2002). PKA therefore plays an important role in regulating and amplifying Ca
2+ 
signals 
during glucose-induced insulin secretion. 
 
In addition to PKA, cAMP can mediate its physiological effects through several other effector 
proteins, including cAMP receptor protein (CRP), cyclic nucleotide-gated (CNG) channels and 
cAMP-activated GTP-exchange factor (Epac) (Seino and Shibasaki, 2005). In β-cells, it was 
found that cAMP can stimulate exocytosis of insulin vesicles in the presence of PKA 
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inhibition, suggesting that cAMP regulates insulin secretion in a PKA-independent fashion 
(Renstrom et al., 1997). Subsequent experiments identified Epac1 and Epac2 expression in β-
cells and it was demonstrated that Epac1/2 interacts with the SUR1 subunit of KATP channels 
(Ozaki et al., 2000; Shibasaki et al., 2004). It was also shown that Epac2 mediates Ca
2+ 
mobilisation via activating RyRs independent of PKA (Kang et al., 2001; Kang et al., 2003). In 
addition, Epac2 can also regulate insulin vesicle exocytosis through interaction with two other 
proteins, Rim2 and Piccolo, and their absence results in impaired docking and fusion steps of 
insulin secretion. Rim2 is known to interact with Rab3, which is involved in the exocytosis 
process of RRP in β-cells, while Piccolo interacts with Rim2 in a Ca2+-dependent manner, 
acting as a Ca
2+
 sensor (Fujimoto et al., 2002; Kashima et al., 2001; Ozaki et al., 2000). Epac2, 
together with Rim2, Piccolo and Rab3, may form a complex that senses intracellular cAMP 
and Ca
2+
 levels. Although the exact role of cAMP and the Epac/Rim2/Piccolo complex in 
insulin vesicle exocytosis remains unclear, results published so far indicate that they play a 
significant role in regulating insulin secretory response to glucose. 
 
It has been suggested that the cAMP signalling system works together with the Ca
2+
 signalling 
cascade to regulate β-cell function. This was first proposed when Ca2+ influx after β-cell 
membrane depolarisation was reported to induce elevations in intracellular cAMP levels via 
Ca
2+
-regulated ACs (Charles et al., 1975). Several isoforms of ACs (type I, III and VIII) and 
PDEs (PDE1s) contain CaM-binding sites (Taussig et al., 1994; Yan et al., 1995), indicating 
that cAMP levels can be regulated in a Ca
2+
/CaM-dependent manner. This is further supported 
by studies in β-cell lines demonstrating that Ca2+ regulates cAMP production (Delmeire et al., 
2003; Landa et al., 2005; Leech et al., 1999; Walz et al., 2007). On the other hand, it was 
described previously that cAMP modulates VGCC activities and Ca
2+
 influx via PKA 
(Ammala et al., 1993; Yada et al., 1993). cAMP can further regulate [Ca
2+





 release via both PKA-dependent and PKA-independent 
mechanisms (Islam, 2002; Kang et al., 2001; Kang et al., 2003). Hence, it is likely that there is 
Chapter 1 Introduction 
Role of the novel cannabinoid receptor GPR55 in islets of Langerhans 20 
 
a dual cAMP and Ca
2+
 signalling pathway playing a significant role in regulating insulin 




Figure 1.1.5 Schematic representation of cAMP signalling in insulin secretion. 
Glucose uptake and metabolism lead to an increase in ATP, membrane depolarisation and 
opening of voltage-gated calcium channels (VGCCs) in β-cells. Adenylate cyclase (AC), 
which can be activated by G protein-coupled receptors (GPCRs) via Gs proteins, converts ATP 
into the second messenger cAMP in a Ca
2+
-dependent manner. Increases in cytosolic cAMP 
lead to activations of its downstream effectors, such as protein kinase A (PKA) and cAMP-
activated GTP-exchange factor (Epac). PKA, anchored via A-kinase anchor protein (AKAP, 
not shown) to its substrates, phosphorylates VGCCs and ryanodine receptor (RyR) on the ER 
membrane to increase [Ca
2+
]i. Epac (1 & 2) also interacts with RyR and the SUR1 subunit of 
KATP channels to modulate [Ca
2+
]i. In addition, Epac2 can facilitate docking and fusion steps of 
insulin vesicle exocytosis through interaction with two other proteins, Rim2 and Piccolo (not 
shown). Collectively, cAMP enhances glucose-induced insulin secretion via both PKA-
dependent and PKA-independent mechanisms.  
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1.1.2.2 Regulation of insulin secretion by GPCRs 
Glucose-induced insulin secretion from islet β-cells is modulated by other factors to optimise 
insulin secretion according to the metabolic demand. Many of these factors act through the 
largest class of cell surface receptors, the G-protein coupled receptor (GPCR) family, and 
nearly 300 members have been identified in islets (Amisten et al., 2013). Although functions 
of many of these GPCRs remain unknown in islet biology, the others are known to be 
regulated by a diverse range of extracellular signals including neurotransmitters, hormones and 
nutrient factors, such as lipids and peptides. Several of these GPCRs have been examined as 
potential therapeutic targets to stimulate insulin secretion to treat Type 2 diabetes mellitus, and 
drugs activating islet glucagon-like peptide-1 (GLP-1) receptor were successfully introduced 
for clinical use in 2005. 
 
GPCRs are membrane-bound proteins that have seven transmembrane domains connected by 
various intracellular and extracellular domains. Each GPCR is associated with a membrane-
bound heterotrimer protein complex known as GTP-binding proteins (G proteins). The G 
protein complex consists of α, β and γ subunits. In the inactive form, the receptor-associated α 
subunit binds to guanosine diphosphate (GDP) and forms a complex with βγ subunits. 
Activation of the GPCR results in a conformational change in the α subunit to release GDP in 
exchange for guanosine triphosphate (GTP). GTP binding leads to the release of the βγ 
complex and α and βγ complexes each regulate a variety of downstream signalling proteins. 
Each GPCR is associated with an α subunit from four main classes (Gs, Gi, Gq and G12/13) 
with a total of 20 subtypes. In addition, there have been five β subunits and 13 γ subunits 
identified to date, allowing various combinations of βγ complex. Research so far has focused 
on the regulatory role of α subunits in GPCR-mediated regulation of insulin secretion from β-
cells and it remains unclear what role βγ complexes play in islet biology. The effect of each α 
subunit subclass on insulin secretion is summarised below and illustrated in Figure 1.1.6. 
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Gs α subunit 
Activation of Gs subunits leads to AC activation and increases in cAMP, thereby potentiating 
glucose-induced insulin secretion through PKA and Epac (Figure 1.1.5). A wide range of 
GPCRs signal through the Gs-mediated signalling pathway to stimulate insulin secretion. 
These include GLP-1 receptor (GLP-1R) (Doyle and Egan, 2007), glucose-dependent 
insulinotropic peptide (GIP) receptor (Flatt, 2008), glucagon receptor (Jiang and Zhang, 2003), 
β2-adrenoceptor (McGraw and Liggett, 2005), lipid amide-activated GPR119 (Soga et al., 
2005) and many others (Amisten et al., 2013).   
 
Gi α subunit 
The Gi subunit acts opposite to the Gs subunit to negatively regulate intracellular cAMP levels 
via inhibition of ACs. Activation of Gi-coupled GPCRs, therefore, leads to inhibition of 
insulin secretion. Islet hormone ghrelin secreted by ε-cells inhibits insulin secretion in a 
paracrine manner via activating the Gi-coupled ghrelin receptor (Reimer et al., 2003). Other 
islet GPCRs associated with Gi subunits include melatonin receptor (Ramracheya et al., 2008) 
and neurotransmitter receptors, α2-adrenoceptors (Chan et al., 2001) and neuropeptide Y 
receptors (Morton and Schwartz, 2001).  
 
Gq α subunit 
The Gq subunit stimulates β class of PLC to generate IP3 and DAG from PIP2. As previously 
described in Figure 1.1.4, IP3 and DAG potentiate insulin secretion via triggering the release of 
Ca
2+
 from the ER and activating PKC, respectively. Muscarinic acetylcholine receptor subtype 
3 (Gautam et al., 2006), cholecystokinin A receptor (Berna et al., 2007), kisspeptin receptor 
GPR54 (Bowe et al., 2009), GPR40 activated by medium- to long-chain fatty acids (Itoh et al., 
2003) are all well-established Gq-coupled GPCRs in islets. 
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G12/13 α subunit 
In contrast to other G subunits, the G12/13 subunit is unusually linked to activation of the Rho 
small GTPase family, such as Cdc42, Rac and Rho, which are known to play a vital role in 
actin cytoskeleton dynamics. Cdc42 and Rac both stimulate insulin secretion from β-cells 
(Kowluru et al., 1997; Li et al., 2004; Nevins and Thurmond, 2005), while Rho and its effector 
Rho-associated kinase (ROCK) were suggested to inhibit insulin vesicle exocytosis (Hammar 
et al., 2009). It remains unclear how the G12/13 subunit may regulate insulin secretion and 
research to date has not identified any GPCRs that are coupled to G12/13 in β-cells. The 
function of this class of α subunit in islet biology remains to be explored.  
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Figure 1.1.6 Schematic representation of GPCR-stimulated pathways in insulin secretion. 
Extracellular factors, such as neurotransmitters, hormones and nutrient factors, potentiate or 
inhibit glucose-induced insulin secretion from β-cells via GPCRs. Each GPCR is specifically 
coupled to one of the α subunits to induce its downstream effects. Four main types of α 
subunits (Gs, Gi, Gq and G12/13) exist. The Gs subunit is coupled to activation of ACs and 
accumulation of cAMP within the cell, which in turn potentiates insulin secretion via PKA and 
Epac. The binding of agonists to Gi-coupled GPCR inhibits insulin secretion via inhibition of 
ACs. On the other hand, the Gq subunit is coupled to PLC/PKC pathway to stimulate insulin 
secretion. In addition, the role of G12/13 subunits in the regulation of insulin secretion remains 
unknown (not shown). 
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1.1.3 Regulation of β-cell mass 
The amount of insulin that can be secreted by β-cells is not only determined by their secretory 
capacity, but is also governed by β-cell mass. It is hypothesised that β-cell mass regulation is 
an important tool to maintain energy homeostasis via changes in insulin supply (Rhodes, 2005). 
For example, research in rodents has shown that during pregnancy the maternal β-cell 
population can dramatically increase to meet the extra metabolic demand (Parsons et al., 1992; 
Sorenson and Brelje, 1997). Although it is not possible to make the same observations in 
humans, it is thought that up-regulation of β-cell mass also occurs during pregnancy and it is 
highly adaptive to other changes in metabolic demand, such as obesity and insulin resistance in 
humans.  
 
There are three independent cellular mechanisms that are regarded to be responsible for 
maintaining β-cell mass: proliferation (replication of existing β-cells), neogenesis 
(transformation from precursor cells) and apoptosis (programmed cell death). Replication and 
neogenesis are mechanisms of β-cell expansion, while apoptosis is a mechanism of controlling 
β-cell populations through programmed cell death. A mathematical model has been proposed 
to summarise how these three mechanisms work together to regulate β-cell mass: the sum of 
the rates of β-cell replication and neogenesis, minus the rate of β-cell apoptosis gives the net 




The contribution made by different mechanisms may vary in response to the different stages of 
life or changes in metabolic demand. Studies in rodents have suggested that there is an 
increase in β-cell mass shortly after birth and during childhood and adolescence. β-cell mass 
stays relatively constant during adulthood and may decrease later in life (Rhodes, 2005). 
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Increases in β-cell mass in the early stages of life are results from the neonatal burst of β-cell 
replication and neogenesis, in combination with a modest amount of β-cell apoptosis. After 
reaching adulthood, only approximately 0.5% of β-cells undergo apoptosis in parallel to β-cell 
replication and neogenesis at a similar rate to maintain optimised β-cell mass (Bonner-Weir, 
2000). In elderly individuals, overall β-cell mass may decrease since the rate of apoptosis may 
exceed the rate of replication and neogenesis as a result of ageing. On the other hand, β-cell 
mass dramatically increases during pregnancy and evidence in rodents suggested that this is a 
result of an increase in β-cell replication stimulated by the pregnancy hormones prolactin and 
placental lactogen (Sorenson and Brelje, 1997). β-cell mass returns to normal after gestation 
via a decreased rate of replication coupled with increased apoptosis. 
 
It is important to note that the model of β-cell mass regulation is primarily obtained from 
studies in rodents, with only minor observations from human (Rhodes, 2005). There are 
technical difficulties and ethical reasons hampering detailed study of β-cells in human subjects, 
although it is believed that a similar model occurs in both rodent and human. Some studies 
have reported species specificity in terms of the relative contribution of each mechanism. For 
example, it has been suggested that β-cell replication is primarily responsible for maintaining 
β-cell mass in adult mice (Dor et al., 2004; Georgia and Bhushan, 2004), while both replication 
and neogenesis are important in humans (Butler et al., 2003).  
 
1.1.3.1 Regulation of β-cell mass by glucose 
Glucose itself has been shown to have an effect on β-cell mass dynamics. Studies in rats have 
reported that glucose infusion resulted in significant increases in β-cell numbers (Paris et al., 
2003; pGarofano et al., 1999), and an in vitro study using primary rat β-cells demonstrated that 
glucose was able to promote cell survival by activating synthesis of anti-apoptotic proteins 
(Hoorens et al., 1996). Further intracellular signalling studies in β-cell lines have revealed that 
glucose may act through the Ca
2+
/CaM-dependent protein kinase 4 (CaMK4)-cAMP 
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responsive element-binding protein (CREB) pathway to regulate β-cell mass (Hennige et al., 
2003; Jhala et al., 2003; Liu et al., 2012). Following GLUT-2 mediated entry into β-cells, 





, together with the Ca
2+
-binding protein CaM, activates Ca
2+
/CaM-dependent 
protein kinase kinase (CaMKK), which then phosphorylates CaMK4 (Liu et al., 2012). 
Activated CaMK4 translocates into the nucleus where it phosphorylates CREB. This 
phosphorylation is responsible for CREB activation which, in turn, binds to the cAMP 
response element (CRE) on the IRS-2 promoter to increase IRS-2 gene expression (Persaud et 
al., 2011). IRS-2 maintains β-cell mass by stimulating proliferation and inhibiting apoptosis 
through modulating the PI3K/Akt pathway and Ras pathway (Rhodes, 2005). 
 
1.1.3.2 Regulation of β-cell mass by GLP-1 
GLP-1 and its analogues improve glycaemic control and enhance β-cell mass (Brubaker and 
Drucker, 2004). GLP-1 activates the Gs-coupled GLP-1 receptor (GLP-1R) that is linked to 
cAMP signaling cascade (Brubaker and Drucker, 2002). Current investigations on the 
mechanism of GLP-1-mediated increase in β-cell mass have indicated three potential pathways: 
enhancement of proliferation, inhibition of apoptosis and stimulation of neogenesis. Treatment 
of β-cell lines with GLP-1 increased their rate of proliferation in vitro and short- and long-term 
treatment of rodents with GLP-1R agonists resulted in increased numbers of proliferating β-
cells (Brubaker and Drucker, 2004). The proliferating pathway downstream of GLP-1R 
involves multiple metabolically important proteins, including PI3K, Akt/PKB, MAPK and 
IRS-2 (Buteau et al., 1999; Trumper et al., 2002). In addition, GLP-1 has also been shown to 
protect β-cells from undergoing apoptosis both in vivo and in vitro (Li et al., 2003; Wang and 
Brubaker, 2002). It also increases the survival rate of β-cell lines in response to the challenges 
of cytokines, peroxide and fatty acids (Hui et al., 2003; Kwon et al., 2004; Li et al., 2003). 
More importantly, GLP-1 protects freshly isolated human islets from undergoing apoptosis 
(Farilla et al., 2003). Biochemistry studies have supported that GLP-1 modulates both 
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proapoptotic (e.g. caspase 3) and antiapoptotic factors (e.g. Bcl-2, Bcl-xL) via PI3K, Akt/PKB 
and MAPK (Farilla et al., 2003; Hui et al., 2003; Li et al., 2003; Trumper et al., 2002). Another 
study suggested that GLP-1 mediates its antiapoptotic effect through CREB-induced up-
regulation of IRS-2 gene expression (Jhala et al., 2003). Furthermore, GLP-1 induces the 
expression of transcription factor pancreas-duodenum homeobox (PDX-1) in ductal precursor 
cells (Stoffers et al., 2000). The PDX1 gene is important for the embryonic development of 
endocrine pancreas and GLP-1 may induce PDX1 expression to initiate β-cell neogenesis. It 
has been shown that GLP-1R agonists were able to induce differentiation of human pancreatic 
progenitor or duct cells to cells with β-cell-like phenotypes (Abraham et al., 2002; Movassat et 
al., 2002). Findings so far strongly implicate that GLP-1 regulates multiple signaling pathways 
that contribute to overall increases in β-cell mass.  
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1.2 Diabetes mellitus 
Diabetes mellitus is a chronic disorder characterised by elevated glucose levels in the blood 
and urine in affected individuals. In the past few decades, diabetes has grown rapidly into a 
global epidemic affecting nearly 6% of the world population and causing approximately 5.1 
million deaths worldwide per annum. As one of the most serious health issues impinging upon 
the world community, the disease is costing at least 327 billion pounds a year in health 
expenditure, 11% of total spending on adults (IDF, 2013). Untreated or poorly managed 
diabetes results in high risks of developing complications such as cardiovascular disease, 
neuropathy, retinopathy and nephropathy and it has been estimated that 70-80% of mortality 
among diabetic patients is due to diabetes-related complications (Meetoo et al., 2007). 
Diabetes is posing a significant financial and emotional burden to the people of most countries. 
 
Diabetes mellitus is classified into two main types: Type 1 diabetes mellitus (T1DM), formly 
known as insulin-dependent diabetes mellitus (IDDM) and Type 2 diabetes mellitus (T2DM), 
which was previously called non-insulin-dependent diabetes mellitus (NIDDM) (Rhodes, 
2005). Both types of diabetes involve the failure of the endocrine pancreas to secrete sufficient 
amount of insulin to meet the body’s metabolic demands. There are also two less common 
subtypes of diabetes known as maturity-onset diabetes of the young (MODY) and latent 
autoimmune diabetes of adulthood (LADA). MODY occur when mutations are found in 
autosomal dominant genes disrupting pancreatic β-cell functions (Stride and Hattersley, 2002), 
while LADA is caused by autoantibody-induced destruction of β-cells in individuals at the age 
of 30 years or older (Leslie et al., 2006).  
 
It is estimated that 5-10% of diabetic patients suffer from T1DM, with incidence rates varying 
greatly between countries: from 0.6 incidences/100,000 per year in China to 57.4 
incidences/100,000 per year in Finland (IDF, 2013). The majority of T1DM patients are 
diagnosed during their teenage years and the disease occurs due to self-destruction of β-cells 
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and loss of insulin secretion. At the time of clinical diagnosis, approximately 60-80% of β-
cells have been destroyed by infiltrating immune cells such as macrophages and CD8 T cells 
(Notkins and Lernmark, 2001). Previous studies have suggested that T1DM may be inherited 
and a large number of target genes have since been identified (Anjos and Polychronakos, 2004; 
Eerligh et al., 2004; Eisenbarth, 2007; Van Belle et al., 2010). A particularly strong correlation 
was proposed between T1DM and HLA class II immune recognition molecule genes (known 
as IDDM1, insulin-dependent diabetes mellitus locus 1) found on chromosome 6. In addition, 
Another high risk locus, IDDM2, was found on chromosome 11 which contains the insulin 
gene promoter, and it is not surprising that mutations in this locus may also contribute to 
disease susceptibility (Van Belle et al., 2010). It is estimated that IDDM1 and IDDM2 
contribute to approximately 42% and 8%, respectively, of the genetic heritable risks of T1DM 
(Eerligh et al., 2004). Furthermore, CTLA-4 (cytotoxic T lymphocyte-associated 4) gene, 
which locates on chromosome 2 and regulates T-cell functions, has also been associated with 
T1DM, as well as other autoimmune diseases (Anjos and Polychronakos, 2004). Other genes 
that have been suggested to contribute to the progression of T1DM include PTPN22 (protein 
tyrosine phosphatase non-receptor type 22) and IL2RA (interleukin-2 receptor-α) (Eisenbarth, 
2007). On the other hand, there is evidence, such as studies in monozygotic twins indicated 
that only 13-33% are pairwise concordant for T1DM, suggest that environmental factors also 
play a critical role in the pathogenesis of T1DM (Knip et al., 2005). Putative environmental 
triggers for T1DM include viruses, bacteria, cow’s milk, wheat proteins and vitamin D 
deficiency (Van Belle et al., 2010).  
 
T2DM, which affects 90-95% of diabetic patients, is characterised by chronic hyperglycaemia 
as a result of insulin resistance of peripheral tissues, combined with insufficient insulin 
secretion from islet β-cells to compensate for the reduced insulin sensitivity. It is estimated that 
532 million people will have T2DM by 2030 and the majority of these patients will be between 
40 to 59 years old (IDF, 2013). It is generally accepted that T2DM occurs as a result of both 
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lifestyle and genetic factors. Lifestyle factors that are important to the development and 
progression of the disease include physical inactivity, high calorie diet, smoking and drinking 
(Hu et al., 2001). In addition, obesity has been found to be associated with approximately 55% 
of T2DM incidences (CDC-US, 2004). On the other hand, studies have identified a spectrum 
of genes that are linked to T2DM. For example, TCF7L2 (transcription factor 7-like 2), which 
is responsible for regulating proglucagon gene expression, has been suggested to have the 
strongest link with the disease (Ridderstrale and Groop, 2009). Other candidate genes include 
KCNJ11 encoding for the Kir6.2 subunit of the KATP-channel (Gloyn et al., 2003), peroxisome 
proliferator-activated receptor gamma (PPARγ) (Altshuler et al., 2000), CAPN10 which 
encodes a Ca
2+
-sensitive cysteine protease (Horikawa et al., 2000), and SLC30A8, coding for 
the zinc transporter ZnT8 (Sladek et al., 2007).  
 
1.2.1 Therapies for diabetes 
The more common treatment prescribed to T1DM patients is insulin replacement therapy, 
which delivers exogenous insulin to compensate for the lack of insulin secretion by β-cells. 
Exogenously administered insulin regulates glucose production, utilisation and storage thus 
maintaining normal glycaemia. In addition, islet transplantation therapy may be an option for 
patients who have severe hypoglycaemia unawareness or who have had a kidney transplant 
(McCall and Shapiro, 2012).  
 
While insulin can be used to treat T2DM, anti-diabetic medicines that improve insulin 
sensitivity or stimulate insulin secretion are initially recommended in combination with 
lifestyle intervention (Figure 1.1.7). Agents that increase insulin sensitivity include metformin 
and thiazolidinediones (TZDs). Metformin is currently used as the first-line treatment for 
newly diagnosed T2DM patients (WHO, 2009). The primary mechanism of action of 
metformin is to inhibit hepatic glucose production, partly through activating 5’-
monophosphate-activated protein kinase (AMPK) (Bailey and Turner, 1996). TZDs are 
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peroxisome proliferator activated receptor γ (PPARγ) agonists, which improve systemic 
insulin sensitivity and peripheral glucose uptake (Krentz et al., 2008). However, several 
members of the TZDs, such as rosiglitazone and pioglitazone, have received black box 
warnings from the FDA and its European counterpart due to an increased risk of myocardial 
ischemia and heart failure in some patients receiving this treatment (Dykens et al., 2007), and 
rosiglitazone is no longer prescribed in the UK. 
 
Sulphonylureas, GLP-1 mimetics and dipeptidyl peptidase-4 (DPP-4) inhibitors are also 
prescribed to T2DM patients to improve insulin release. In addition to metformin, 
sulphonylureas are another first-line prescription for newly diagnosed T2DM patients due to 
their efficacy and long history of use to treat diabetes (WHO, 2009). They directly increase 
insulin secretion from β-cells by inhibiting the KATP-channel through binding to its SUR1 
subunit. This results in immediate membrane depolarisation and elevated [Ca
2+
]i, facilitating 
insulin release (See Figure 1.1.2). Meglitinides are a class of glucose regulatory medication, 
which acts similarly to sulphonylureas, but with a weaker binding affinity at the SUR1 subunit 
and it is, therefore, ideal for offering rapid and short-lived insulin secretion that is needed after 
meals. GLP-1 mimetics and DPP-4 inhibitors act in a similar principle by regulating GLP-1R 
receptor activation in T2DM patients. As described in Section 1.1.3.4, GLP-1 enhances 
nutrient-induced insulin secretion and increases β-cell mass (Wang et al., 1997). Due to its 
short half-life of less than 2 minutes, long-lasting GLP-1 mimetics or inhibitors of DPP-4, an 
enzyme that degrades GLP-1, have been developed for treating T2DM patients. Clinical 
studies have revealed that T2DM patients treated with the GLP-1 mimetic, exenatide, have 
reduced on body weight compared to control individuals (Verspohl, 2009). Thus, the GLP-1 
mimetics serve as attractive candidates for glycaemic control in obese T2DM patients.  
 
Individuals unable to use the glucose-lowering medications mentioned above are advised to 
use α-glucosidase inhibitors, which delay intestinal carbohydrate digestion and thus delay 
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elevations in blood glucose levels (NICE, 2009). Moreover, A new class of anti-diabetic drug, 
sodium-glucose transport protein 2 (SGLT-2) inhibitors, which inhibit SGLT-2-mediated 
glucose re-absorption by the proximal tubule in the kidneys, was approved for clinical use in 
2012. Results from randomised clinical trials have demonstrated that administration of SGLT-
2 inhibitors as monotherapy or in combination with other therapies provide durable glucose-




Figure 1.1.7 Therapies for T2DM. 




Most of the conventional therapies for diabetes listed above were developed and marketed with 
little understanding of defined molecular targets or underlying mechanisms of action and, 
therefore, have significant mechanism-based limitations and side effects. For example, 
hypoglycaemia is a severe side effect associated with treatment with insulin or sulphonylureas. 
Long-term administration of sulphonylureas and TZDs has also been reported to cause notable 
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weight gain (Krentz and Bailey, 2005). Moreover, there is an increased risk (almost doubled) 
of genito urinary infections in female patients receiving SGLT-2 treatment during the clinical 
trials (Tahrani et al., 2013). Therefore, new types of glucose-lowering agents are needed to 
offer not just complementary and additional effectiveness to existing drugs, but also benefits 
that are not routinely accomplished, such as reducing risks of secondary complications.  
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1.3 The novel cannabinoid receptor GPR55 
Studies on the physiological effects of Cannabis sativa have identified the endocannabinoid 
system (ECS), which classically consists of GPCR cannabinoid receptors 1 and 2 (CB1 and 
CB2), the endogenous ligands 2-arachidonoyl glycerol (2-AG) and N-
arachidonoylethanolamine (AEA) and the enzymes responsible for their synthesis and 
degradation. CB1, the most abundant GPCR expressed in the brain, is a major regulator in the 
hypothalamic reward system controlling food intake and AEA and 2-AG trigger hyperphagia 
through activation of CB1 (Williams and Kirkham, 1999; Williams et al., 1998). Thus, the 
CB1 antagonist Rimonabant (SR141716A) was developed as an anti-obesity agent, and 
although it was effective in reducing food intake and body weight, it was withdrawn from 
clinical use after only two years due to its adverse psychological effects (Sam et al., 2011). In 
addition to the function of the ECS in the brain, recent research in the endocrine pancreas has 
revealed the expression of CB1 and CB2 in the islets of Langerhans and their coupling to 
second messenger generation and islet hormone secretion (Di Marzo, 2008; Li et al., 2011b). 
However, there is a lack of agreement on the effects of cannabinoid receptor activation on 
insulin secretion from islets. Thus it has been reported that pharmacological activation of CB1 
and CB2 in rodent and human islets results in either stimulation (Anderson et al., 2013; 
Bermudez-Silva et al., 2008; Li et al., 2011a; Li et al., 2010) or inhibition (Anderson et al., 
2013; Juan-Pico et al., 2006; Nakata and Yada, 2008) of insulin secretion. The reason for the 
inconsistent data may be because of differences in experimental design, as one recent study has 
shown that AEA inhibited glucose-induced insulin secretion from freshly isolated rat islets, but 
caused a marked increase of insulin secretion from islets cultured overnight (Anderson et al., 
2013).  
 
Research on the ECS in other cell types has demonstrated that some cannabinoid ligands that 
were originally thought to be specific for CB1 or CB2 can also act independently of these 
receptors, suggesting the existence of a third cannabinoid receptor (Curran et al., 2005; Derocq 
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et al., 1998; Kaplan et al., 2005; Nieri et al., 2003). GPR55 was first suggested as a novel 
cannabinoid receptor when in silico screening of patents from GlaxoSmithKline and 
AstraZeneca revealed that it interacts with some cannabinoid receptor agonists and antagonists 
(Brown, 2007). Deorphanisation of GPR55 occurred as recently as 2007, with the report that a 
range of endogenous and pharmacological cannabinoids activated this receptor when it was 
transiently expressed in human embryonic kidney 293 (HEK293) cells (Ryberg et al., 2007). 
Emerging evidence on the expression and signalling pathways downstream of GPR55, as 
described below, suggest that it may play an important role in regulating islet function and 
energy homeostasis. 
 
1.3.1 GPR55 expression 
Since the cloning of GPR55 in 1999 and its identification as a novel GPCR highly expressed in 
the human brain (Sawzdargo et al., 1999), it has been detected in various regions of the brain 
including the frontal cortex, striatum, hypothalamus, brain stem, hippocampus, cerebellum, 
caudate and putamen in rodents and humans (Baker et al., 2006; Henstridge et al., 2011; 
Lauckner et al., 2008; Ryberg et al., 2007; Sawzdargo et al., 1999). Intriguingly, in mouse 
striatum, hypothalamus and brain stem, expression levels of GPR55 mRNA are comparable to 
those of CB1, suggestive of an important role for GPR55 in these regions (Henstridge et al., 
2011; Ryberg et al., 2007). Consistent with this, it has recently been reported that GPR55 plays 
a role in motor co-ordination (Wu et al., 2013).  
 
GPR55 is also expressed in a wide range of peripheral tissues, including spleen, adrenals and 
bone (Ryberg et al., 2007; Sawzdargo et al., 1999; Whyte et al., 2009), and also in 
metabolically important cells such as adipocytes (Moreno-Navarrete et al., 2012) and the 
gastrointestinal tract (Lin et al., 2011; Ryberg et al., 2007; Schicho et al., 2011). In addition, 
GPR55 mRNA and protein have been identified in rodent -cell lines (BR1N-BD11and MIN6) 
and islets. Immunohistochemical analyses have indicated that GPR55 is expressed by -cells 
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in mouse and rat islets, but it was not detected in - or -cells (McKillop et al., 2013; Romero-
Zerbo et al., 2011), suggesting that it might play a physiological role in regulating glucose 
homeostasis through effects on insulin secretion. 
 
1.3.2 GPR55 pharmacology 
GPR55 is a seven transmembrane spanning GPCR that shares only approximately 14% 
sequence identity with CB1 and CB2 (Baker et al., 2006) and lacks their typical ‘cannabinoid 
binding pocket’ (Kotsikorou et al., 2011). It is therefore rather surprising that GPR55 was 
considered to be a third cannabinoid receptor, and this low homology and altered cannabinoid 
binding site might underlie some of the controversy surrounding the interactions between 
cannabinoids and GPR55, as described below. Details of compounds that are reported to have 
significant pharmacological effects at GPR55 are described below and the key information is 
summarised in Table 1.3.2.1.  
 
The abilities of AEA and 2-AG, endocannabinoids that are agonists at CB1 and CB2, to 
activate GPR55 were first demonstrated in GTPS binding assays, which indicated that AEA 
was equipotent in activating GPR55, CB1 and CB2, while 2-AG was up to 200-fold more 
potent in activating GPR55 than it was in stimulating either CB1 or CB2 (Ryberg et al., 2007). 
However, other experiments using GPR55-expressing HEK293 cells demonstrated that AEA, 
but not 2-AG, triggered GPR55-dependent increases in intracellular calcium ([Ca
2+
]i) and 
activation of Rho small GTPases (Lauckner et al., 2008; Ryberg et al., 2007), casting doubt on 
2-AG exerting its effects via GPR55. Further evidence that AEA acts via GPR55 was provided 
by observations that elevations in [Ca
2+
]i in primary human endothelial cells in response to this 
cannabinoid were absent following siRNA-mediated down-regulation of GPR55 (Henstridge et 
al., 2009b; Waldeck-Weiermair et al., 2008). Conversely, other studies using GPR55-HEK293 
cells reported that AEA did not increase [Ca
2+
]i (Oka et al., 2007; Oka et al., 2009), and it did 
not act as a GPR55 agonist in -arrestin recruitment assays (Sharir and Abood, 2010), and it is 
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clear that AEA has promiscuous receptor selectivity with agonist actions at TRPV1 receptors 
(Ross, 2003) as well as at cannabinoid receptors. Thus, although several studies do support 
activation of GPR55 by AEA and 2-AG, there is currently no consensus between published 
studies on whether these cannabinoids are bona fide GPR55 agonists and their actions at other 
receptors makes it difficult to draw firm conclusions on their cellular mode of action. 
 
Several studies have demonstrated that a bioactive lipid, L--lysophosphatidylinositol (LPI), 
has agonist effects in GPR55-HEK293 cells leading to suggestions that LPI is an endogenous 
non-cannabinoid ligand of the receptor (Henstridge et al., 2009b; Lauckner et al., 2008; Oka et 
al., 2007; Oka et al., 2009; Waldeck-Weiermair et al., 2008). In addition, loss of LPI-induced 
cellular responses following GPR55 knockdown have been observed in human endothelial 
cells (Kargl et al., 2013), cancer cell lines (Pineiro et al., 2011) and in rodent synaptic cells 
(Sylantyev et al., 2013). Despite these findings, GPR55-independent effects of LPI occurring 




 channels have also been reported (Bondarenko et al., 2011a, 
b). 
 
The phytocannabinoid cannabidiol (CBD) is a major component of cannabis and a synthetic 
CBD analogue, O-1602, is reported to be a potent and selective GPR55 agonist that lacks 
significant binding affinity for either CB1 or CB2 (Johns et al., 2007; Ryberg et al., 2007; 
Waldeck-Weiermair et al., 2008). O-1602 was first reported to activate a putative cannabinoid 
receptor distinct from CB1 and CB2 more than a decade ago (Jarai et al., 1999; Offertaler et al., 
2003). It was only a relatively recent study that showed that O-1602 was able to induce 
activation of Rho small GPTases in GPR55-HEK293 cells (Ryberg et al., 2007). Subsequent 
studies in human endothelial cells have demonstrated that O-1602 treatment elevated [Ca
2+
]i 
and this response was attenuated after siRNA-mediated down-regulation of GPR55 expression 
(Waldeck-Weiermair et al., 2008). O-1602-induced physiological effects were also observed in 
mouse and human osteoclasts and similar effects were not reported in osteoclasts isolated from 
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GPR55 knockout mice (Whyte et al., 2009). In contrast to the proposed GPR55 agonist effects 
of O-1602, native CBD is an effective GPR55 antagonist (Ryberg et al., 2007), which has been 
widely used to inhibit GPR55 agonist-induced biological effects (Lauckner et al., 2008; 
Ryberg et al., 2007; Whyte et al., 2009). However, a recent study has proposed that CBD may 
have GPR55 agonist activity since it provided protection against acute pancreatitis in mice to a 
similar extent to that seen using O-1602 (Yu et al., 2013). Currently there is a lack of selective 
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Compounds Activity at GPR55 [ref.] Other activities [ref.] 
Anandamide (AEA) 
Agonist (Henstridge et al., 
2009b; Lauckner et al., 2008; 
Ryberg et al., 2007; Waldeck-
Weiermair et al., 2008) 
CB1 and CB2 agonist (Li 
et al., 2011b)  
2-Arachidonoylglycerol (2-
AG) 
Agonist (Ryberg et al., 2007) 
CB1 and CB2 agonist (Li 
et al., 2011b) 
Lysophosphatidylinositol 
(LPI) 
Agonist (Henstridge et al., 
2009b; Lauckner et al., 2008; 
Oka et al., 2007; Oka et al., 








(Bondarenko et al., 
2011a, b) 
O-1602 
Agonist (Johns et al., 2007; 
Romero-Zerbo et al., 2011; 
Ryberg et al., 2007; Waldeck-
Weiermair et al., 2008) 
--- 
Cannabidiol (CBD) 
Antagonist (Lauckner et al., 
2008; Ryberg et al., 2007; 
Whyte et al., 2009) 
Weak CB1 and CB2 
antagonist (Petitet et al., 
1998) 
SR141716A 
Agonist (Kapur et al., 2009; Yin 
et al., 2009) 
CB1 antagonist (Li et al., 
2011b) 
AM251 
Agonist (Kapur et al., 2009; Yin 
et al., 2009) 
CB1 antagonist (Li et al., 
2011b) 
 
Table 1.3.2.1 Agonist and antagonist ligands for GPR55. 
The key compounds that are reported to have significant pharmacological effect at GPR55, 
either as agonists or antagonists, are listed in the table and information is provided on whether 
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A divergence in the effects of some ligands at CB1 and GPR55 has been observed, such that 
the synthetic CB1 antagonists AM251 and Rimonabant (SR141716A) have agonist effects in 
-arrestin and luminescence reporter assays in cell lines engineered to express GPR55 (Kapur 
et al., 2009; Yin et al., 2009). Subsequent functional studies revealed that AM251 promoted 
GPR55-dependent Ca
2+
 mobilisation and both AM251 and SR141716A activated ERK1/2 
mitogen-activated protein (MAP) kinases and phosphorylation of the transcription factors 
CREB and NF-κB via GPR55 (Henstridge et al., 2010). The concentrations of these ligands 
that activate GPR55 are higher than those required to antagonise CB1 (Pertwee, 2005; Ryberg 
et al., 2007), but it is possible that Rimonabant may reach sufficient concentrations when 
administered in vivo to both inhibit CB1 and activate GPR55. The activation of GPR55 by 
Rimonabant, may contribute to the off-target effects associated with its therapeutic use in 
obesity (Kapur et al., 2009).  
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1.3.3 GPR55 signalling cascades 
The G protein subunits with which GPR55 associates and the signalling cascades downstream 
of its activation have been examined in detail using GPR55-HEK293 cells. Pretreatment with 
pertussis toxin to ADP ribosylate Gi or with peptides to block specific Gα protein subunits 
indicated that GPR55 is coupled to G12/13, but not to Gs, Gi or Gq (Ryberg et al., 2007). This 
was confirmed in a study where overexpression of catalytically inactive G12/13 abolished LPI-
induced Ca
2+
 mobilisation (Henstridge et al., 2009b). In contrast, involvement of both Gq and 
G12/13 was suggested by another group who reported that co-transfection of GPR55-HEK293 
cells with dominant negative Gq or G12/13 reduced calcium responses to GPR55 ligands 
(Lauckner et al., 2008).  
 
Experiments in cell lines and primary cells have shown that pharmacological activation of 
GPR55 by cannabinoids and phospholipid-derived agonists induced elevations in [Ca
2+
]i 
(Henstridge et al., 2010; Kargl et al., 2013; Oka et al., 2007; Pineiro et al., 2011; Sylantyev et 
al., 2013; Waldeck-Weiermair et al., 2008; Yu et al., 2013), and these responses were a 
consequence of Ca
2+
 release from the ER following activation of PLC and IP3 generation 
(Lauckner et al., 2008; Waldeck-Weiermair et al., 2008). Both Gq and G12/13 were found to 
be involved in GPR55-mediated PLC activation (Lauckner et al., 2008). In addition, Rho small 
GTPases, including RhoA, Cdc42 and Rac1, are another class of second messengers that are 
considered to be activated by GPR55 via G12/13 (Obara et al., 2011; Ryberg et al., 2007; 
Whyte et al., 2009). These small GTPases in turn activate ROCK, which can increase [Ca
2+
]i 
both via PLC-mediated PIP2 hydrolysis and IP3 generation, and through actin cytoskeleton 
remodelling (Lauckner et al., 2008).  
 
Activation of GPR55 also leads to phosphorylation of the MAP kinases ERK1/2 via the RhoA-
ROCK pathway and/or increases in [Ca
2+
]i (Anavi-Goffer et al., 2012; Henstridge et al., 2009b; 
Oka et al., 2010; Pineiro et al., 2011; Waldeck-Weiermair et al., 2008). The transcription 
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factors NF-κB and CREB, which are downstream of the ERK pathway, are activated by 
GPR55 (Henstridge et al., 2010), as is activating transcription factor 2 (ATF-2), although this 
occurs via p38 MAPK, not through ERK1/2 (Oka et al., 2010). In addition, GPR55 can also 
activate the transcription factor nuclear factor of activated T-cells (NFAT) in a RhoA-
dependent manner (Henstridge et al., 2009b). Once activated, these transcription factors 
regulate expression of key genes that are responsible for transducing the effects of GPR55 in a 
diverse range of cellular functions including tumorigenesis, bone resorption and neuropathic 
pain (Henstridge, 2012). It is interesting to note that some of the GPR55-mediated signalling is 
ligand-specific. For instance, AM251 and SR141716A, but not LPI, were able to induce CREB 
phosphorylation (Henstridge et al., 2010). It is clear that further research is needed to fully 
elucidate the GPR55 signal transduction cascades, but our current understanding of the key 
pathways through which this receptor is reported to act are summarised in Figure 1.1.8.  
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Figure 1.1.8 Schematic representation of signalling pathways downstream of GPR55 
activation.  
The diagram shows the main pathways through which GPR55 signals to exert its effects on 
cellular function. It is widely accepted to be coupled to the G12/13 subunit, which activates 
Rho small GTPases and their downstream effector ROCK. Activated ROCK can elevate 
intracellular Ca
2+
 either through PLC-induced PIP2 hydrolysis and IP3-mediated Ca
2+
 
mobilisation from the ER or cytoskeleton remodelling. In addition, ROCK can modulate a 
range of gene transcription factors including nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), activating transcription factor 2 (ATF-2), nuclear factor of activated 
T-cells (NFAT) and cAMP response element-binding protein (CREB), through activation of 
mitogen-activated protein kinases (MAPKs) such as ERK1/2 and p38 MAPK. GPR55 can also 
couple to Gq, which increases intracellular Ca
2+
 through PLC activation. Ca
2+
 and DAG 
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1.3.4 Regulation of islet functions by GPR55 
During the course of this thesis, two studies were published that reported GPR55 expression in 
rodent β-cells and islets (McKillop et al., 2013; Romero-Zerbo et al., 2011), suggesting that it 
might play a physiological role in regulating glucose homeostasis through effects on insulin 
secretion. Indeed, O-1602 potentiated glucose-stimulated insulin secretion from mouse and rat 
islets, indicative of a direct stimulatory role for GPR55 in -cells (McKillop et al., 2013; 
Romero-Zerbo et al., 2011). In the recent report evaluating the effects of various GPR55 
ligands on insulin secretion it was found that all agonists used -AM251, O-1602, abnormal 
CBD (a synthetic GPR55-activating CBD analogue) and the phospholipid-derived 
endocannabinoids oleoylethanolamine (OEA) and phenethylamine (PEA) - stimulated insulin 
secretion from insulin-secreting cell line BR1N-BD11 cells and mouse islets, and their effects 
were inhibited by CBD (McKillop et al., 2013), suggesting that they acted via GPR55 
activation. In vivo studies have also confirmed that short-term administration of GPR55 
agonists to rats or mice increased plasma insulin levels and improved glucose tolerance 
(McKillop et al., 2013; Romero-Zerbo et al., 2011). These observations imply that GPR55 
agonists have acute, beneficial effects on insulin secretion and glucose handling. 
 
LPI has long been known to be an insulin secretagogue (Metz, 1986), and although LPI-
induced insulin secretion was suggested to be at least partly mediated by the mobilisation of 
[Ca
2+
]i in -cells (Metz, 1988), its precise mode of action in islets has never been established. 
The identification of LPI as an endogenous ligand of GPR55 (Oka et al., 2007) points to a 
possibility that the insulinotropic effect of LPI could be mediated through activation of this 
receptor, but there is no published data that has addressed this hypothesis.  
 
There has been some investigation of the signalling cascades downstream of GPR55 activation 
in -cells that suggest that elevations in [Ca2+]i are important in transducing the stimulatory 
effects of GPR55 agonists. Thus, O-1602 induced transient increases in [Ca
2+
]i in rat islets 
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(Romero-Zerbo et al., 2011), and AM251, O-1602, abnormal CBD, OEA and PEA all caused 
rapid increases in [Ca
2+
]i in insulin-secreting MIN and BR1N-BD11 cells (McKillop et al., 
2013; Ning et al., 2008), consistent with GPR55 signalling via PLC activation in -cells 
(Figure 1.1.8). These agonists also stimulated small increases in β-cell intracellular cAMP 
levels (McKillop et al., 2013; Ning et al., 2008), which are likely to be secondary to activation 
of calcium-sensitive isoforms of ACs since there is no evidence that GPR55 is directly coupled 
to Gs to promote cAMP accumulation.  
 
GPR55-mediated activation of PLC can occur both via conventional Gq coupling and also by 
the G12/13 pathway (Figure 1.1.8) so it is possible that GPR55 also regulates -cells via 
G12/13 signalling since this G protein has previously been identified in islets (Hammar et al., 
2009; Skoglund et al., 1999). However, inhibition of the Rho kinase ROCK causes increased 
insulin release from FACS-purified rat -cells (Hammar et al., 2009) and this negative role for 
RhoA on insulin release is inconsistent with the observed stimulatory effects of GPR55 
agonists summarised above. It is therefore possible that there are both stimulatory and 
inhibitory cascades activated by GPR55 agonists in islets, via separate G proteins and further 
work is required to define the signalling cascades that regulate insulin exocytosis downstream 
of GPR55 activation.  
 
GPR55 may also play a role in maintaining functional insulin-producing -cells, since OEA 
can protect -cells from palmitate-induced apoptosis, an effect that was not mediated via 
another OEA receptor, GPR119 (Stone et al., 2012). O-1602 was reported to promote 
phosphorylation of ERK1/2 and CREB in various cell types (Andradas et al., 2011; Henstridge 
et al., 2010; Pineiro et al., 2011; Whyte et al., 2009) (Figure 1.1.8), effectors that are known to 
regulate -cell mass (Burns et al., 2000; Jhala et al., 2003). Two studies in cancer cell lines 
demonstrated that activation of GPR55 promotes cell proliferation through PI3K/Akt or 
MAPK pathways (Andradas et al., 2011; Pineiro et al., 2011). However, there has been no 
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published studies investigating whether activation of GPR55 in β-cells contributes to 
maintenance of β-cell mass.  
 
1.3.5 GPR55 knockout mice 
GPR55 knockout (KO) mice were first generated and backcrossed into the C57/BL6 mouse 
strain by a research group at the University of Aberdeen (Whyte et al., 2009).  A GPR55 KO 
mouse colony was established at the Guy’s Campus of King’s College London in accordance 
with UK Home Office standards in 2012, and these mice were used in some of the experiments 
described in this thesis. General phenotypic analysis of GPR55 KO mice revealed no obvious 
primary differences to their wildtype littermates. However, they were reported to have 
increased bone mass (Whyte et al., 2009) and impaired coordination towards tasks requiring 
challenging motor responses (Wu et al., 2013), suggesting that GPR55 plays a role in bone 
metabolism and motor coordination. Another study using these mice has shown that GPR55 
KO mice failed to develop mechanical hyperalgesia against inflammatory and neuropathic pain 
(Staton et al., 2008). In our lab, we have also observed that GPR55 KO mice have a larger rib 
cage, possibly due to the suggested regulatory role of GPR55 in bone metabolism (Whyte et al., 
2009). In terms of metabolism, preliminary data generated from an in vivo project on GPR55 
in our lab, separate from the studies described in this thesis, have shown that GPR55 KO mice 
had normal glucose tolerance when fed on a normal chow diet, but they were more susceptible 
to diet-induced obesity and glucose intolerance that wildtype mice when they were fed on a 
high fat diet (Liu and Persaud, unpublished). These observations strongly suggest that GPR55 
plays a role in maintaining glucose homeostasis, at least under conditions of metabolic stress, 
and the in vitro investigations described in this thesis will provide further insights into the role 
of this receptor in islets.  
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1.4 Aims 
The principal objective of the experiments described in this thesis was to determine the 
expression and functional roles of GPR55 in islets of Langerhans, and identify the signalling 
mechanisms that are involved in the processes by which GPR55 ligands regulate insulin 
secretion. Experiments detailed in this thesis will use the pharmacological GPR55 agonist O-
1602, the putative endogenous ligand LPI and the GPR55 antagonist CBD to manipulate 
GPR55 activity in islets. Islets isolated from GPR55 KO mice will also be investigated in an 
attempt to understand whether these ligands act specifically on GPR55 to regulate islet 
functions. In addition, due to the lack of knowledge of GPR55 in human islets, this thesis will 
also investigate the expression and functional roles of GPR55 for the first time in isolated 
human islets. An outline of the aims of this thesis is given below. 
 
 To determine the expression of GPR55 in MIN6 β-cells, and in mouse and human 
islets. 
 To investigate the role of GPR55 activity and the specificity of GPR55 ligands in 
regulating [Ca
2+
]i and RhoA activity in MIN6 cells, and when possible, in isolated 
mouse and human islets.  
 To examine the effects and specificity of GPR55 ligands on insulin secretion from 
isolated mouse and human islets. 
 To investigate the effects of pharmacological manipulations of GPR55 and GPR55 
deletion on mouse islet apoptosis.  
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CHAPTER 2 METHODS 
2.1 Materials 
Tissue culture flasks, Petri dishes and cover slips were supplied by Thermo Fisher Scientific 
(Leicestershire, UK). L-α-lysophosphatidylinositol sodium salt from Glycine max, cell 
dissociation solution, cell culture media, agarose gel and all other chemicals and reagents were 
purchased from Sigma-Aldrich (Dorset, UK). Protease inhibitor cocktail (X100) reagent was 
bought from Calbiochem (Nottingham, UK). 10% pre-made polyacrylamide gels, NuPAGE
®
 
sample buffer and transfer buffer were purchased from Invitrogen (Paisley, UK). RNA 
isolation kits, PCR reaction reagents and DNA purification kits were purchased from Qiagen 
(Cambridge, UK). ECL western blotting reagents and Hyperfilm were from GE Healthcare 
(Little Chalfont, UK). The rabbit anti-GPR55 antibody was obtained from Cayman Cemical 
Company (Cambridge, UK) and anti-rabbit secondary antibody was bought from Thermo 
Fisher Scientific (Leicestershire, UK). Rainbow protein molecular weight markers and 
polyvinylidene fluoride (PVDF) membrane were bought from Millipore (Watford, UK). Cell-
Tak
TM
 cell and tissue adhesive was purchased from BD Bioscience (Oxford, UK). CBD and O-
1602 (5-methyl-4[(1R,6R)-3-methyl-6-(1-cyclohexen-1-yl)]-1,3-benzenediol) were supplied 
by Tocris Biosciences (Bristol, UK). The RhoA activation assay kit was purchased from 
Cytoskeleton Inc. (Denver, USA).  
 
2.2 Cell Culture 
2.2.1 Mouse insulinoma (MIN6) β-cells 
Although β-cells are the primary cell type in islets, the presence of other endocrine and non-
endocrine cells can lead to difficulties in defining β-cell-specific roles when using whole islets. 
For this reason, clonal insulin-secreting cell lines are often used experimentally as a readily 
available source of pure -cells (Persaud, 1999). Mouse insulinoma (MIN6) β-cells 
preferentially express GLUT-2 and glucokinase for glucose transport and phosphorylation 
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respectively. They also have a relatively high insulin content (~20% of an average mouse β-
cell) in comparison to other insulin-secreting lines such as RIN-m5F cells (Persaud, 1999). 
These functional similarities to primary islet β-cells, together with their rapid growth 
characteristics, made them the -cell line of choice for some of the experiments described in 
this thesis. 
 
2.2.2 Maintenance of MIN6 cells  
MIN6 cells of passage 28-40 were cultured as monolayers on negatively charged tissue culture 
plastic and were maintained in culture in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 25mM glucose supplemented with 10% foetal bovine serum (FBS), 2mM L-
glutamine and 100U/ml penicillin/100µg/ml streptomycin. Cells were maintained at 37°C in an 
atmosphere of 95% air/5% CO2 and the growth medium was replaced every 3-4 days.  
 
2.2.3 Subculturing 
MIN6 cells were subcultured by trypsinisation to maintain them at a logarithmic growth rate 
when they reached approximately 70% confluency. The growth medium was removed and 
cells were rinsed with phosphate buffered saline (PBS) before being exposed to trypsin/EDTA 
(0.1%/0.02%) for 3 minutes at 37°C. Trypsin helps to remove cells by enzymatically cleaving 
the adhesion molecules between the cells and the tissue culture surface and the EDTA chelates 
Ca
2+
 which is required for Ca
2+
-dependent adhesion. Activity of trypsin was inhibited by 
adding medium supplemented with FBS and the suspended MIN6 cells were subcultured in 
fresh culture flasks. 
 
2.2.4 Estimation of cell number 
A Neubauer haemocytometer is used when an estimation of cell number is required. Following 
trypsinisation, the cells were re-suspended in 1ml growth medium and a 10µl aliquot of the 
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cell suspension was added to 90µl PBS (1:10 dilution), of which 10µl was loaded onto the 
haemocytometer (Figure 2.1.1) is a thick glass microscope slide with a grid of perpendicular 
grooves. By placing a cover-slip on top of it, chambers of 0.1mm in depth and sides of 1mm in 
diameter are formed. A diluted MIN6 cell suspension was loaded against the cover-slip, and 
was dispersed into the chambers due to capillary action. The number of cells was counted in 
each of the four 1x1mm corner squares under a light microscope. Total cell number per ml was 
estimated using the following calculation: 
Cell number per ml =  average cell number per 0.1mm
2
 x dilution factor 
(e.g. 10 for 1 in 10 dilution) x 10
4 
 
Figure 2.1.1 Cell number estimation with a Neubauer haemocytometer.  
The haemocytometer is engraved with grids of perpendicular lines to make up 9 large squares. 
Each square is 1mm
2
 with a depth of 0.1mm below the cover-slip giving a total volume of 
0.1mm
3
 per square. By counting the number of cells in each square, the total number of cells in 
the original cell suspension can be calculated. Figure adapted from: 
(http://www.who.int/vaccines/en/poliolab/webhelp/Chapter_04/4_2_Cell_culture_procedures.h
tm) 
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2.2.5 Freezing down and thawing of cells 
In order to preserve MIN6 cells for future use, they were trypsinised, pelleted and re-
suspended in cryopreservant (90% FCS/10% dimethyl sulfoxide (DMSO), v/v). Cryo-safe 
tubes containing 1ml aliquots of cell suspension were stored at -80°C in isopropanol to allow a 
gradual freezing process before being stored in liquid nitrogen (-196°C). 
 
To retrieve frozen cells, cell suspensions were rapidly thawed in a 37°C water bath and 
transferred to a 15ml centrifuge tube. 10ml pre-warmed growth medium was added and cells 
were pelleted and resuspended in fresh growth medium. This process removed DMSO in the 
cryopreservant, which is detrimental to cell growth. The cell suspension was then transferred 
into a fresh tissue culture flask.   
 
2.3 Islet isolation 
2.3.1 Isolation of human islets of Langerhans 
Human pancreata were removed from healthy, hearting-beating cadaver organ donors and 
human islets were isolated from these pancreata under aseptic conditions at the King’s College 
Human Islet Isolation Unit by Dr. Guocai Huang. Islets were then maintained at 37°C (95% air, 
5% CO2) in Connaught Medical Research Laboratories (CMRL) culture medium containing 
5.6mM glucose and supplemented with 10% foetal bovine serum (FBS), 2mM L-glutamine 
and 100U/ml penicillin / 100µg/ml streptomycin. Human islets were kept at Human Islet 
Isolation Unit for 12-24 hours before transferring to Guy’s Campus and they were used within 
48 hours after arrival. Ethical approval for the use of human islets for research was given by 
King’s College Hospital Ethics Committee and agreement for using human material for 
research was reached with donor relatives. 
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2.3.2 Isolation of mouse islets of Langerhans 
Mouse islets were isolated from either ICR, WT C57/BL6 mice and GPR55 KO C57/BL6 
mice (described in Section 1.3.5) after collagenase digestion of the pancreas. The duct 
connecting the pancreas with the intestines was first clamped before injection of collagenase 
into the pancreas via the bile duct. Approximately 2ml of 1mg/ml collagenase solution was 
injected using a 2mm needle and the inflated pancreas was removed from the mouse and 
transferred to a 50ml centrifuge tube on ice. The collected pancreas tissues were incubated in 
37°C water bath for 10 minutes to allow collagenase digestion of exocrine tissues. Digestion 
was stopped by transferring tubes to ice and tissues were washed with ice cold Minimum 
Essential Medium (MEM) (supplemented with 10% FBS and 100U/ml penicillin/100µg/ml 
streptomycin) before filtering through a 2μm sieve to remove undigested exocrine tissue and 
other tissues such as fat. Digested pancreas tissues were re-suspended in a purification gradient 
Histopaque
®
 solution, containing 1.077g/ml polysucrose. MEM was gently added on top of the 
Histopaque
®
 solution before centrifugation at 11,000 rpm and islets were retrieved from the 
interface between the Histopaque
®
 solution and MEM. Islets were further washed in aseptic 
conditions to remove residual Histopaque
®
 solution and potential contaminants. Islets were 
cultured in RPMI-1640 medium containing 11mM glucose supplemented with 10% FBS, 
2mM L-glutamine and 100U/ml penicillin/100µg/ml streptomycin, and maintained at 37°C 
(95% air, 5% CO2) for up to 2 days before experimental use.  
 
2.4 Gene expression 
2.4.1 RNA extraction 
In order to investigate expression of particular genes by eukaryotic cells, a complementary 
DNA (cDNA) library containing the coding regions is prepared from total cellular messenger 
RNA (mRNA). In this thesis, total RNA was isolated from MIN6 cells or islets and mRNA 
was separated from other RNAs such as ribosomal RNA (rRNA) and transfer RNA (tRNA) 
using the RNeasy Mini kit from Qiagen, according to the manufacturer’s instructions.  
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MIN6 cells (P28-40) grown as monolayers in T75 flasks (30-50% confluency) or 
approximately 100 islets were harvested and re-suspended in 350μl RLT Buffer (provided with 
the RNeasy kit) supplemented with 0.1% β-mercaptoethanol in a 1.5ml Eppendorf tube. MIN6 
cells were lysed by vortexing and islets were passed through an RNeasy Shredder Column for 
homogenisation. 350μl of 70% ethanol was added to lysed samples before being transferred 
onto an RNeasy Mini spin column placed in a 2ml collection tube. The mixture was spun for 
15 seconds at 12,000 rpm and the flow-through was discarded. The spin column was washed 
with 350μl RW1 Buffer before the mixture of 10μl DNase I stock solution and 70μl RDD 
Buffer was directly pipetted on top of the spin column membrane, with incubation for 15 
minutes at room temperature. The DNase solution was washed off by adding 350μl of RW1 
Buffer and centrifugation at 12,000 rpm for 15 seconds. The spin column membrane was 
further washed twice with 500μl RPE Buffer and total RNA was eluted through the spin 
column membrane in 20-40μl of RNase-free water (12,000 rpm for 1 minute).  
 
Concentrations of isolated RNA were quantified using the ND1000 spectrophotometer 
(NanoDrop). 1μl of each RNA sample was loaded onto the aperture and absorbances at 260nm 
and 280nm were measured from the samples. The NanoDrop software applies the Beer-
Lambert law, which predicts a linear change in absorbance in a solution, to determine RNA 
concentration, and the ratio of A260nm/A280nm was used to assess the quality of RNA samples. A 
ratio of <1.6 indicates contamination of samples with proteins, phenol or other compounds that 
absorb 280nm emission. RNA samples with A260nm/A280nm >1.6 were stored at -80°C and used 
for cDNA synthesis (Section 2.3.2).  
 
2.4.2 cDNA synthesis 
In order to amplify RNA expression using PCR, isolated single-stranded mRNA is transcribed 
into complementary DNA (cDNA) by an RNA-dependent DNA polymerase (reverse 
transcriptase). Isolated mRNA was first diluted with DNase/RNase-free water to give 
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approximately 50ng/μl, and 10μl of diluted mRNA was added to a DNase/RNase-free 
Eppendorf tube. 0.5μl of 10-meroligonucleotide (2μg/μl stock) and 0.5μl oligo-(dT)18 (2μg/μl 
stock) were added to the same tube. The mixtures were vortexed and heated up to 70°C for 5 
minutes to denature mRNA secondary structure. Samples were then placed on ice to avoid 
possible heat-inactivation of MMLV-Reverse Transcriptase (MMLV-RT) in the following 
procedure: 9μl of Master Mix containing MMLV-RT was prepared as shown in Table 2.3.2.1 
and added to 11μl of the RNA/oligo mixture. Reverse transcription was then carried out using 
a thermal cycler (50 minutes incubation at 42°C followed by 15 minutes incubation at 72°C), 





For 1 sample 
Final Concentration 
(in 20μl) 
5X RT buffer (Promega MMLV-RT kit) 4μl -- 
DNase/RNase-free H2O 0.5μl -- 
DTT (400mM) 0.5μl 10mM 
RNasin (40U/μl) 2μl 4U/μl 
dNTPs (10mM) 1μl 500μM 
MMLV-RT (200U/μl) 1μl 10U/μl 
 
Table 2.3.2.1 Master Mix for Reverse Transcription. 
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2.4.3 Reverse-transcriptase polymerase chain reaction (RT-PCR) 
PCR is a technique used to amplify specific regions of interest from template cDNAs in vitro. 
Pairs of sequences designed to bind complementarily to two ends of the region of interest are 
known as primers, which are essential for DNA polymerase to replicate DNA for amplification 
(Figure 2.3.3.1). In brief, PCR amplifications are carried out in a thermal cycler in repeated 
cycles of three phases: denaturing of double stranded DNAs at 95°C, annealing between 
primers and DNA templates at ~50-60°C, and extension of newly amplified DNAs of interest 
at 72°C. The annealing temperatures are usually determined by the percentage of guanine and 
cytosine nucleotides in the DNA sequence of interest and by primer length. 
Annealing temperature = 61.2%±0.41 x (%GC pairs)-(500/primer length) 
In this PhD thesis, cDNAs from MIN6 cells, mouse islets and human islets were analysed by 
PCR amplifications. Specific pairs of primers were designed using Primer3web and ordered 
from Integrated DNA Technology to amplify GPR55 mRNA. Primers were designed to be 
intron-spanning to avoid co-amplification of the same amplicon size from any contaminating 
genomic DNA, and their GC content was 55% for an optimum annealing temperature allowing 
high PCR yield and specificity. Annealing temperatures were further optimised after running 
the reactions under temperature gradient ± 3°C from the predicted annealing temperature 
according to the formula above. 
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Figure 2.3.3.1 PCR amplification.  
Template DNA is denatured at 95°C to give single-stranded DNA. The reaction is then cooled 
to ~50-60°C to allow annealing of primers onto template strands. DNA polymerase then 
recognises the 5’ end of primers and extends DNA in a 5’ to 3’ direction to produce a new 





PCR master mixes of total 19μl containing Promega Go-Taq® Flexi DNA Polymerase, MgCl2 
and specific primers were prepared in DNase/RNase-free Eppendorf tubes according to Table 
2.3.3.1. 1μl of target cDNA, or H2O as a negative control, was added to the PCR master 
mixture, which was then vortexed and loaded onto a thermal cycler. PCR reactions proceeded 
as described above using primer sequences, annealing temperature, number of PCR cycles and 
predicted product size as listed in Table 2.3.3.2. 
 
After the reactions were complete, 8μl of PCR products were loaded on a 1.8% agarose gel 
containing 5μg/ml ethidium bromide and separated by electrophoresis (70V, 40 minutes). The 
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gel was visualised under UV light after electrophoresis. The size of each product was 
compared against a Promega 100bp DNA ladder containing 100bp fragments of DNAs 
between 100-1,000bp. The size of each product was then compared against the predicted size 










 Flexi Buffer 4μl -- 
DNase/RNase-free H2O 10.8μl -- 
cDNA or DNase/RNase-free H2O 1μl -- 
Forward primer (100μM) 1μl 5μM 
Reverse primer (100μM) 1μl 5μM 
GoTaq DNA Polymerase (5U/μl) 0.2μl 0.05U/μl 
dNTPs (10mM) 0.8μl 0.4mM 
MgCl2 (25mM) 1.2μl 1.5mM 
 






















60°C 38 60bp 
Table 2.3.3.2 PCR product information. 
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2.5 Protein expression 
2.5.1 Protein extraction 
MIN6 cells were maintained as monolayers in 10cm Petri dishes up to 75% confluency and 
then harvested by trypsinisation and washed with PBS. Mouse and human islets were 
maintained in culture, pelleted and washed with PBS. Cell lysis buffer supplemented with 
phosphatase and protease inhibitors (Table 2.4.1.1) was added to pelleted MIN6 cells and islets, 
followed by brief sonication on ice to facilitate lysis (15s, 4~6μ). Samples were centrifuged at 
10,000 rpm for 1 minute at 4°C and supernatants were transferred to fresh 0.5ml pre-chilled 
Eppendorf tubes. 5-10μl of samples were used for protein content quantification (Section 2.4.2) 
and the remaining samples were kept at -20°C in 4x NuPAGE
®
 sample buffer containing 
denaturing agents, prior to electrophoresis on polyacrylamide gels (Section 2.4.3).  
 
 
Material Amount Enzyme Name Final Concentration 
RIPA buffer (Sigma) 10ml -- -- 
Phosphatase inhibitors 
tablet (Roche PhosSTOP 
tablet) 
1 tablet 
Calf Alkaline Phosphatase 
Potato Acidic Phosphatase 






















Table 2.4.1.1 Cell lysis buffer. 
Phosphatase inhibitors and protease inhibitors tablets were added to 10ml RIPA buffer and 
kept on ice to allow complete dissolution. Prepared cell lysis buffer can be stored at 4°C for up 
to 4 weeks. 
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2.5.2 BCA protein content quantification assay 
Thermo Scientific bicinchoninic acid (BCA) protein assay reagent was used to determine 
protein content of samples obtained after protein extraction. In brief, protein in an alkaline 




 and BCA will react with the reduced cation to form the 
BCA/Cu
1+
 complex. The complex is water-soluble and exhibits a strong linear absorbance at 
550-570nm with increasing protein concentrations.   
 
Protein samples were assayed at dilutions of 1 in 10 and 1 in 100 in cell lysis buffer, together 
with a series of reference standards (0, 0.03125, 0.0625, 0.125, 0.25, 0.5, 1 and 2mg/ml) 
prepared by serial dilution of 2mg/ml BSA in cell lysis buffer. 25μl of standards and samples 
were added to designated wells in triplicate on a 96-well plate. 200μl of BCA working solution 
(BCA solution A to BCA solution B: 50:1) was added to each well and solutions were mixed 
by placing on a plate shaker for 30 seconds. The plate was then incubated at 37°C for 30 
minutes before reading on a Chameleon plate reader on an absorbance setting of 562nm. 
Sample protein concentrations were estimated based on a standard curve of absorbance versus 
protein concentration (Figure 2.4.1.1). 
Chapter 2 Methods 




Figure 2.4.1.1 Typical standard curve for the BCA protein assay. 
The absorbance of each set of standards (in triplicate) is measured at 562nm using a plate 
reader. A standard curve is then generated by plotting the average absorbance against the 
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2.5.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is carried out to separate proteins according to their molecular weights across an 
electric field. Sodium dodecyl sulphate (SDS) is an anionic detergent that will unfold proteins 
into their primary structures and apply them with a negative charge. When an electric field is 
applied, negatively charged proteins migrate towards the cation pole through a porous gel 
matrix of polyacrylamide. The percentage of polyacrylamide determines the efficiency of 
protein mobility resulting in a fractionation according to their mass-to-charge ratio. The Life 
Sciences Technology NuPAGE Bis-Tris electrophoresis system was used here. Pre-determined 
amounts of proteins were loaded onto a pre-made 10% Bis-Tris-HCl buffered (pH 6.4) 
polyacrylamide gel. The gel was then secured in the NuPAGE mini cell apparatus and MOPS 
running buffer containing antioxidant was added to the inner chamber (Table 2.4.3.1). The 
outer chamber was filled with approximately 600ml MOPS running buffer before the gel was 
run at 200V for 70 minutes. A Rainbow
®
 coloured protein molecular weight marker containing 
a mixture of coloured proteins of a variety of sizes was loaded and run in parallel to the sample 










MOPS 209.3 g/mol 104.6g 1M 
Tris Base 121.1 g/mol 66.6g 1M 
SDS 288.4 g/mol 10g 69.3mM 
EDTA 292.2g/mol 3g 20.5mM 
Table 2.4.3.1 Preparation of 20x MOPS running buffer. 
Reagents listed above were first dissolved in 400ml DI H2O and adjusted to a final volume of 
500ml. the 20xMOPS running buffer is kept at 4°C and diluted 1 in 20 with DI H2O before use. 
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2.5.4 Western blotting 
After SDS-PAGE, the separated proteins are transferred onto a polyvinylidene difluoride 
(PVDF) membrane to allow blotting with suitable antibodies. The transfer procedure is carried 
out by technique known as Western blotting in which the PVDF membrane and 
polyacrylamide gel are placed in between two layers of transfer buffer-soaked (Table 2.4.4.1) 
filter paper and an electric current is applied to pull proteins from the gel onto the PVDF 
membrane (Figure 2.4.4.1).  
 
After transferring the proteins, non-specific binding sites on the membrane were blocked by 
incubating it in a protein-rich blocking buffer (5% skimmed milk powder dissolved in Tris-
buffered Saline (TBS)-Tween) for 1 hour at room temperature. After this, the protein of 
interest was immunoblotted by incubating the membrane (16 hours, 4°C) in blocking buffer 
containing primary antibody raised against the target protein (1:160 dilution for the anti-
GPR55 primary antibody).  
 
 
Figure 2.4.4.1 A diagrammatic representation of the polyacylamide gel/PVDF membrane 
blotting module assembly. 
The PVDF membrane is placed on top of the gel and both are sandwiched between filter 
papers and blotting pads, pre-soaked in transfer buffer. The gel/membrane assembly is placed 
in the module such that the gel is closest to the cathode plate. When an electric current is 
applied, proteins are transferred from the gel to the PVDF membrane. 
 
Chapter 2 Methods 
Role of the novel cannabinoid receptor GPR55 in islets of Langerhans 65 
 
After primary antibody incubation, the membrane was washed with TBS-Tween buffer and 
blocking buffer to remove unbound primary antibody. The membrane was further incubated 
for 1 hour in blocking buffer supplemented with horseradish peroxidase-conjugated secondary 
antibody (1:7,500 dilution for anti-rabbit secondary antibody) at room temperature. The 
membrane was washed again with TBS-Tween buffer before detecting immunoreactive 
proteins using a chemiluminescent detection method following addition of enhanced 
chemiluminescent (ECL) reagents. Light signals emitted by the secondary antibody were 
captured by photographic film and detected immunoreactive proteins were compared against 
migration of the Rainbow
®






DI H2O 849ml 
20x NuPAGE transfer buffer 50ml 
NuPAGE sample antioxidant 1ml 
Methanol 100ml 
Table 2.4.4.1 Preparation of 1x Transfer Buffer. 
Reagents listed above were mixed together to give 1l of 1x Transfer Buffer for Western 
blotting. 1x Transfer Buffer is stored at room temperature. 
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2.6 Measurement of second messenger generation 
2.6.1 Calcium microfluorimetry 
The single cell calcium microfluorimetry technique was used in this thesis to investigate 
changes in [Ca
2+
]i in MIN6 cells and mouse and human islet cells. Fura-2 AM, a fluorescent 
dye, was used to measure change in intracellular calcium concentrations since its peak 
excitation wavelength changes from 380nm to 340nm after binding to divalent cations. 
Emitted fluorescent signals from Fura-2 AM were recorded at 510nm and the ratio of changes 




Approximately trypsinised 30,000 MIN6 cells in 100μl of serum-free DMEM were seeded 
onto 2.2cm circular acid/ethanol-washed sterile glass cover-slips. 50-80 mouse or human islets 
were first dissociated using Cell Dissociation Solution before being resuspended in 40μl 
serum-free RPMI and seeded onto Cell-Tak
®
-coated cover-slips (prepared as in Table 2.6.1.1). 
Each cover-slip with cells were incubated in culture in one well of a 6-well plate at 37°C to 
allow cell adhesion. After 2 hours incubation, 2ml of DMEM (MIN6) or RPMI (islets) 
supplemented with 10% FBS was added to each well and cells were then cultured overnight. In 
the next day, the cells were incubated in DMEM or RPMI containing 5μM Fura-2 AM for at 
least 30 minutes before the experiments. The cover-slip with Fura-2-loaded cells was placed 
onto a 37°C-heated stage of a fluorescence microscope and cells were treated with different 
compounds through a perifusion system. A charge coupled device digital camera recorded 
signals emitted while switching exciting emission between 340nm and 380nm. Data were 
recorded as the ratio of 340nm:380nm by OptoFluor software to indicate fluctuations of [Ca
2+
]i. 
A physiological salt solution (Gey and Gey, 1936) (Table 2.6.1.2) containing 2mM glucose 
was used to establish a stable baseline of [Ca
2+
]i and ATP, carbachol and/or tolbutamide were 
administered at the end of experiments as positive controls. 10μM O-1602, 5μM LPI and 1M 
CBD were used as these concentrations have been previously shown to modify [Ca
2+
]i in other 
cell types (Oka et al., 2007; Waldeck-Weiermair et al., 2008; Whyte et al., 2009). 
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 Adhesive Reagent 
(in 5% acetic acid) 
10μl 
0.1M NaHCO3 (pH 8) 285μl 
1M NaCl 5μl 





 solution was made by the mixing reagents above in a 0.5ml Eppendorf tube and 1M 
NaCl was added immediately before the solution was deposited onto a 2.2cm circular 
acid/ethanol-washed sterile glass cover-slip. Cell-Tak
®
 protein comes out of solution and 
spontaneously adsorbs to the cover-slips upon changing the pH from 2.4 to neutral. Cell-Tak
®
 
solution was kept on cover-slips at room temperature for 20 minutes to allow adsorption. 
Coated cover-slips were then washed twice with sterile DI H2O, air dried and stored at 4°C 







Amount for 2l 
Final 
Concentration 
NaCl 58.4g/mol 26g 111mM 
KCl 74.6g/mol 1.48g 5mM 
NaHCO3 84.0g/mol 9.08g 27mM 
MgCl2.6H2O 203.3g/mol 0.84g 1mM 
KH2PO4 136.1g/mol 0.12g 0.22mM 
MgSO4.7H2O 246.5g/mol 0.28g 0.28mM 
Table 2.6.1.2 Preparation of 2x Gey and Gey buffer. 
The Reagents listed above were dissolved in ~1.5l DI H2O and adjusted to 2l with DI H2O. 
The final pH should be ~8.4 before being diluted 1 in 2 in DI H2O for use. To make 1x 
working buffer for calcium microfluorimetry experiments, HEPES and CaCl2 solution were 
added giving final concentrations of 10.5mM and 2mM, respectively. The pH of the buffer was 
adjusted to 7.4 using 1M HCl. 
 
 
Chapter 2 Methods 
Role of the novel cannabinoid receptor GPR55 in islets of Langerhans 68 
 
2.6.2 RhoA activation assay 
The RhoA Activation (Pull-down) Assay Kit
TM
 from Cytoskeleton Inc. was used to measure 
activity of the small RhoA GTPase in MIN6 cells. The Rho binding domain (RBD) of Rho 
effector rhotekin protein binds specifically to GTP-bound RhoA and it is genetically-modified 
to be expressed as a GST-fusion protein bound to glutathione-sepharose beads. This allows 
‘pull-down’ of activated RhoA and the amount of activated protein can be determined using 
SDS-PAGE and Western blotting analysis (Figure 2.6.2.1). 
 
Serum-starved MIN6 cells were maintained as monolayers in 10cm Petri dishes between 50-
70% confluency and were treated with a physiological salt solution (Table 2.6.1.1) containing 
2mM glucose or 20mM glucose, in the presence or absence of agonist of interest for 10 
minutes. Petri dishes were immediately placed on ice and protein extractions were carried out 
as described in Section 2.4.1. 10μl of extracted samples were removed for protein content 
quantification (Section 2.4.2) and the remaining samples were immediately snap-freezed in 
liquid nitrogen to avoid lost of RhoA activity. Samples were kept at -80°C and were defrosted 
in a 37°C water bath prior to use. 50μg of rhotekin-RBD beads was added to each sample and 
the mixtures were incubated at 4°C on a rotator for 1 hour. Beads were then pelleted by 
centrifugation at 10,000 rpm at 4°C for 3 minutes. Supernatants were carefully removed and 
the beads were washed once with wash buffer before adding the beads to 15μl NuPAGE® 
sample buffer. The samples were boiled for 2 minutes before being analysed by SDS-PAGE 
and Western blotting (primary antibody: anti-RhoA, 1:500 dilution, w/v; secondary antibody: 
anti-mouse, 1:5,000 dilution) (Section 2.4.3 and 2.4.4).  
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Figure 2.6.2.1 Schematic of RhoA Activation (Pull-down) Assay. 
Rhotekin-RBD affinity beads were added to cell lysates and bound specifically to GTP-bound 
RhoA. Beads were then collected by centrifugation and bound RhoA was eluted from pelleted 
beads in SDS buffer. RhoA activity levels were then analysed by western blot using an anti-
RhoA antibody. The amount of immunoreactive proteins reflected the amount of active RhoA 
in the original cell lysates. Diagram adapted from Cytoskeleton Inc. RhoA Activation Assay 
Kit
TM
 Manual (www.cytoskeleton.com/bk036). 
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2.7 Measurement of insulin secretion  
2.7.1 Perifusion 
Perifusion experiments were performed to measure dynamic insulin secretion from isolated 
mouse and human islets. The perifusion apparatus was set up in a temperature-controlled room 
at the optimal temperature for insulin secretion (37°C) and it consists of 16 chambers each 
containing a 1μm filter to retain the islets (Jones et al., 1986). Mouse or human islets were 
handpicked using a Gilson pipette into each chamber and pre-perifused for ~70 minutes with 
physiological salt buffer (Gey and Gey, 1936) containing 2mM glucose (Table 2.7.1.1). The 
pH of the buffer was adjusted to 7.4 by passing 95%CO2/5%O2 gas through the NaHCO3-
buffered solution. Islets were then perifused with physiological salt buffer supplemented with 
different concentrations of glucose and compounds of interest at a constant rate (0.5ml/min) 
using a peristaltic pump. Perifusates were collected every 2 minutes from series of tubes 
connected to the chambers and samples were assayed for insulin content by radioimmunoassay 
(Section 2.7.2).  
 
Reagent Amount for 2l Final Concentration 
2x Gey and Gey buffer 1l -- 
DI H2O 1l -- 
Glucose 0.72g 2mM 
BSA 1g 0.5g/l 
CaCl2 (1M) 4ml 2mM 
Table 2.7.1.1 Preparation of Gey and Gey buffer for perifusion. 
2x Gey and Gey buffer was prepared according to Table 2.6.1.1 and diluted 1 in 2 with DI H2O. 
The prepared solution was first buffered to pH 7.4 using 95%CO2/5%O2 before adding the 
reagents listed above.  
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2.7.2 Insulin radioimmunoassay 
Radioimmunoassay (RIA) uses a specific antibody to measure the amount of an antigen of 
interest in vitro. RIA was first applied to measure insulin concentration in 1960 (Yalow and 
Berson, 1960) and an assay based on the same principles were used in this thesis. The 
molecular basis of insulin RIA is competitive binding of radiolabelled insulin (Ag*) or 
unlabelled insulin (Ag) to a rat anti-insulin antibody (Ab). A fixed, rate-limiting concentration 
of Ab was incubated with a mixture of 
125
I-insulin (Ag*) and defined concentrations of insulin 
(as standards) or unknown concentrations of insulin (as samples). The mixture was kept at 4°C 
for 48 hours to allow binding equilibrium between antibody and Ag* or Ag as follows: 
 
By keeping Ab and Ag* constant, the concentration of Ab:Ag* will vary according to the 
concentration of Ag. A standard curve can be plotted from which the insulin content of the 
samples can be determined. 
 
In order to prepare a standard curve, standards of various mouse insulin concentrations (0.04, 
0.08, 0.16, 0.32, 0.64, 1.25, 2.5, 5 and 10ng/ml) were prepared by serial dilution of 10ng/ml 
insulin stock in borate buffer (Table 2.7.2.1). 100μl of insulin standards and samples were 
added to 200μl of borate buffer containing 125I-insulin tracer (total activity: 10,000 count per 
minute (cpm)) and anti-insulin antibody (1:10,000 dilution). When used at a final dilution of 
1:10,000, the anti-insulin antibody had a detection limit of 8pg of insulin per tub, with intra- 
and inter-assay coefficients of variants of 5.2 and 14%, respectively as described before (Jones 
et al., 1988). Standards were assayed in triplicate and samples were assayed in duplicate. After 
48 hours of incubation at 4°C, 1ml of precipitant (12% polyethylene glycol) was added before 
centrifugation (3,000rpm at 4°C, 15 minutes) to separate bound Ab:Ag* complexes from free 
Ag* molecules. Supernatant was aspired off and the radioactivity of pellet was read using a 
Packard Wizard γ counter. A standard curve of radioactivities (cpm) from bound Ab:Ag* 
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against insulin concentrations (ng/ml) was constructed and insulin contents of test samples 
were calculated from this curve by the γ counter software (Figure 2.7.2.1). 
 
       
Figure 2.7.2.1 Typical standard curve for the insulin RIA. 
Radioactivity (cpm) of each set of standards in triplicate was measured by a γ-counter and was 
plotted against corresponding insulin concentration to generate a standard curve. The insulin 
concentration axis was expressed as logarithm of 10 to allow linearisation of the standard 









Amount for 2l 
Final 
Concentration 
Boric acid 61.8g/mol 16.5g 133mM 
NaOH 40.0g/mol 5.4g 67.5mM 
EDTA 292.2g/mol 7.4g 10mM 
Figure 2.8.1.1 Preparation of Borate buffer.  
The reagents listed above were dissolved in ~1.8l of DI H2O. The pH was adjusted to 8 with 
concentrated HCl and the volume was made up to 2l with DI H2O. 2g BSA was added before 
the solution was stored at 4°C. 
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2.8 Measurement of caspase activity  
The Promega Caspase-Glo
®
 3/7 Assay is a luminescent assay that measures cell apoptosis in 
vitro. Cells in suspension were first transferred into wells of a 96-well cell culture plate 
followed by addition of the Caspase-Glo
®
 3/7 reagent. Cells were lysed immediately and 
proluminescent capase-3/7 substrates in the reagent were cleaved enzymatically by active 
caspase-3 and -7 to release aminoluciferin. Aminoluciferin is a substrate of luciferase in the 
reagent to produce light. Amount of luminescent signals generated are proportional to the 
apoptosis level of lysed cells and it was recorded by a Veritas Microplate Luminometer.  
 
Approximately 40-60 mouse islets were incubated in 2ml of RPMI medium supplemented with 
compounds of interest in a 35mm Petri dish for 48 hours under standard cell culture conditions. 
A cytokine cocktail (Table 2.8.1.1) was added to groups of islets 20 hours prior to the end of 
the incubation period to induce apoptosis. After 48 hours incubation, 8-11 sets of 3 islets were 
picked in 50μl RPMI medium and transferred into wells of a 96-well cell culture plate. 
Triplicates of 50μl of fresh RPMI medium were also transferred to 3 different wells for 
reference of background reading. 50μl of Promega Caspase-Glo® 3/7 reagent was added to 
each well and the plate was mixed for 1 minute on a plate shaker. The plate was then incubated 
at room temperature for 1 hour before acquisition of luminescent signals using the Veritas 
Microplate Luminometer. The value of mean background signal readings from RPMI medium 
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Amount Final Concentration 
IL-1β 100U/μl 1μl 0.05U/μl 
TNF-α 1000U/μl 2μl 1U/μl 
INF-γ 1000U/μl 2μl 1U/μl 
Table 2.8.1.1 Preparation of cytokine cocktail.  
5μl of cytokine cocktail was prepared by mixing all reagents listed above in a 0.5ml Eppendorf 
tube. The mixture was then transferred into the corresponding 35mm Petri dish containing 
islets and 2ml RPMI medium in the absence or presence of compounds of interest. Islets were 





2.9 Statistical analysis 
Numerical data are expressed as mean ± standard error of mean (SEM) in this thesis. All 
statistical analyses was performed using Student’s t-tests and P-values of <0.05 were 
considered statistically significant when comparing between different sets of data. For time 
course experiments where dynamic changes in intracellular calcium and insulin secretion were 
measured, data of the peak responses after addition of test compounds were statistically 
compared against the data at the time before the addition of the corresponding compounds. 
 
Chapter 3 Expression of GPR55 by islets of Langerhans 








Chapter 3 Expression of GPR55 
by islets of Langerhans 
Chapter 3 Expression of GPR55 by islets of Langerhans 
Role of the novel cannabinoid receptor GPR55 in islets of Langerhans 76 
 
CHAPTER 3 EXPRESSION OF GPR55 BY ISLETS OF LANGERHANS 
3.1 Introduction 
The endocannabinoid system (ECS) consists of phospholipid-derived endocannabinoids, the 
G-protein coupled cannabinoid receptors and enzymes responsible for endocannabinoid 
biosynthesis and degradation. Three subtypes of cannabinoid receptors have been identified in 
mammals, including CB1 (Matsuda et al., 1990), CB2 (Munro et al., 1993) and the novel 
cannabinoid receptor GPR55 (Baker et al., 2006). The CB1 receptor is widely expressed in the 
central nervous system (Pertwee et al., 2010), as well as in some peripheral tissues including 
testes, prostate, heart, lung and bone marrow (Howlett et al., 2002). The CB2 receptor is 
predominantly found in immune cells and it is expressed at a low level in other tissues (Munro 
et al., 1993; Van Sickle et al., 2005; Walter et al., 2003). High levels of GPR55 mRNA 
expression have been detected in the central nervous system and in peripheral tissues, such as 
adrenals, jejunum, ileum and spleen (Ryberg et al., 2007; Wu et al., 2013). GPR55 mRNA has 
also been found in various cells types, including endothelial cells and Schwann cells (Daly et 
al., 2010), osteoclasts and osteoblasts (Whyte et al., 2009), and several cancer cell lines 
(Andradas et al., 2011; Ford et al., 2010; Pineiro et al., 2011). GPR55 protein expression was 
detected by immunoblotting in human ovarian cancer cell line OVCAR3, human prostate 
cancer cell lines PC-3 and DU145 (Pineiro et al., 2011).   
 
The ECS has been shown to play an important role in regulating energy balance and metabolic 
homeostasis, and most studies have focusing on signalling via CB1 receptors in both central 
and peripheral tissues, including liver, adipose tissue, gastrointestinal tract, skeletal muscle and 
pancreas (Li et al., 2011b). A number of studies have shown that the CB1 receptor is expressed 
by islets of Langerhans, but its cellular localisation within islets remains controversial 
(Bermudez-Silva et al., 2008; Juan-Pico et al., 2006; Li et al., 2011a; Li et al., 2010; Nakata 
and Yada, 2008; Tharp et al., 2008). Less is known about the CB2 receptor due to its low 
expression level in non-immune cells, such as islet endocrine cells (Nakata and Yada, 2008; 
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Starowicz et al., 2008; Tharp et al., 2008). However, some studies have detected expression of 
the CB2 receptor in islets, but there is no consistency in reports on the localisation of this 
receptor (Bermudez-Silva et al., 2008; Juan-Pico et al., 2006; Li et al., 2010; Starowicz et al., 
2008). The role of GPR55 in metabolic regulation has recently emerged: GPR55 mRNA 
expression has been detected in human visceral and subcutaneous adipose tissues, as well as in 
livers retrieved post mortem from both patients and normal controls (Moreno-Navarrete et al., 
2012). Another study has demonstrated that GPR55 mRNA expression was detectable in rat 
islets at a higher level than in rat liver and adipose tissue and its expression co-localised with 
islet β-cells, but not with α- or δ-cells (Romero-Zerbo et al., 2011).   
 
The aim of the experiments described in this chapter was to investigate the expression of 





cDNAs from MIN6 cells and from mouse and human islets were obtained as described 
(Section 2.3.1). RT-PCR was performed using the primers designed for complementary 
binding with mouse and human GPR55 mRNAs. Detailed primer sequences, annealing 
temperatures and the number of amplification cycles are listed in Table 2.3.3.2. The PCR 
products were visualised under UV light after electrophoretic separation on 1.8% agarose gels 
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3.2.2 SDS-PAGE and Western blotting 
Protein samples of MIN6 cells, islets isolated from WT and GPR55 KO mice and human islets 
were prepared as described in Section 2.4.1 and protein content of each sample was quantified 
by the BCA assay (Section 2.4.2). Protein separation was carried out via SDS-PAGE and 
fractionated proteins were probed using a commercially available antibody raised in rabbit 
against the human GPR55 receptor. Immunoreactitivies of GPR55 receptors were detected 
using enhanced chemiluminescence (ECL) after probing with an anti-rabbit secondary 
antibody (Section 2.4.3 and Section 2.4.4).  
 
3.3 Results 
3.3.1  Detection of mRNAs encoding GPR55 in MIN6 cells, mouse and human islets. 
RT-PCR experiments identified expression of mRNA coding for the GPR55 receptor when the 
templates of cDNAs from MIN6 cells, mouse and human islets were used in amplifications 
(Figure 3.3.1.1). All PCR products were of the predicted size of 60bp and no product was 
amplified when cDNA was substituted with molecular biology grade water. Sequencing of the 
amplicons (by Source Bioscience) indicated 97-99% homology to the corresponding predicted 
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Figure 3.3.1.1 Detection of mRNAs encoding GPR55 in MIN6 cells, mouse and human 
islets. 
Products of RT-PCR reactions were visualised shown under UV light after separation on a 
1.8% agarose gel. Amplicons of the correct size (60bp) coding for GPR55 were amplified from 
MIN6 cells, mouse and human islet cDNAs. Molecular biology grade water was used as a 
negative control. The results shown here are representative of data collected from cDNAs 




3.3.2  Protein expression of GPR55 in MIN6 cells, mouse and human islets. 
GPR55 is composed of 319 amino acids and has an expected molecular weight of 37kDa, and 
human GPR55 has 78% sequence homology with the murine protein (Ryberg et al., 2007). 
Expression of GPR55 in islets was confirmed by immunoblotting analysis shown in Figure 
3.3.2.1, which identified an immunoreactive protein of approximately 37kDa in protein extract 
from MIN6 cells, islets from WT mice and human islets, but not in protein extract from islets 
isolated from GPR55 KO mice. It can be seen that two additional immunoreactive proteins 
were also detected in the MIN6 cell and islet extract from WT mice, with molecular weights of 
33kDa and 50kDa. The 33kDa protein might be a product of GPR55 degradation or it may 
represent a protein recognised by the GPR55 antibody through non-specific binding. Post-
translational modifications, such as glycosylation can retard protein electrophoretic migration, 
and this may have resulted in the 50kDa immunoreactive protein that was identified. The 
33kDa and 50kDa immunoreactive proteins were not detected in the islet extract obtained from 
GPR55 KO mice, confirming that they were either degradation or post-translational 
modification products of GPR55. In addition, an immunoreactive protein with molecular 
weight of 90kDa was identified in all samples and this is likely to have occurred through non-
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specific binding of the primary antibody, since the same protein was also detected in islet 
extracts from GPR55 KO mice. 
 
The commercially available anti-GPR55 antibody used here was raised against a human 
GPR55 protein fragment (antigen alignment sequence: ILLGRRDHTQDWV) and this 
sequence is not conserved in murine GPR55 (antigen alignment sequence: 
ILL_RRPDSTEDWV, underlined amino acids are not matched to the human GPR55). This 
may explain why a greater amount of immunoreactive protein was detected in human islets 
compared to the protein-matched MIN6 and mouse islet samples shown in Figure 3.3.2.1. 
 
 
Figure 3.3.2.1 Protein expression of GPR55 in MIN6 cells, mouse and human islets. 
An anti-human GPR55 antibody was used to identify GPR55 receptor expression in MIN6 
cells, islets isolated from WT and GPR55 KO mice, and human islets. 20μg of each sample 
were loaded onto 10% polyacrylamide gels and immunreactive proteins were detected by ECL. 
The blots shown here are representative of 4 experiments using samples obtained from 5 
populations of MIN6 cells, 3 WT and GPR55 KO mice and 2 human islet donors. 
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3.4 Discussion 
GPR55 has been suggested to play important roles in the cardiovascular system, bone 
metabolism, inflammation, neuronal function and cancer proliferation. (Andradas et al., 2011; 
Daly et al., 2010; Obara et al., 2011; Pineiro et al., 2011; Staton et al., 2008; Whyte et al., 
2009). Very little is known about the role of GPR55 in islets, apart from two papers suggested 
that GPR55 regulates insulin secretion from islets (McKillop et al., 2013; Romero-Zerbo et al., 
2011). However, more research is needed to validate the finding in rodents and to explore the 
importance of GPR55 in the regulation of human metabolism. The aim of this thesis is to 
identify the roles of GPR55 in islet functions. So it was therefore important to investigate if the 
receptor is expressed by MIN6 cells, mouse and human islets which are the models that will be 
used in subsequent functional studies in the following chapters.  
 
The data in this chapter, showing that GPR55 is expressed at both mRNA and protein levels in 
MIN6 cells, mouse and human islets, are consistent with the previous study and demonstrate 
for the first time, that GPR55 is expression by human islets. The immunoblotting analysis, 
where products larger and smaller than the 37kDa predicted sequence of GPR55 were detected, 
indicate the possible presence of GPR55 degradation and post-translational modification 
products in mouse islets. It will be interesting to perform parallel experiments with protein 
extracts from other mouse tissues to investigate whether these findings are islet-specific. An 
earlier study has demonstrated that GPR55 mRNA is expressed by rat islets and 
immunostaining analysis has detected GPR55 in β-cells from paraffin-fixed rat pancreas 
(Romero-Zerbo et al., 2011). This is in agreement with another immunostaining experiment 
showing that mouse β-cells expressed GPR55, while there was no evidence of the receptor in 
α-cells (McKillop et al., 2013).  
 
Generation of second messengers, such as intracellular calcium, are common downstream 
signalling mechanisms of GPCRs in regulating islet functions and it has been shown that 
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GPR55 couples to Gq α protein to elevate intracellular calcium concentration (Ross, 2009; 
Sharir and Abood, 2010). In addition, GPR55 has been shown to activate another class of 
second messengers, Rho small GTPases, which are involved in reorganisation and remodelling 
of filamentous actin in the regulation of insulin release (Kalwat et al., 2013; Ross, 2009; Sharir 
and Abood, 2010). The following chapter presents data showing how the second messenger 
levels in islet cells change in response to pharmacological manipulations of GPR55.  
 
Chapter 4 Second messenger generation 
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CHAPTER 4 PHARMACOLOGICAL MANIPULATION OF GPR55 IN ISLETS:  
SECOND MESSENGER GENERATION 
 
4.1 Introduction 
Expression studies in the last chapter have shown that GPR55 is expressed by islets of 
Langerhans. In order to investigate if GPR55 plays a role in regulating islet functions, it is 
important to understand the signalling cascade downstream of GPR55 in islets. Studies in other 
cell types have suggested that GPR55 is coupled to either Gq or G12/13 α subunits (Ross, 
2009; Sharir and Abood, 2010). Activation of the Gq α subunit is linked to elevations in 
intracellular calcium ([Ca
2+
]i) through the PLC/PKC signalling pathway and it has been well 
established that activation of GPR55 stimulates generation of this second messenger (Ross, 
2009; Sharir and Abood, 2010). In addition, experiments using the GPR55-transfected human 
embryonic kidney cell line HEK293 have shown that pharmacological activation of GPR55 by 
cannabinoids and other phospholipid-derived compounds induced elevations in [Ca
2+
]i and 
pharmacological inhibition and siRNA-knockdown of GPR55 expression abolished these 
effects (Henstridge et al., 2010; Oka et al., 2007; Waldeck-Weiermair et al., 2008). Increases 
in [Ca
2+
]i after administration of GPR55 agonists were also reported in primary endothelial 
cells (Kargl et al., 2013), cultured neonatal cardiomyocytes (Yu et al., 2013), the PC-3 human 
prostate cancer cell line (Pineiro et al., 2011) and primary CA3 pyramidal cells (Sylantyev et 
al., 2013).  
 
The GPR55 agonist O-1602 is widely used as a specific activator of the receptor. It was able to 
elicit increases in [Ca
2+
]i (Sylantyev et al., 2013; Waldeck-Weiermair et al., 2008) and 
knockdown of GPR55 with siRNA diminished O-1602-induced Ca
2+
 signalling in endothelial 
cells (Waldeck-Weiermair et al., 2008). Moreover, lysophospholipid, lysophosphatidylinositol 
(LPI), was reported to unexpectedly activate GPR55 in 2007 (Oka et al., 2007) and 
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accumulating research has suggested that LPI is an endogenous GPR55 ligand (Ross, 2009; 
Sharir and Abood, 2010). However, it remains controversial that the effects of LPI on [Ca
2+
]i 
were mediated through GPR55. Thus, while some studies demonstrated that GPR55 inhibitors 
and knockdown of GPR55 gene abolished the effect of LPI on [Ca
2+
]i (Oka et al., 2007; 
Pineiro et al., 2011; Sylantyev et al., 2013; Waldeck-Weiermair et al., 2008), other studies 
reported GPR55-independent effects of LPI on [Ca
2+
]i (Bondarenko et al., 2010). Subsequent 
studies suggested that LPI regulated [Ca
2+





(Bondarenko et al., 2011a, b).  
 
In addition to activating the Gq α subunit, GPR55 was also suggested to be linked to the 
G12/13 α subunit by the demonstration that an anti- G12/13 peptide was able to reduce O-
1602-induced GPR55 signalling in a concentration-dependent manner (Ryberg et al., 2007). 
The G12/13 α subunit is known to activate a second messenger family of Rho small GTPases, 
including RhoA, Cdc42 and Rac1 (Fromm et al., 1997). It has been reported that O-1602-
induced activation of GPR55 caused RhoA activation in HEK293 cells and osteoclasts 
(Ryberg et al., 2007; Whyte et al., 2009), and these effects were inhibited by antagonising 
GPR55 and in vivo knockdown of GPR55 (Ryberg et al., 2007; Whyte et al., 2009). LPI-
induced activations of RhoA were also demonstrated separately in osteoclasts and also in the 




]i are involved in both first and second phases of glucose-induced insulin 
secretion (Jing et al., 2005; Rorsman and Renstrom, 2003; Schulla et al., 2003). Some receptor 
ligands such as acetylcholine can also potentiate glucose-induced insulin secretion from β-cells 
via activating Gq-coupled GPCRs and elevating [Ca
2+
]i. In addition, increased calcium influx 
is linked to the regulation of transcription factors important to islet survival, such as CREB and 
NFAT (Liu et al., 2012; Soleimanpour et al., 2010). Interestingly, some studies suggest that 
RhoA and its downstream effector Rho-associated kinase (ROCK) have a negative 
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consequence on insulin secretion, but their roles on other islet functions remain unknown 
(Hammar et al., 2009; Tomas et al., 2010). In order to find out the roles of GPR55 in islets, it 
is important to understand how this receptor regulates these two second messenger pathways in 
islets.  
 
Experiments described in this chapter therefore investigated the effects of O-1602, LPI and the 
GPR55 antagonist cannabidiol (CBD) on regulating [Ca
2+
]i and RhoA in MIN6 β-cells and 
primary mouse and human islets. The specificity of these agents on modulating [Ca
2+
]i was 
also explored using islets isolated from GPR55 KO mice.  
 
4.2 Methods 
4.2.1 Calcium microfluorimetry  
Approximately 30,000 MIN6 β-cells (p31-40) were seeded onto 2.2cm circular acid/ethanol-
washed Cell-Tak
®
-coated sterile glass coverslips (Section 2.6.1). Around 100 islets isolated 
from WT and GPR55 KO mice, or 100 isolated human islets, were dispersed using Cell 
Dissociation Solution before seeding in the same procedure for MIN6 cells. After 24 hours in 
culture, Fura-2 AM was added to the culture medium (final concentration: 5μM), and cells 
were incubated for 30 minutes prior to experiments. The Fura-2-loaded cells were then 
perifused with physiological buffer (Gey and Gey, 1936) in the presence of compounds of 
interest and appropriate positive controls. Cells were excited with 340nm and 380nm 
wavelengths and the fluorescence intensity, recorded at 510nm as a ratio of 340nm/380nm, 




4.2.2 RhoA activation assay 
MIN6 cells grown to 50~70% confluence in 90mm Petri dishes were serum-starved overnight 
in DMEM supplemented with 5mM glucose and penicillin / streptomycin. On the next day, 
DMEM was replaced with 10ml physiological buffer (Gey and Gey, 1936) containing 2mM or 
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20mM of glucose in the absence or presence of 10μM O-1602 and cells were incubated at 
37°C for 10 minutes. Petri dishes were immediately placed on ice and protein extractions were 
carried out as described in Section 2.4.1. 10μl of extracted samples were removed for protein 
content quantification (Section 2.4.2) and total RhoA activity measurements and the remaining 
samples were immediately snap-frozen in liquid nitrogen to avoid loss of RhoA activity. 
Samples were thawed in a water bath at 37°C, 50μg rhotekin-RBD beads was added to each 
sample and the mixtures were incubated at 4°C on a rotator for 1 hour. Beads were then 
pelleted by centrifugation and washed once with wash buffer before adding 15μl NuPAGE® 
sample buffer. The samples were then analysed by SDS-PAGE and Western blotting (primary 
antibody: anti-RhoA, 1:500 dilution; secondary antibody: anti-mouse, 1:5,000 dilution, Section 
2.4.3 and 2.4.4).  
 
4.3 Results 
4.3.1 Effects of pharmacological manipulation of GPR55 on [Ca
2+
]i in MIN6 cells. 
The effects of pharmacological manipulation of GPR55 on [Ca
2+
]i were first studied in MIN6 
cells. 10μM O-1602 and 5μM LPI were used as these concentrations have been previously 
shown to elevate [Ca
2+
]i (Oka et al., 2007; Waldeck-Weiermair et al., 2008). 1μM CBD since 
this concentration has previously been shown to inhibit O-1602- and LPI-mediated elevations 
in [Ca
2+
]i (Whyte et al., 2009). MIN6 cells were also challenged with two positive control 
agonists at the end of each experiment to demonstrate that they were still viable. The 
puringeric receptor agonist ATP (100μM) was used as a positive control for GPCR-mediated 
increases in [Ca
2+
]i via PLC activation in β-cells (Hauge-Evans et al., 2002; Squires et al., 
1995). In addition, tolbutamide (100μM) was used as another positive control since it is able to 
depolarise β-cell through inhibition of KATP-channel via interaction with the SUR1 subunit 
(Hatlapatka et al., 2009).  
Administration of ATP and tolbutamide caused immediate and reversible increases in [Ca
2+
]i 
in Fura-2-loaded MIN6 cells. The effect of ATP was transient since [Ca
2+
]i decreased toward 
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basal level before the withdrawal of ATP, while the effect of tolbutamide on [Ca
2+
]i was long 
lived. It is worth noting from Figure 4.3.1.1B and 4.3.1.1C that ATP- and tolbutamide-induced 
elevation in [Ca
2+
]i peaked at a similar amplitude when cells were exposed to ATP before 
tolbutamide. However, if the cells were treated with ATP after tolbutamide, only a small and 
transient [Ca
2+
]i increase was observed as illustrated in Figure 4.3.1.1A (64±19%, peak 
stimulation as a percentage of maximum response to 100μM tolbutamide, mean ± SEM, n=10). 
The reason for the reduced response to ATP may be that a limited amount of intracellular Ca
2+
 
was available after tolbutamide stimulation, via calcium-induced calcium release from the 
endoplasmic reticulum.  
 
Figure 4.3.1.1A demonstrates that 10μM O-1602 was able to induce a robust increase in [Ca2+]i 
in MIN6 cells (106±28%, of maximum response to 100μM tolbutamide, mean ± SEM, n=10). 
The response was maintained in the presence of O-1602 and returned towards basal after its 
removal. Further experiments, as shown in Figure 4.3.1.1B, demonstrated that 5μM LPI also 
caused a reversible and long-lived elevation in [Ca
2+
]i in MIN6 cells. However, amplitude of 
the response to LPI was considerably less than that of O-1602. (50±12%, of maximum 
response to 100μM tolbutamide, mean ± SEM, n=8).  
 
CBD has been reported to cause a small, but insignificant increase in [Ca
2+
]i in HEK293 cells 
overexpressing GPR55 (Lauckner et al., 2008), but it was suggested to be an antagonist of 
GPR55 in various studies where it inhibited the physiological effects of O-1602 and LPI (Li et 
al., 2013; Ryberg et al., 2007; Whyte et al., 2009). Before testing how CBD would affect O-
1602- and LPI-induced changes in [Ca
2+
]i, the effect of CBD alone on [Ca
2+
]i of MIN6 cells 
was studied first. Unexpectedly, addition of 1μM CBD resulted in elevation in [Ca2+]i in MIN6 
cells, which was slow in onset and slowly reversible after removal of CBD (Figure 4.3.1.1C, 
88±48% of maximum response to 100μM tolbutamide, mean ± SEM, n=17). The stimulatory 
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effect of CBD means that it cannot be used as an antagonist of GPR55 for measurement of 
Ca
2+
 in islet cells. 
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Figure 4.3.1.1 Effects of O-1602, LPI and CBD on [Ca
2+
]i in MIN6 cells. 
Fura-2-loaded MIN6 cells were perifused with physiological buffer containing 2mM glucose 
and supplemented with O-1602 (A), LPI (B), CBD (C) and appropriate positive controls 
(100μM ATP and 100μM tolbutamide), as shown. Changes in [Ca2+]i were measured by 
single-cell calcium microfluorimetry and expressed as a ratio of 340nm/380nm fluorescence. 
Results shown here are mean values of individual cells within a single field of view 
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4.3.2 Effect of pharmacological manipulation of GPR55 on [Ca
2+
]i in dispersed mouse islet cells 
from WT and GPR55 KO mice. 
The preceding data demonstrated that O-1602 increased [Ca
2+
]i in MIN6 cells so further 
experiments were performed to determine whether the agonist would be able to induce the 
same effect in mouse islet primary cells. Data presented here represent [Ca
2+
]i measurements 
from single cells due to the heterogeneity of responses recorded from dispersed mouse islet 
cells. Only approximately 50% of seeded cells responded to 20mM glucose, 500M carbachol 
and 100μM tolbutamide and they were considered to be islet β-cells, since they showed the 
characteristic changes in [Ca
2+
]i in response to these agonists. The results presented in Figure 
4.3.2.1A demonstrate that 10μM O-1602 was able to induced an increase in [Ca2+]i in 
dispersed mouse islet cells at 2mM glucose as it did in MIN6 cells. However, the effect was 
observed only in 50% of glucose/carbachol/tolbutamide-positive islet cells. In addition, Figure 
4.3.2.1C demonstrated that O-1602 was also able to potentiate glucose-induced increase in 
[Ca
2+
]i and 33% of β-cells responded to the agonist at 20mM glucose.  
 
In order to investigate if O-1602 acted specifically on GPR55 to mediate its effects on β-cell 
[Ca
2+
]i, further experiments were conducted using dispersed islet cells from GPR55 KO mice. 
Representative Ca
2+
 traces shown in Figure 4.3.2.1B and D show that O-1602 did not stimulate 
elevation in [Ca
2+
]i in the absence of GPR55 and analysis of all data indicated that only 7% of 
β-cells responded to O-1602 at 2mM glucose after GPR55 deletion, and none responded at 
20mM glucose. 
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Figure 4.3.2.1 O-1602 increases [Ca
2+
]i in islet β-cells from WT mice, but not in cells from 
GPR55 KO mice. 
Fura-2-loaded mouse islet cells were perifused with physiological buffer containing 2mM 
glucose and supplemented as shown. Addition of O-1602 (10μM, 4-6 min) at 2mM glucose 
caused an elevation in [Ca
2+
]i in β-cells from WT mice (A), but not in β-cells from GPR55 KO 
mice (C). Similar effects on [Ca
2+
]i by O-1602 (10μM, 15-17 min) at 20mM glucose were also 
observed from β-cells from WT mice (B), but not in β-cells from GPR55 KO mice (D). Islet β-
cells were characterised by responding to 20mM glucose, 0.5mM carbachol and 100μM 
tolbutamide. Results shown here are single cell calcium traces representing at least 10 cells 
from one experiment. E Percentage of β-cells from WT and GPR55 KO mice that responded to 
O-1602 at either 2mM or 20mM glucose. Data are representative of 4 separate experiments.  
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Further experiments were performed to investigate the effect of LPI on [Ca
2+
]i in β-cells from 
WT and GPR55 KO mice. Similar to O-1602, Figure 4.3.2.2A and B illustrated that 5μM LPI 
induced increases in [Ca
2+
]i at both basal and stimulatory glucose levels in β-cells from WT 
mice. The results here agreed with observations of the effects of LPI on [Ca
2+
]i in MIN6 cells 
at 2mM glucose from Figure 4.3.1.1B, but the magnitude of its effect was greater in dispersed 
mouse β-cells. The same proportion of β-cells (65%) responded to LPI at 2mM and 20mM 
glucose. In contrast to the lack of effects of O-1602 observed in β-cells from GPR55 KO mice, 
Figure 4.3.2.2C and 4.3.2.2D demonstrated that LPI induced evelations in [Ca
2+
]i at both 2mM 
and 20mM glucose in β-cells from the same group of mice. Figure 4.3.2.2E illustrated that, 
similar to the proportion of β-cells from WT mice that responded to LPI, 62% and 67% of β-
cells from GPR55 KO mice had elevations in [Ca
2+
]i after administration of LPI at 2mM and 
20mM glucose, respectively. 
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Figure 4.3.2.2 LPI increases [Ca
2+
]i in islet β-cells from both WT and GPR55 KO mice. 
Fura-2-loaded mouse islet cells were perifused with physiological buffer containing 2mM 
glucose and supplemented as shown. Addition of LPI (5μM, WT: 6-8 min; GPR55 KO: 5-7 
min) at 2mM glucose caused an elevation in [Ca
2+
]i in β-cells from both WT (A) and GPR55 
KO mice (C). Similar effects on [Ca
2+
]i by LPI (5μM, 14-16 min) at 20mM glucose were also 
observed in β-cells from WT (B) and GPR55 KO mice (D). Islet β-cells were characterised by 
responding to 20mM glucose, 0.5mM carbachol and 100μM tolbutamide. Results shown here 
are single cell calcium traces representing at least 10 cells from one experiment. E Percentage 
of β-cells from WT and GPR55 KO mice that responded to LPI at either 2mM or 20mM 
glucose. Data are representative of 4 separate experiments.  
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My experiments in MIN6 cells unexpectedly demonstrated that CBD was able to induce 
elevations in [Ca
2+
]i, inconsistent with its antagonising effects on GPR55 reported in other 
studies. To determine whether that stimulatory effects occurred via activation of GPR55, 
further experiments were performed using islets isolated from WT and GPR55 KO mice. 55% 
and 50% of β-cells from WT mice reponded to CBD with increases in [Ca2+]i at 2mM and 
20mM glucose, respectively (Figure 4.3.2.3 A and B). The magnitude of response observed at 
2mM glucose in β-cells is similar to that obeserved in MIN6 cells as shown in Figure 4.3.1.1C. 
These effects were still observed in β-cells from GPR55 KO mice, as illustrated in Figure 
4.3.2.3C and D. It is interesting to note that more β-cells from GPR55 KO mice (56% at 2mM 
glucose and 67% at 20mM glucose) responded to CBD with an elevation in [Ca
2+
]i (Figure 
4.3.2.3E)., possibly due to an upregulation of gene expression of the true target protein(s) of 
CBD after GPR55 deletion.  
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Figure 4.3.2.3 CBD increases [Ca
2+
]i in islet β-cells from both WT and GPR55 KO mice. 
Fura-2-loaded mouse islet cells were perifused with physiological buffer containing 2mM 
glucose and supplemented as shown. Addition of CBD (1μM, 6-8 min) at 2mM glucose caused 
an elevation in [Ca
2+
]i in β-cells from both WT (A) and GPR55 KO mice (C). Similar effects 
on [Ca
2+
]i by CBD (1μM, 18-20 min) at 20mM glucose were also observed in β-cells from WT 
(B) and GPR55 KO mice (D). Islet β-cells were characterised by responding to 20mM glucose, 
0.5mM carbachol and 100μM tolbutamide. Results shown here are single cell calcium traces 
representing at least 10 cells from one experiment. E Percentage of β-cells from WT and 
GPR55 KO mice that responded to CBD at either 2mM or 20mM glucose. Data are 
representative of 4 separate experiments. 
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4.3.3 Effect of activation of GPR55 on [Ca
2+
]i in dispersed human islets cells. 
Since O-1602 and LPI stimulated increases in [Ca
2+
]i in MIN6 cells and mouse β-cells, it was 
important to determine if these ligands also trigger the same responses in human islet cells. In 
order to further investigate the effect of O-1602 and LPI on regulating calcium handling in 
human islet cells, isolated human islets were dispersed as described in Section 2.6.1 and loaded 
with Fura-2 for calcium microfluorimetry. In accordance with the data generated from MIN6 
cells and mouse β-cells, Figure 4.3.3.1 shows that 10μM O-1602 and 5μM LPI were able to 
induce elevations in [Ca
2+
]i. similar to dispersed mouse islet cells, data presented here were 
also [Ca
2+
]i measurement from single cell due to the heterogeneity of responses recorded from 
dispersed human islet cells. The response of O-1602 in dispersed human islets cells was early 
onset and dismissed after O-1602 removal, but the magnitude of the effect was considerable 
smaller compared to that in MIN6 cells (Figure 4.3.1.1A) and mouse β-cells (Figure 4.3.2.1A). 
On the other hand, the response of LPI was also early onset, but maintained after the 
withdrawal of LPI. The magnitude of the effect of LPI at 2mM glucose was similar to 100μM 
tolbutamide in dispersed human islet cells, which was not observed in MIN6 cells (Figure 
4.3.1.1B) and mouse β-cells (Figure 4.3.2.2A). The effect of CBD on [Ca2+]i in dispersed 
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A Dispersed human islet cells with O-1602 
 
B Dispersed human islet cells with LPI 
 
Figure 4.3.1.1 Effect of O-1602 and LPI on [Ca
2+
]i in dispersed human islet cells. 
Fura-2-loaded dispersed human islet cells were perifused with physiological buffer containing 
2mM glucose and supplemented with O-1602 (A) and LPI (B) as shown. Changes in [Ca
2+
]i 
were measured by single-cell calcium microfluorimetry and expressed as a ratio of 
340nm/380nm fluorescence. Results shown here are single cell traces representative of at least 
12 cells within a single field from 2 different experiments. 100μM tolbutamide was used at the 
end of each experiment as a positive control. 
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4.3.4 Effect of O-1602 on RhoA small GTPase activation in MIN6 cells.  
Data presented so far have demonstrated that O-1602 is able to act via GPR55 to trigger 
increases in [Ca
2+
]i in islet cells, possibly by activating the Gq subunit. Other studies have 
suggested that GPR55 can also be coupled to the G12/13 subunit, which activates a class of 
second messenger known as Rho small GTPases. To determine if this is the case in islet cells, 
activities of RhoA, a key Rho small GTPase activated by GPR55 in other cells (Henstridge et 
al., 2009a; Obara et al., 2011; Ryberg et al., 2007; Whyte et al., 2009), were measured in 
serum-starved MIN6 cells after exposure to buffers supplemented with 20mM glucose and 
10μM O-1602. As shown in Figure 4.3.4.1, MIN6 cells maintained overnight in low glucose 
(5mM) and serum-free conditions expressed RhoA, but there was very low detectable RhoA 
activity. Exposure of MIN6 cells to 20mM glucose for 10 minutes induced RhoA activation, 
which was detected by immunoblotting after the pull-down assay described in Section 2.6.2 
(8.3 ± 3.7 fold increase in RhoA activity, mean ± SEM, n=3). Parallel experiments showed that 
10μM O-1602 failed to elicit RhoA activation at 2mM glucose, and, then at 20mM glucose, 
Figure 4.3.4.1B indicated that there was no significant change in fold increase of RhoA 
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Figure 4.3.4.1 O-1602 does not promote RhoA activation in MIN6 cells. 
MIN6 cells grown in low glucose (5mM) and serum-free conditions overnight were incubated 
with physiological buffer containing 2mM or 20mM glucose supplemented with or without 
10μM O-1602. Immunoblot (A) and fold change in RhoA activity relative to control (B) 
illustrated that 20mM glucose induced RhoA activation in MIN6 cells. No effect was observed 
when MIN6 cells were treated with O-1602 at 2mM glucose and 20mM glucose. Data is 
presented as mean ± SEM, n=3.  
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4.4 Discussion 
Research in other cell types has suggested that GPR55 is coupled to either Gq or G12/13 α 
subunits (Henstridge et al., 2009a; Lauckner et al., 2008; Ryberg et al., 2007). Activated Gq 
recruits phospholipase C β (PLCβ) to the cell membrane and activated PLCβ which then 
converts phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). IP3 diffuses into the cytosol and activates IP3 receptors to release Ca
2+
 
from the endoplasmic reticulum. It has been reported that pharmacological activation of 
GPR55 resulted in elevations of [Ca
2+
]i (Sylantyev et al., 2013; Waldeck-Weiermair et al., 
2008). One study working with rat islets reported that O-1602 potentiated glucose-induced 
increase in [Ca
2+
]i (Romero-Zerbo et al., 2011). An increase in [Ca
2+
]i is responsible for 
regulating a variety of islet functions such as hormone secretion and cell survival. On the other 
hand, the G12/13 α subunit is linked to activation of Rho small GTPases and RhoA was 
suggested as the key GTPase activated by GPR55 ligands. However, RhoA and its downstream 
kinase ROCK were demonstrated to have an inhibitory effect on insulin secretion (Hammar et 
al., 2009; Tomas et al., 2010). It is important to determine which pathway is activated by 
GPR55 in order to better understand its physiological roles in islets. 
 
The previous chapter has shown that GPR55 is expressed at both mRNA and protein levels in 
MIN6 cells, and in mouse and human islets. Calcium microfluorimetry data herein have 
demonstrated that the GPR55 agonist O-1602, the putative endogenous ligand LPI and the 
GPR55 antagonist CBD all stimulated increases in [Ca
2+
]i in MIN6 cells and mouse β-cells. In 
addition, O-1602 and LPI also caused elevations in [Ca
2+
]i in dispersed human islet cells. 
When comparing the effects of these compounds on calcium handling by β-cells from WT and 
GPR55 KO mice, it was shown that O-1602 required expression of the GPR55 receptor to 
stimulate [Ca
2+
]i, while LPI and CBD acted independently of GPR55.  
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The ability of O-1602 to increase [Ca
2+
]i by O-1602 has been demonstrated in a variety of cell 
types (Sylantyev et al., 2013; Waldeck-Weiermair et al., 2008), including islet β-cells 
(McKillop et al., 2013; Romero-Zerbo et al., 2011). It was shown that O-1602 stimulated 
increases in [Ca
2+
]i in rat insulin-secreting cell line BRIN-BD11 cells at both 5.6mM and 
16.7mM glucose (McKillop et al., 2013). On the other hand, another study reported that O-
1602 had no effect on calcium oscillations in rat islets at 2mM glucose, but it potentiated 
glucose-induced increase in [Ca
2+
]i (Romero-Zerbo et al., 2011). Data presented in this chapter 
are consistent with findings in BRIN-BD11 cells, which showed that O-1602 increased [Ca
2+
]i 
in islet cells at both sub-stimulatory and stimulatory concentrations of glucose. Elevations in 
[Ca
2+
]i at 2mM glucose were not reported in rat islets, possibly due to whole rat islets were 
used for calcium measurement in the previous publication. It is interesting to observe that only 
approximately 50% and 40% of β-cells (those that were glucose/CCh/tolbutamide-responsive) 
responded to O-1602 treatment at 2mM and 20mM glucose, respectively. This suggests 
functional heterogeneity among islet β-cells and it has been reported before that islet β-cells 
are different in their [Ca
2+
]i responses (Squires et al., 2000; Squires et al., 2002). However, it is 
unclear why a smaller percentage of β-cells responded to O-1602 at 2mM glucose, than at 
20mM glucose. In order to further investigate if O-1602 interacted with GPR55 to mediate its 
effect on [Ca
2+
]i in islet cells, calcium handling by islet cells from GPR55 KO mice was also 
investigated. Less than 10% GPR55 null β-cells responded to O-1602 at 2mM glucose and 
none of them responded at 20mM glucose. This suggested that O-1602 signals mainly through 
GPR55 at a sub-stimulatory concentration of glucose and acts specifically via GPR55 at a 
maximum stimulatory concentration of glucose to manipulate changes in [Ca
2+
]i in mouse islet 
cells. This agrees with other studies describing O-1602 as a specific GPR55 agonist (Lauckner 
et al., 2008; Waldeck-Weiermair et al., 2008). On the other hand, O-1602 may potentially 
interact with other cell surface proteins in islet cells isolated from GPR55 KO mice and it was 
recently shown that O-1602 was able to trigger migration of HEK293 cells overexpressing the 
GPR18 receptor (McHugh et al., 2010). However, a recent study by our group did not detect 
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GPR18 mRNA expression in human islets (Amisten et al., 2013) and GPR18 expression by 
mouse islets has not been investigated to date. 
 
LPI is believed by some researchers to interact specifically with GPR55 to mediate changes in 
[Ca
2+
]i (Oka et al., 2007; Pineiro et al., 2011; Sylantyev et al., 2013; Waldeck-Weiermair et al., 
2008), but GPR55-independent mobilisation of intracellular calcium by LPI were also reported 
(Bondarenko et al., 2010; Bondarenko et al., 2011a, b). The ability of LPI to stimulate 
elevations in [Ca
2+
]i in islets has been demonstrated previously (Metz, 1988; Rustenbeck and 
Lenzen, 1992), but no studies have addressed whether LPI acts specifically on GPR55 to 
mediate these effects. Experiments presented in this chapter also showed that LPI was able to 
induce elevations of [Ca
2+
]i in MIN6 cells, mouse β-cells and dispersed human islet cells. More 
mouse β-cells responded to LPI (Figure 3.4.2.2E) at both 2mM and 20mM glucose in 
comparison to O-1602 (Figure 4.3.2.1E). However, parallel experiments using islet cells from 
GPR55 KO mice demonstrated that a similar number of β-cells from GPR55 KO mice 
responded to LPI with increases in [Ca
2+
]i at 2mM and 20mM glucose as has been observed 
with WT islets. This finding is in line with previous research showing that LPI increased 
[Ca
2+
]i independently from GPR55 activation (Bondarenko et al., 2010; Bondarenko et al., 
2011a, b). It is not clear how LPI elevates [Ca
2+
]i in β-cells, but it has been suggested to 





and L-type voltage-gated calcium channel (Ben-Zeev et al., 2010; Bondarenko et al., 2010; 
Bondarenko et al., 2011a, b). These cation channels are expressed by islet β-cells and play a 
regulatory role in β-cell electrophysiology (Braun et al., 2008; Ferrer et al., 1996; Leech and 
Habener, 1998). LPI may interact with them to induce the stimulatory effects observed in this 




 ATPase to alter [Ca
2+
]i 
independently of GPR55 (Bondarenko et al., 2010) and it may exert its effects via this 
mechanism in islets. 
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CBD has been reported to be an effective GPR55 antagonist (Li et al., 2013; Ryberg et al., 
2007; Whyte et al., 2009) and it caused an insignificant calcium increase in HEK293 cells 
overexpressing GPR55 (Lauckner et al., 2008). However, data presented here have 
demonstrated that CBD was able to induce elevations in [Ca
2+
]i similar to those obtained 
following exposure to O-1602 and LPI in MIN6 cells at 2mM glucose, and in approximately 
50% of mouse β-cells at both 2mM and 20mM glucose. Subsequent experiments investigating 
β-cells from GPR55 KO mice revealed that CBD did not require GPR55 receptor expression to 
mediate its effects on increase in [Ca
2+
]i in islet cells. Two studies have shown that CBD was 
able to activate [Ca
2+
]i in neuronal cells (Mato et al., 2010; Qin et al., 2008) and one of them 
suggested that CBD acted via regulating transient receptor potential cation channel subfamily 
V member 2 (TRPV2) (Qin et al., 2008). It has also been reported that CBD activated 
peroxisome proliferator-activated receptor γ (PPARγ) (O'Sullivan et al., 2009) and stimulated 
PPARγ thus is known to stimulate insulin secretion from hamster insulinoma cells through 
KATP channels and Ca
2+
 influx (Shimomura et al., 2004). The mode of action of CBD in islet 
cells by CBD remains to be discovered. 
 
The effect of O-1602 on RhoA activation was also investigated in MIN6 β-cells using a 
commercially available RhoA activation assay kit. Figure 4.3.4.1 has shown that 20mM 
glucose was able to activate RhoA in MIN6 cells, which are consistent with observations in 
other studies (Zhang et al., 2012). In contrary with the findings in other cell types (Henstridge 
et al., 2009a; Obara et al., 2011; Ryberg et al., 2007; Whyte et al., 2009), O-1602 did not 
induce RhoA activation in MIN6 cells. A 10 minute incubation time was selected for these 
experiments since it has been demonstrated to be an effective stimulation period for O-1602-
induced RhoA activation in other cell lines (Ryberg et al., 2007; Whyte et al., 2009). However, 
it is possible that RhoA activity may be regulated over a different time course in MIN6 -cells 
and further studies are required over a range of incubation periods (e.g. 1, 2, 5, 15 and 30 
minutes) for a comprehensive understanding of whether O-1602 regulates the RhoA activity in 
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-cells. Since O-1602-induced RhoA activation in islet cells has not been reported previously 
by the literature, data so far suggests that O-1602-mediated GRP55 activation is not linked to 
the RhoA-ROCK pathway. Despite that, this cannot exclude that GPR55 is coupled to G 12/13 
subunit since one paper has suggested activation of GPR55 also leaded to upregulations of 
other Rho small GTPases, Cdc42 and Rac1 (Ryberg et al., 2007). 
 
 
Figure 4.4.1.1 Second messenger generation mediated by O-1602, LPI and CBD. 
O-1602 activates GPR55 to induce increase in [Ca
2+
]i in β-cells and it does not activate the 
small GTPase RhoA. It remains unknown whether O-1602 activates other Rho small GTPases 
such as Cdc42 and Rac1. LPI and CBD also stimulate increases in [Ca
2+
]i in β-cells, but these 
effects are not transduced via GPR55 activation. LPI and CBD may interact with cation 
channels to mediate their effects and. In addition, CBD is highly membrane permeable (Deiana 




As described before, Ca
2+
 plays important roles in the regulation of insulin exocytosis during 
both stages of the biphasic secretary response to glucose and an increase in [Ca
2+
]i in β-cells is 
considered an initiator of insulin release (Antunes et al., 2000; Charles et al., 1975; Henquin, 
2000; Howell et al., 1994; Prentki and Matschinsky, 1987b; Squires et al., 2002). On the other 
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hand, studies have suggested that the RhoA-ROCK pathway plays an inhibitory role in insulin 
secretion (Hammar et al., 2009; Tomas et al., 2010). Data presented in this chapter 
demonstrated that O-1602 activates GPR55 to stimulate increase in [Ca
2+
]i in islet cells and it 
does not activate the RhoA small GTPase in MIN6 cells as illustrated in Figure 4.4.1.1. CBD 
and LPI also activate [Ca
2+
]i, but their actions are independent of GPR55. These observations 
lead to a hypothesis that O-1602, LPI and CBD may stimulate insulin secretion and the next 
chapter will investigate the effects of these ligands on insulin secretion from mouse and human 
islets. 
Chapter 5 Insulin secretion 
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There is good evidence that the CB1 and CB2 cannabinoid receptors play an important role in 
regulating hormone secretion from islets of Langerhans (Di Marzo, 2008; Li et al., 2011b). 
Perifusion experiments carried out by our group and experiments by others have shown that 
activation of CB1 and CB2 stimulated insulin secretion (Li et al., 2011a; Li et al., 2010; 
Vilches-Flores et al., 2010), while a reduction in insulin output from islets following 
pharmacological activation of cannabinoid receptors has been demonstrated by other studies 
using static incubation experiments (Juan-Pico et al., 2006; Nakata and Yada, 2008). The 
differences in the reported effects of cannabinoids on insulin secretion may be a consequence 
of the model used, since a comparison of the effects of the endocannabinoid anandamide in rat 
islets indicated that it stimulated insulin secretion from islets that had been maintained in 
culture overnight, while it exerted inhibitory effects on freshly isolated islets (Anderson et al., 
2013).  
 
The effects of GPR55 on islet hormone secretion were unknown until recent studies, published 
during the course of this thesis, demonstrated that activation of GPR55 by pharmacological 
agonists stimulated insulin secretion from BRIN-BD11 insulin-secreting cells and potentiated 
glucose-induced insulin secretion from rat and mouse islets (McKillop et al., 2013).  
 
A stimulatory effect of LPI on insulin secretion was first reported in a 1986 study, which 
indicated that this phospholipid induced a concentration-dependent, reversible increase in 
insulin secretion from rat islets (Metz, 1986), and a subsequent study by the same author 
reported that LPI was able to elevate [Ca
2+
]i in whole rat islets (Metz, 1988). A more recent 
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study demonstrated that LPI stimulated intracellular cAMP accumulation in a concentration-
dependent manner in the NIT-1 β-cell line (Soga et al., 2005). Elevations in intracellular 
cAMP may indicate that LPI signals through a receptor coupled to the Gs α subunit. 
Alternatively, the increases in cAMP may be secondary to activation of Ca
2+
-sensitive 
isoforms of adenylate cyclase as a consequence of LPI-induced elevation of [Ca
2+
]i, both of 
which would result in enhanced insulin secretion. 
 
Only in the last few years has the revelation that LPI may act as a GPR55 endogenous agonist 
(Henstridge et al., 2009a; Lauckner et al., 2008; Oka et al., 2007; Oka et al., 2009; Waldeck-
Weiermair et al., 2008) provided new insight into the possible mode of action of LPI in 
regulating insulin secretion. It has been reported that GPR55 couples to either Gq or G12/13 α 
subunits (Ross, 2009; Sharir and Abood, 2010). The lack of interaction with Gs indicates that if 
LPI induces cAMP accumulation through GPR55 activation this does not occur through direct 
G-protein coupling. In addition, calcium microfluorimetry experiments in the last chapter have 
shown that LPI-induced increases in β-cell [Ca2+]i were not dependent on GPR55, but the exact 
mechanism of action responsible for LPI-induced effects in islets remains to be discovered.  
 
Experiments in the previous chapter demonstrated that O-1602 and LPI stimulated increases in 
[Ca
2+
]i in MIN6 -cells, and in dispersed mouse and human islet cells. In addition, studies 
using islets from GPR55 KO mice illustrated that the effects of O-1602, but not LPI, were 
dependent on GPR55 expression. The GPR55 antagonist CBD unexpectedly had stimulatory 
effects on [Ca
2+
]i in mouse -cells, and, similar to LPI, the stimulatory effects of CBD were 
shown to be GPR55-independent. The experiments described in this chapter investigated 
whether O-1602, LPI and CBD are able to stimulate insulin secretion from mouse and human 
islets, and studies using islets isolated from WT and GPR55 KO C57/BL6 mice further 
examined if these effects were GPR55-dependent. A perifusion system was used to measure 
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dynamic insulin secretion from islets, since it is more sensitive to detect small changes in 




5.2.1 Measurement of insulin secretion from perifused isolated mouse and human islets 
Mouse islets were isolated from either ICR or C57/BL6 mice as described in Section 2.2.1 and 
human islets were obtained from the King’s College London Human Islet Isolation Unit with 
appropriate ethical approval (Section 2.2.2). For dynamic measurements of insulin secretion 
using the perifusion system, 40-50 mouse or human islets were transferred to chambers 
containing 1μm pore-size nylon filters and perifused at a flow rate of 0.5ml/ml with 
physiological buffers (Table 2.7.1.1) containing 2mM or 20mM glucose in the absence or 
presence of ligands of interest (10μM O-1602, 5μM LPI or 1μM CBD) in a temperature-
controlled environment (37°C) (Section 2.7.1). Medium containing insulin secreted from islets 
in the chambers was collected every 2 minutes and insulin was quantified by 
radioimmunoassay (Section 2.7.2).  
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5.3 Results 
5.3.1 Effects of O-1602 on insulin secretion from mouse islets 
The effects of O-1602 on insulin secretion were initially studied using islets from ICR mice, as 
this is the strain of mice used by the islet biology group at King’s College London for 
determining insulin secretagogue effects of ligands of interest. 10μM of O-1602 was used 
since data presented in the previous chapter indicated that it was able to induce elevations in 
islet β-cell [Ca2+]i. Figure 5.3.1.1A shows that O-1602 induced a small, but significant increase 
in insulin secretion from isolated, perifused ICR mouse islets at 2mM glucose. Addition of 
10µM O-1602 caused an approximately two-fold increase in insulin release, which was 
abolished following its removal. After exposure to O-1602 the islets responded further to 
20mM glucose with a biphasic increase in insulin secretion that peaked at approximately six-
fold higher than secretion at 2mM glucose. Figure 5.3.1.1B shows that O-1602 also potentiated 
glucose-induced insulin secretion from mouse islets. A rapid elevation in insulin secretion was 
caused by 20mM glucose and addition of 10µM O-1602 during the second phase induced a 
short-lived increase in insulin secretion. This response first peaked at approximately two-fold 
higher than the 20mM glucose plateau and returned back to the second phase of glucose-
induced secretion before the withdrawal of O-1602.  
 
To assess whether the effects of O-1602 were mediated via activation of GPR55, perifusion 
experiments were performed using islets isolated from WT and GPR55 KO C57/BL6 mice. 
Consistent with the data presented in Figure 5.3.1.1A, islets from WT C57/BL6 mice 
responded to the challenge of 10μM O-1602 with a small, prolonged increase in insulin 
secretion at 2mM glucose. This stimulatory effect of O-1602 on basal insulin secretion was 
absent in islets isolated from GPR55 KO mice (Figure 5.3.1.1C). Both groups of islets were 
then perifused with buffer supplemented with 20mM glucose followed by administration of 
10μM O-1602. 20mM glucose induced a rapid, biphasic increase in insulin release from both 
WT and GPR55 null mouse islets. O-1602 was able to potentiate glucose-induced insulin 
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secretion from WT mouse islets to two-fold higher than the 20mM glucose plateau, but it was 
longer-lived compared to the transient response obtained with islets from ICR mice (Figure 
5.3.1.1B). In contrast, the effects of O-1602 on glucose-induced insulin secretion from GPR55 
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Figure 5.3.1.1 O-1602 stimulates insulin secretion from mouse islets through GPR55 
activation. 
Islets isolated from ICR mice (panels A and B) and C57/BL6 WT or GPR55 KO mice (panel C) 
were perifused with physiological buffer containing 2mM glucose and supplemented as shown. 
A Addition of 10μM O-1602 at 2mM glucose resulted in a two-fold, reversible increase in 
insulin secretion and these islets further responded to 20mM glucose with a biphasic 
stimulation of insulin secretion. B 10μM O-1602 induced a transient potentiation of glucose-
induced insulin secretion. C O-1602 also stimulated basal and glucose-induced insulin 
secretion from islets isolated from WT C57/BL6 mice (black triangle). Parallel experiments 
using islets isolated from GPR55 KO mice showed that the effects of O-1602 were abolished 
at 2mM glucose and significantly reduced at 20mM glucose (white triangle). Data are 
representative of three separate experiments and expressed as means ± SEM, n=4. * p < 0.05, 
peak stimulation vs. basal.  
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5.3.2 Effects of O-1602 on insulin secretion from human islets 
Perifusion experiments were also performed to investigate the effects of O-1602 on insulin 
secretion from isolated human islets, and these indicated that this GPR55 agonist also had 
stimulatory effects on human -cells. Thus, it can be seen from Figure 5.3.2.1A that 10µM O-
1602 caused a biphasic elevation in insulin secretion from perifused, isolated human islets at 
2mM glucose. Due to the difficulties in obtaining purified human islets, free from 
contaminating exocrine tissues, it cannot be guaranteed that all samples loaded into the 
perifusion chambers were human islets. Therefore the data here have been presented as 
percentage of insulin secretion at 2mM glucose rather than pg insulin/islet/min, which was 
used for mouse islet perifusion studies where highly purified mouse islet preparations were 
used. The insulin secretory response reached a five-fold peak stimulation within 8 minutes 
exposure to O-1602, which was greater than the O-1602-induced peak stimulation from mouse 
islets. Insulin release then reached a plateau at approximately two-fold basal in the continued 
presence of O-1602, and this was readily reversible upon withdrawal of the agonist. This 
secretion profile was similar to that obtained with 20mM glucose after the O-1602 treatment in 
the same group of human islets (Figure 5.3.2.1A). Consistent with the finding from perifusion 
experiments with mouse islets (Figure 5.3.1.1B), 10µM O-1602 also potentiated, but not 
significantly, glucose-induced insulin secretion from human islets, with a transient response 
that peaked approximately two-fold higher than the 20mM glucose plateau (Figure 5.3.2.1B). 
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Figure 5.3.2.1 O-1602 stimulates insulin secretion from human islets. 
Isolated human islets were perifused with physiological buffer containing 2mM glucose and 
supplemented as shown. A Addition of 10M O-1602 at 2mM glucose resulted a two-fold, 
reversible increase in insulin secretion from perifused isolated human islets, which further 
responded to 20mM glucose with a biphasic stimulation of insulin secretion. B 10μM O-1602 
induced a transient, but not significant potentiation of glucose-induced insulin secretion. Data 
are representative of three separate experiments using islets from different donors and are 
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5.3.3 Effects of LPI on insulin secretion from mouse islets 
The stimulatory effect of LPI on insulin secretion from rat islets was first reported nearly thirty 
years ago (Metz, 1986), but it was only much more recently that LPI was proposed as an 
endogenous ligand of GPR55. Perifusion experiments with mouse islets isolated from ICR 
mice confirmed the earlier report of stimulation of insulin secretion by exogenous LPI, with 
the demonstration that 5µM LPI caused a sustained elevation of insulin release that was 
approximately five-fold higher than basal secretion at 2mM glucose (Figure 5.3.3.1A). The 
maintained response to LPI was similar to that obtained with O-1602 at 2mM glucose (Figure 
5.3.1.1A and C). In addition, LPI enhanced glucose-induced insulin secretion, inducing a 
sustained, three-fold potentiation after mouse islets had responded to 20mM glucose with a 
biphasic insulin secretion profile (Figure 5.3.3.1B).  
 
Perifusions were also performed using islets isolated from GPR55 KO mice to determine 
whether the stimulatory effects of LPI were dependent on GPR55. When investigating the 
effects of 5M LPI using WT C57/BL6 mouse islets in several separate experiments it was 
observed that there was only a transient, non-significant elevation of insulin release at 2mM 
glucose (Figure 5.3.3.1C), in contrast to the large, sustained response to LPI obtained with ICR 
mouse islets (Figure 5.3.3.1A). Nonetheless, LPI stimulated a sustained potentiation of 
glucose-induced insulin secretion from C57/BL6 islets (Figure 5.3.3.1C), similar to the effect 
seen in ICR islets (Figure 5.3.3.1B). This potentiation of insulin release by LPI was 
independent of GPR55 activation since te same stimulatory profiles of LPI were observed in 
mouse islets obtained from both WT and GPR55 KO mice.  
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Figure 5.3.3.1 LPI stimulates insulin secretion from mouse islets, independent of GPR55 
receptor activation. 
Islets isolated from ICR mice (panels A and B) and C57/BL6 WT or GPR55 KO mice (panel C) 
were perifused with physiological buffer containing 2mM glucose and supplemented as shown. 
A Addition of 5μM O-LPI at 2mM glucose resulted in a five-fold, reversible increase in insulin 
secretion and these islets further responded to 20mM glucose with a biphasic stimulation of 
insulin secretion. B 5μM LPI induced a sustained potentiation of glucose-induced insulin 
secretion. C LPI failed to significantly stimulate insulin release at 2mM glucose, but it induced 
a two-fold potentiation of glucose-induce insulin secretion from islets isolated from WT 
C57/BL6 mice (black triangle). LPI also potentiated secretion in parallel experiments using 
islets isolated from GPR55 KO mice (white triangle). Data are representative of three separate 
experiments and expressed as means ± SEM, n=4. * p < 0.05, peak stimulation vs. basal. 
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5.3.4 Effects of LPI on insulin secretion from human islets 
A further series of perifusion experiments was conducted to investigate the effects of LPI on 
insulin secretion from isolated human islets. The addition of 5µM LPI at 2mM glucose 
resulted in a biphasic insulin secretory response (Figure 5.3.4.1A), similar to O-1602-induced 
insulin secretion from human islets at 2mM glucose (Figure 5.3.2.1A). Insulin secretion after 
the addition of LPI reached a maximum ten-fold stimulation over basal and it returned to a 
level about two-fold higher than basal before the removal of LPI. The LPI-induced insulin 
secretion profile was similar to that of the glucose-induced response when the same groups of 
human islets were treated with 20mM glucose after exposure to LPI. LPI also caused a large, 
sustained potentiation of glucose-induced insulin secretion from perifused human islets (Figure 
5.3.4.1B), which was consistent with the profile obtained with ICR mouse islets (Figure 
5.3.3.1B). 
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Figure 5.3.4.1 LPI stimulates insulin secretion from human islets. 
Isolated human islets were perifused with physiological buffer containing 2mM glucose and 
supplemented as shown. A Addition of 5M LPI at 2mM glucose resulted a biphasic 
stimulation of insulin secretion from perifused isolated human islets, which further responded 
to 20mM glucose with a biphasic stimulation of insulin secretion. B 5μM LPI induced an 
approximately eight-fold, sustained enhancement of the second phase of glucose-induced 
insulin secretion. Data are representative of three separate experiments using islets from 
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5.3.5 Effects of CBD on insulin secretion from mouse islets. 
The effects of the GPR55 antagonist CBD on insulin secretion were also studied. Data 
presented in the last chapter indicated that CBD did not show antagonist activity on -cell 
[Ca
2+
]i. Instead, it stimulated elevations in [Ca
2+
]i in MIN6 cells and mouse islets, effects that 
were maintained in GPR55 null islets. Consistent with this agonist effect of CBD, perifusion 
experiments using islets isolated from ICR mice demonstrated that 1μM CBD caused an 
approximately four-fold sustained increase in insulin secretion at 2mM glucose (Figure 
5.3.5.1A), larger in amplitude than the effect obtained with the pharmacological GPR55 
agonist O-1602. When ICR islets were exposed to 1μM CBD after 20mM glucose, CBD 
potentiated the glucose-induced secretory response to approximately two-fold higher than the 
second phase plateau (Figure 5.3.5.1B). The effects seen with CBD were similar in magnitude 
and duration to those observed with LPI.  
 
Investigation of the requirement of GPR55 for the stimulatory effects of CBD on insulin 
secretion was carried out in perifusion experiments, comparing responses of islets isolated 
from WT and GPR55 KO C57/BL6 mice. In line with the observations made with ICR mouse 
islets (Figure 5.3.5.1A and B), 1μM CBD induced insulin secretion at 2mM glucose and 
potentiated glucose-induced insulin secretion from islets isolated from WT mice (Figure 
5.3.5.1C). However, the stimulatory effects of CBD at 2mM glucose were not significant in 
islets from both WT and GPR55 KO mice. In addition, CBD induced an transient effect at 
20mM glucose in C57/BL6 islets, in contrast to its prolonged effect in islets from ICR mice. 
The stimulation of insulin secretion by CBD was also seen in islets isolated from GPR55 KO 
mice. Thus, although glucose-induced insulin secretion from GPR55 KO islets peaked at a 
lower level than that from WT islets, 1μM CBD was still able to induce a potentiation with a 
similar magnitude, and its secretagogue effects at 2mM glucose were also preserved (Figure 
5.3.5.1C).   
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Figure 5.3.5.1 CBD stimulates insulin secretion from mouse islets, independent of GPR55 
receptor activation.  
Islets isolated from ICR mice (panels A and B) and C57/BL6 WT or GPR55 KO mice (panel C) 
were perifused with physiological buffer containing 2mM glucose and supplemented as shown. 
A Addition of 1μM CBD at 2mM glucose resulted in a four-fold, reversible increase in insulin 
secretion and these islets further responded to 20mM glucose with a biphasic stimulation of 
insulin secretion. B 1μM CBD induced a sustained potentiation of glucose-induced insulin 
secretion. C CBD also stimulated basal (not significant) and glucose-induced insulin secretion 
from islets isolated from WT C57/BL6 mice (black triangle), and these effects were preserved 
in parallel experiments using islets isolated from GPR55 KO mice (white triangle). Data are 
representative of three separate experiments and expressed as means ± SEM, n=4. * p < 0.05, 
peak stimulation vs. basal. 
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5.3.6 Effects of CBD on insulin secretion from human islets 
Stimulatory effects of 1M CBD on basal and glucose-stimulated insulin secretion were also 
seen in experiments using perifused human islets. (Figure 5.3.6.1). However, in contrast to the 
sustained stimulation seen in mouse islets at 2mM glucose (Figure 5.3.5.1A), CBD-inducted 
insulin secretion from human islets peaked at an approximately four-fold increase above basal 
and then declined to the pre-stimulatory level before the removal of CBD. A prolonged two-
fold potentiation of glucose-induced insulin secretion was recorded when human islets were 
treated with 1μM CBD in the presence of 20mM glucose (Figure 5.3.6.1B).  
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Figure 5.3.6.1 CBD stimulates insulin secretion from human islets  
Isolated human islets were perifused with physiological buffer containing 2mM glucose and 
supplemented as shown. A Addition of 1M CBD at 2mM glucose resulted a transient 
stimulation of insulin secretion from perifused isolated human islets, which further responded 
to 20mM glucose with a biphasic stimulation of insulin secretion. B 1μM CBD potentiated 
glucose-induced insulin secretion. Data are representative of three separate experiments using 
islets from different donors and are expressed as means ± SEM, n=4. * p < 0.05, peak 
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5.4 Discussion 
The roles of GPR55 in regulating insulin secretion have only been investigated in the past 
three years, during the course of the experiments described in this thesis. In vivo studies have 
demonstrated that short-term administration of GPR55 agonists to rats or mice increased 
plasma insulin levels and improved glucose tolerance (McKillop et al., 2013; Romero-Zerbo et 
al., 2011). Direct effects of GPR55 agonists at -cells were reported in a recent study 
evaluating the effects of various GPR55 ligands on insulin secretion from BR1N-BD11 
insulin-secreting cells and mouse islets (McKillop et al., 2013). These experiments indicated 
that all agonists used - O-1602, AM251, abnormal CBD (a synthetic GPR55-activating CBD 
analogue) and the phospholipid-derived endocannabinoids OEA and PEA - stimulated insulin 
secretion. O-1602 has also been reported to stimulate insulin release from rat islets (Romero-
Zerbo et al., 2011), and the data shown here extend these observations to human islets, where 
O-1602 produced significant elevations in insulin output.  
 
The insulin secretion data in response to O-1602 that are presented in this chapter are in 
agreement with the stimulatory effects of O-1602 on [Ca
2+
]i shown in the previous chapter 
(Section 4.3.3 and 4.3.4) and on insulin secretion from BRIN-BD11 cells and mouse islets 
reported previously (McKillop et al., 2013). However, the data are not consistent with another 
publication reporting that 10μM O-1602 had no effect on insulin secretion from rat islets at 
both sub-stimulatory and stimulatory concentrations of glucose (Romero-Zerbo et al., 2011), 
although stimulation was observed with 0.1M O-1602. The reasons for this discrepancy are 
not immediately obvious, although Romero-Zerbo and colleagues used static incubations, 
while the experiments described here were performed in a dynamic perifusion system, which 
allows assessment of the time-course and reversibility of hormone release. However, this does 
not fully explain the different outcome of the experiments since static incubations were also 
carried out in the study by McKillop. A role for GPR55 in mediating the stimulatory effects of 
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O-1602 was evident from the perifusion experiments carried out using islets from GPR55 KO 
mice, which demonstrated that O-1602-induced increases in insulin secretion were abolished at 
2mM glucose and significantly reduced at 20mM glucose. This is consistent with the 
observations made in the calcium microfluorimetry experiments (Section 4.3.3) and, 
collectively, the data suggest that O-1602 acts at GPR55 to exhibit its stimulatory effects in 
islets. There is the possibility that O-1602 may regulate glucose-induced insulin secretion in 
part via a GPR55-independent mechanism since it still caused a small and delayed potentiation 
of glucose-induced insulin secretion in islets from GPR55 KO mice towards the end of the 20 
minute treatment period. Full evaluation of the requirement of GPR55 for O-1602-induced 
potentiation of glucose-stimulated insulin secretion would benefit from perifusion experiments 
in which islets were exposed to buffers containing 20mM glucose in the absence and presence 
of O-1602 so that the secretory response to 20mM glucose alone could be determined in the 
same batches of islets. This would allow evaluation of whether the apparent delayed increase 
in insulin secretion in from the GPR55 knockout islets after exposure to O-1602 was actually a 
bona fide response rather than reflecting the profile of the secretory response to 20mM glucose. 
GPR18 has been suggested to be activated by O-1602 (McHugh et al., 2010), but its 
expression and roles in mouse islets remain to be investigated.  
 
The pathways through which O-1602 activation of GPR55 causes insulin secretion were not 
fully examined here, but are likely to be secondary to GPR55-mediated activation of PLC and 
elevation in [Ca
2+
]i and diacylglycerol, both of which are known to be involved in insulin 
secretion (Jones and Persaud, 2010). In addition, PLC activation can occur by the G13 
pathway in addition to conventional Gq coupling (Lauckner et al., 2008) so it is possible that 
GPR55 also regulates -cells via G13 signalling since this G-protein has previously been 
identified in islets (Hammar et al., 2009; Skoglund et al., 1999). However, inhibition of the 
Rho kinase ROCK causes increased insulin release from FACS-purified rat -cells (Hammar 
et al., 2009; Skoglund et al., 1999) and this negative role for RhoA on insulin release is 
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inconsistent with the observed stimulatory effects of GPR55 agonists summarised above. It is 
therefore possible that there are both stimulatory and inhibitory cascades activated by GPR55 
agonists in islets, via separate G-proteins and further work is required to define the signalling 
cascades that regulate insulin exocytosis downstream of GPR55 activation.  
 
LPI has long been known to be an insulin secretagogue (Metz, 1986), and although its effects 
on insulin secretion were suggested to be at least partly mediated by the mobilisation of [Ca
2+
]i 
in -cells (Metz, 1988), its precise mode of action in islets has never been established. The 
identification of LPI as an endogenous ligand of GPR55 (Henstridge et al., 2009a; Lauckner et 
al., 2008; Oka et al., 2007; Oka et al., 2009; Waldeck-Weiermair et al., 2008) points to a 
possibility that the insulinotropic effect of LPI could be mediated through activation of this 
receptor. The stimulatory effects of LPI observed here in the perifusion experiments with 
mouse and human islets support this phospholipid being an effective insulin secretagogue, but 
there were some differences in the secretion profiles between species. Thus, LPI had sustained 
effects on basal insulin secretion from mouse islets, while it was shorter-lived in human islets, 
and the magnitude of the responses was greater in human islets than mouse islets. There were 
also strain-dependent effects such that in three separate experiments LPI failed to induce any 
significant effects on insulin release from C57/BL6 islets at 2mM glucose, while it consistently 
had effects on basal insulin release from ICR mouse islets. However, data presented in the 
previous chapter demonstrated that LPI was able to stimulate increases in [Ca
2+
]i at 2mM 
glucose in islet cells from C57/BL6 mice. Thus, there may be differences in coupling between 
Ca
2+
 elevations to insulin vesicle exocytosis in ICR and C57/BL6 mice, resulting in the strain-
specific secretion profiles observed here.  
 
The capacity of LPI to stimulate insulin release from both WT and GPR55 KO mice indicate 
that LPI does not require interaction with GPR55 to transduce its effects on insulin exocytosis. 
This is consistent with the Ca
2+
 microfluorimetry data in the previous chapter showing that LPI 
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]i at 2mM and 20mM glucose in islet cells from both WT and GPR55 KO mice. 
These observations also fit with earlier reports of GPR55-independent effects of LPI in other 







 channels (Ben-Zeev et al., 2010; Bondarenko et al., 2010; 
Bondarenko et al., 2011a). If LPI also activates VGCCs in -cells this could lead to a greater 
increase of [Ca
2+
]i than that following GPR55-mediated Ca
2+
 mobilisation as a consequence of 
IP3 generation, and it might help to explain why the magnitude of LPI-induced insulin 
secretion was greater than that of the O-1602-induced effects.  
 
CBD is a major constituent of the cannabis plant, Cannabis sativa, and it is reported to be an 
effective GPR55 antagonist (Ryberg et al., 2007), which has been widely used to inhibit 
GPR55 agonist-induced biological effects (Lauckner et al., 2008; Ryberg et al., 2007; Whyte et 
al., 2009). However, it unexpectedly had similar stimulatory effects to O-1602 and LPI on -
cell Ca
2+ 
levels and the data presented in this chapter have shown for the first time that CBD 
increased basal insulin secretion and potentiated glucose-induced insulin secretion from mouse 
and human islets. As was observed for the other agonists, species differences exist, such that 
CBD-induced increase in insulin release from human islets at 2mM glucose was short-lived 
compared to the sustained increase seen in mouse islets. Agonist effects of CBD have been 
observed in other studies, one of which proposed that CBD may have GPR55 agonist activity 
since it provided protection against acute pancreatitis in mice to a similar extent to that seen 
using O-1602 (Yu et al., 2013). However, perifusion studies using islets from GPR55 KO mice 
demonstrated that, similar to LPI, CBD does not activate GPR55 to mediate its effects in islets. 
These observations are in agreement with the microfluorimtry data (Section 4.3.3) showing 
that CBD was able to elevate [Ca
2+
]i independently of GPR55 in islet cells, and point to 
agonist effects at another site(s). CBD has been implicated in the activation of a range of 
receptors including TRPV2 (Qin et al., 2008), 5-HT1A (Campos and Guimaraes, 2008; De 
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Petrocellis et al., 2008; O'Sullivan et al., 2009; Resstel et al., 2009) and PPAR (O'Sullivan et 
al., 2009) and CBD may mediate its stimulatory effects through these receptors.  
 
In summary, using the sensitive perifusion technique for recording dynamic insulin secretion 
profiles, the results in this chapter have shown that O-1602, LPI and CBD stimulated insulin 
secretion from isolated mouse and human islets at sub-stimulatory (2mM) and maximal 
stimulatory (20mM) concentrations of glucose, although the secretion profiles varied slightly 
between species and mouse strain (Table 5.4.1.1). Studies using islets isolated from GPR55 
KO mice demonstrated that O-1602 requires GPR55 receptor expression for its actions and 
LPI- and CBD-induced effects were independent of GPR55. The mechanisms through which 
LPI and CBD stimulate insulin secretion remain to be revealed, but they are likely to involve 
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Table 5.4.1.1 Effects of pharmacological manipulations of GPR55 on insulin secretion. 
The effects of O-1602, LPI and CBD on insulin secretion from isolated islets from ICR and 
C57/BL6 mice and isolated human islets has been investigated using perifusion experiments. 
In summary, O-1602, LPI and CBD exhibited a stimulatory effect on insulin secretion at sub-
stimulatory (2mM) and maximal stimulatory (20mM) concentration of glucose from all tested 
experimental tissues, except that LPI failed to induce any response in islets isolated from 
C57/BL6 mice at 2mM glucose. N.S., not significant.  
 
 
In addition to stimulatory effects on second messengers such as [Ca
2+
]i and Rho small GTPases, 
it has been reported that activation of GPR55 upregulated expression of the transcription 
factors NFAT and CREB and activated the PI3K/Akt or MAPK cell survival pathways 
(Andradas et al., 2011; Henstridge et al., 2009a; Henstridge et al., 2010; Kargl et al., 2013; 
Pineiro et al., 2011; Waldeck-Weiermair et al., 2008). GPR55 may signal through these 
pathways to promote islet cell survival and the next chapter will investigate the effect of O-
1602, LPI or CBD on basal and cytokine-induced apoptosis in isolated mouse islets. 
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CHAPTER 6 PHARMACOLOGICAL MANIPULATION OF GPR55 IN ISLETS: 
PROTECTION FROM APOPTOSIS 
6.1 Introduction 
Cells undergo programmed death known as apoptosis when exposed to agents such as 
cytokines and reactive oxygen species (ROS). There are two main apoptotic pathways: the 
death receptor pathway and the mitochondrial pathway, also known as the extrinsic and the 
intrinsic pathway, respectively (Elmore, 2007). The perforin/granzyme pathway is suggested 
as an additional apoptotic pathway and some research also indicated that cells can initiate 
apoptosis in response to oxidative damage (Yang et al., 1998; Zamzami et al., 1995). The 
extrinsic, intrinsic and perforin/granzyme pathways signal through the same execution 
pathway by activating caspase-3. Activated caspase-3 triggers a chain of downstream effectors 
including caspase-6 and caspase-7, resulting in nuclear and protein degradations in apoptotic 
cells. Intracellular caspase activity is tightly regulated by a set of various pro- and anti-
apoptotic molecules such as the Bcl-2 family and inhibitors of apoptosis proteins (IAPs). In 
addition, survival pathways such as the PI3K/Akt and MAPK pathway contribute to the 
regulation of apoptosis.  
 
Increased apoptosis in β-cells has been reported in both types of diabetes and inflammatory 
cytokines such as interleukin-1β (IL-1β), tumour necrosis factor α (TNF-α) and interferon γ 
(IFN-γ) are key players in mediating β-cell death. Several in vitro studies have shown that 
cytokines used alone do not trigger apoptosis but their combinations induce β-cell death (Cnop 
et al., 2005). IL-1β, TNF-α and IFN-γ bind to their cell surface receptors on β-cells to activate 
downstream pro-apoptotic effectors. IL-1β and TNF-α signal via activation of NF-κB by 
phosphorylating the inhibitor of NF-κB (IκB) (Elmore, 2007). Activated NF-κB translocates to 
the nucleus to regulate gene expression of a range of pro-apoptotic proteins. On the other hand, 
IFN-γ initiates apoptosis through regulation of the action of the JAK/STAT-1 pathway, which 
activates caspase-3 via interferon regulatory factor 1 (IRF 1) (Cnop et al., 2005; Eizirik and 
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Darville, 2001). There are currently only a limited number of therapeutic approaches to 
prevent β-cell death. The GLP-1 agonist, exendin-4, was recently shown to inhibit β-cell 
apoptosis by activating the GLP-1 receptor (Urusova et al., 2004), and it also stimulates β-cell 
proliferation, most likely via activation of the PI3K/Akt and MAPK pathways (Fan et al., 2010; 
Urusova et al., 2004). However, the cost, route of administration and possible side-effects of 
exendin-4 mean that there is considerable scope for the development of affordable and 
effective agents to prevent β-cell death (Singh et al., 2013). 
 
The data presented in the previous chapter have shown that GPR55 has a stimulatory effect on 
insulin secretion. GPR55 may also play a positive role in regulating cell survival, since studies 
in cancer cell lines demonstrated that its activation promotes cell proliferation via activation of 
survival signalling through PI3K/Akt or MAPK pathways (Andradas et al., 2011; Pineiro et al., 
2011). However, inconsistent with those findings, another study illustrated that anandamide 
activates GPR55 to promote an anti-proliferative action on cholangiocarcinoma cells (Huang et 
al., 2011). There is currently no information on the role of GPR55 in the regulation of β-cell 
mass, but studies in HEK 293 cells and endothelial cells have indicated that pharmacological 
activation of the receptor is linked to up-regulation of transcription factors (NFAT and CREB) 
that have been implicated in β-cell mass expansion (Henstridge et al., 2009a; Henstridge et al., 
2010; Kargl et al., 2013; Waldeck-Weiermair et al., 2008). For example, NFAT has been 
reported to promote β-cell proliferation, while activation of CREB is essential in the GLP-1 
receptor-mediated anti-apoptotic effect in β-cells (Heit et al., 2006; Jhala et al., 2003).  
 
The experiments described in this chapter examined the effect of deletion of GPR55 gene 
expression in vivo on basal and cytokine-induced apoptosis in isolated mouse islets by 
measuring the activities of caspase-3 and -7. The effect of pharmacological manipulations of 
GPR55 activity on basal and cytokine-induced apoptosis of mouse islets was also investigated.  
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6.2 Methods 
6.2.1 Measurement of caspase-3/7 activities 
Groups of approximately 40-60 islets, isolated from WT and GPR55 KO mice, were incubated 
for 48 hours in 35mm Petri dishes containing 2ml of RPMI medium supplemented with 
compounds of interest under standard cell culture conditions. A cytokine cocktail (Table 
2.8.1.1) was added to some groups of islets 20 hours prior to the end of the incubation period 
to induce apoptosis. After 48 hours incubation, 11-16 sets of 3 islets in 50μl medium were 
picked into wells of a white-walled 96-well plate. 50μl of Promega Caspase-Glo® 3/7 reagent 
was added to each well and the plate was mixed for 1 minute on a plate shaker. The plate was 
then incubated at room temperature for 1 hour before acquisition of luminescent signals using 
a luminometer (Section 2.8).  
 
6.3 Results 
6.3.1 Effect of GPR55 gene deletion on apoptosis in mouse islets 
Basal and cytokine-induced apoptosis levels were measured in islets isolated from WT and 
GPR55 KO mice using the Promega Caspase-Glo
®
 3/7 Assay. It can be seen from Figure 
6.3.1.1 that islets isolated from GPR55 KO mice had a significantly higher basal apoptotic 
level compared to islets from WT mice (percentage of increase in luminescence: 67±4%; 
p<0.001, n=16). 20 hours of cytokine cocktail treatment (TNF-α, IL-1β and INF-γ) induced 
significant increases in caspase activities in both groups of islets (percentage of increase in 
luminescence: WT: 269±10%; GPR55 KO: 148±10%; p<0.001, n=16). Similar to the results 
obtained for basal apoptosis, islets isolated from GPR55 KO mice showed a small, but 
significant, increase in caspase activity in response to cytokine cocktail challenge compared to 
the response of islets isolated from WT mice (percentage of increase in luminescence: 16±5%; 
p<0.01, n=16).  
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Figure 6.3.1.1 Islets isolated from GPR55 KO mice have increased apoptosis. 
The presence of a cytokine cocktail (20 hours incubation) significantly increased caspase 
activities of islets isolated from WT mice (grey bars) and GPR55 KO mice (black bars). Islets 
isolated from GPR55 KO mice have higher levels of caspase activity than control islets in the 
absence and presence of cytokines. Data are mean ± SEM, n=16 and are representative of 
experiments using islets isolated from 3 different groups of WT and GPR55 KO mice. ** 
p<0.01, *** p<0.001.  
 
 
6.3.2 Effect of O-1602 and LPI on apoptosis in mouse islets 
The data above demonstrating that deletion of GPR55 gene expression in mouse islets led to an 
increase in both basal and cytokine-induced apoptosis suggest that pharmacological activation 
of GPR55 would be expected to promote islet cell survival in the presence or absence of 
cytokines. This was demonstrated in experiments where islets from WT mice were incubated 
in medium supplemented with 10μM O-1602, 5μM LPI or vehicle control (0.01% DMSO) for 
48 hours. As expected, O-1602 and LPI were able to significantly reduce basal apoptosis in 
islets (percentage reduction in luminescence signal: O-1602: 50±10%; LPI: 64±5%; p<0.001, 
n=11) and data shown in Figure 6.3.2.1A indicated that there was no significant difference 
between the effect of O-1602 and LPI (p>0.2). A cytokine cocktail was added to another group 
of islets for the last 20 hours of incubation to induce apoptosis. Consistent with the results of 
Figure 6.3.1.1, the cytokine cocktail induced an approximately 3-fold increase in caspase 
activity of the control islets (percentage increase in luminescence signal: 312±28%; p<0.001, 
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n=11, Figure 6.3.2.1B). Both O-1602 and LPI were also able to significantly (p<0.001) protect 
islets from cytokine-induced apoptosis and the protective effect of O-1602 was significantly 
greater than that of LPI (p<0.001). However, O-1602 was not able to completely protect islets 
from cytokine-induced apoptosis since islets pre-treated with O-1602 and exposed to the 
cytokine cocktail had shown a greater level of apoptosis compared to the basal apoptotic level 
of control islets (p<0.001).  
 
 
Figure 6.3.2.1 The GPR55 agonist O-1602 and putative GPR55 ligand LPI promote islet 
survival in the presence and absence of cytokines. 
A: 48 hour treatments of islets with 10μM O-1602 (dark grey bar) or 5μM LPI (black bar) 
significantly reduced basal apoptosis. B: Both O-1602 (dark grey bar) and LPI (black bar) also 
protected islets from cytokine-induced apoptosis. Data are mean ± SEM, n=11 and data are 
representative of experiments using islets from 5 different groups of mice. N.S., p>0.2, *** 
p<0.001.  
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6.3.3 Effect of CBD on apoptosis in mouse islets 
Since pharmacological activation of GPR55 promotes islet survival (Figure 6.3.2.1) and 
GPR55 deletion is associated with increased islet apoptosis (Figure 6.3.1.1), it would be 
predicted that a GPR55 antagonist would increase apoptosis. CBD is the only commercially 
available GPR55 antagonist, but results presented in Chapters 4 and 5 of this thesis have 
indicated that it unexpectedly exerts effects in islets similar to those of O-1602 and LPI. CBD 
was therefore also used in islet apoptosis experiments to determine whether it had pro- or anti-
apoptotic effects. It can be seen from Figure 6.3.3.1A that incubation with 1μM CBD for 48 
hours significantly reduced basal apoptosis in mouse islets compared with islets treated with 
vehicle control (percentage reduction in luminescence signal: 39±6%; p<0.001, n=11). After 
exposure to the cytokine cocktail, islets incubated in the presence of CBD also had 
significantly decreased apoptosis, confirming that CBD does not demonstrate GPR55 
antagonist effects in islets (Figure 6.3.3.1B). As for the experiments with O-1602 (Figure 
6.3.2.1B), CBD did not completely abolish the pro-apoptotic effects of the cytokines (p<0.001 
versus basal apoptosis). 
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Figure 6.3.3.1 CBD promotes islet survival in the presence and absence of cytokines. 
48 hours treatment of islets with1μM CBD (black bar) significantly reduced apoptosis in the 
absence (A) and presence of cytokines (B). Data are mean ± SEM, n=11 and are representative 




The role of GPR55 in islet survival has not been studied before, but accumulating evidence in 
non-β-cells has suggested that GPR55 plays a positive regulatory role in cell survival 
(Andradas et al., 2011; Henstridge et al., 2009a; Henstridge et al., 2010; Kargl et al., 2013; 
Pineiro et al., 2011; Waldeck-Weiermair et al., 2008). This chapter investigated the effects of 
deletion of GPR55 gene expression and pharmacological manipulations of the GPR55 receptor 
on basal and cytokine-induced apoptosis in isolated mouse islets by measuring capase-3 and -7 
activities with a commercially available kit.  
 
The experiments shown here have demonstrated that islets isolated from mice with global 
knockout of GPR55 gene expression have higher basal apoptosis in the presence or absence of 
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cytokines compared with islets isolated from age-matched WT mice. This pro-apoptotic effect 
of GPR55 is inconsistent with a study that reported an increase in osteoclast number in GPR55 
KO mice (Whyte et al., 2009). The explanation for this might be that GPR55 plays diverse 
roles in different tissues and this is supported by data from the same earlier study showing that 
although osteoclast number was increased following deletion of GPR55 expression, function 
of these osetoclasts was impaired (Whyte et al., 2009). Regardless of its role in bone 
physiology, the observations made in this chapter suggest that GPR55 may be part of an islet 
self-defence mechanism against apoptosis.  
 
Studies in GPR55-expressing HEK293 cells and endothelial cells have illustrated that 
pharmacological stimulation of GPR55 induced activation of the transcription factors NFAT 
and CREB (Henstridge et al., 2009a; Henstridge et al., 2010; Kargl et al., 2013; Waldeck-
Weiermair et al., 2008). The NFAT family of proteins is regulated primarily by elevations in 
[Ca
2+
]i, which triggers phosphorylation of NFAT by activating calcineurin, and CREB is also a 
downstream target of Ca
2+
 signalling and the MAPK pathway (Hogan et al., 2003; Wu et al., 
2001). Interestingly, data generated from cancer cell lines reported that GPR55 signalled 
through MAPK to promote cancer cell proliferation (Andradas et al., 2011; Pineiro et al., 
2011). The data presented in Chapter 4 of this thesis demonstrated that O-1602 and LPI were 
able to increase [Ca
2+
]i in dispersed islet cells and MIN6 cells, although O-1602, but not LPI, 
required the presence of the GPR55 receptor. Experiments herein have shown that the same 
concentrations of O-1602 and LPI as used in the calcium microfluorimetry experiments 
promoted islet cell survival in the absence and presence of cytokines. This suggests that O-
1602 may promote islet survival by activating GPR55 to elevate [Ca
2+
]i and downstream 
survival pathways as proposed in Figure 6.4.1.1. Although the effects of LPI on islet [Ca
2+
]i 
were independent of GPR55, this agonist may trigger increases in [Ca
2+
]i and inhibit islet cell 




 ATPase (Ben-Zeev et al., 2010; 




 ATPase also leads to 
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reduction in ROS by the mitochondria that will promote cell survival (Xie and Cai, 2003). The 
activity of O-1602 to protect islets against cytokine-induced apoptosis was significantly greater 
than the protective effect of LPI, possibly because they act on different downstream pathways.  
 
The experiments described in this chapter have also shown that CBD protected mouse islets 
from basal and cytokine-induced apoptosis. Although CBD is considered to be a GPR55 
antagonist, these data were as expected since CBD has been shown in this thesis to trigger 
elevations in [Ca
2+
]i in islet cells, an effect that was independent of GPR55 expression (Section 
4.3.2). The ability of CBD to increase [Ca
2+
]i has also been shown in other cell types, and it 
may involve transient receptor potential cation channel subfamily V member 2 (TRPV2) 
(Mato et al., 2010; Qin et al., 2008). Alternatively, CBD may regulate [Ca
2+
]i by activating 
peroxisome proliferator-activated receptor γ (PPARγ) which is reported to protect islets from 
apoptosis by inhibiting the NF-κB pathway (Figure 6.4.1.1) (Kim et al., 2007; O'Sullivan et al., 
2009; Thomas et al., 2007). However, studies in human breast cancer cells demonstrated that 
CBD has an anti-tumour effect (Ligresti et al., 2006; McAllister et al., 2011), suggests that it 
stimulates apoptosis or inhibits proliferation. There is a lack of explanation of the mode of 
action of CBD in these cell lines, but one study surprisingly suggested that CBD activated 
MAPK to reduce breast cancer cell proliferation (McAllister et al., 2011).   
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Figure 6.4.1.1 Anti-apoptotic pathways activated by O-1602, LPI and CBD. 
O-1602 activates GPR55 to trigger increases in [Ca
2+
]i, which leads to activation of 
transcription factors NFAT and CREB and survival pathways such as the MAPK cascade, 
resulting in upregulation of expression of anti-apoptotic genes. It is unclear which cell surface 
protein(s) is activated by LPI or CBD to transduce their anti-apoptotic effects. LPI may elevate 
[Ca
2+




 ATPase to reduce ROS-
mediated cell death. CBD also regulates [Ca
2+
]i by activating cation channels such as TRPV2. 





The current results generated from global deletion of GPR55 gene expression and 
pharmacological manipulations of GPR55 suggest that GPR55 plays an important role to 
promote islet cell survival. Although the detailed signalling mechanism(s) downstream of 
GPR55 activation have not been established, the effect of pharmacological stimulation of 
GPR55 on islet cell survival is consistent with research in several other cell types. It was not 
possible during the course of these experiments to measure insulin secretion from islets under 
the same conditions that had been used for measurements of caspase-3/7 activities, but this 
would be of interest for future work to assess how their secretory capacity had been affected 
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under conditions where apoptosis had been reduced. LPI and CBD also had anti-apoptotic 
effects on islets, but calcium microfluorimetry experiments using islets from GPR55 KO mice 
(Chapter 4) have demonstrated that their actions are independent of interactions with the 
GPR55 receptor. Research in other cell models suggested both LPI and CBD may act on non-
GPR55 cell surface proteins and further work is required to identify the correct downstream 
pathway(s) in islets that are responsible for the action of these two agents. 
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CHAPTER 7 GENERAL DISCUSSION 
7.1 Summary 
T2DM is estimated to affect more than 595 million people globally by 2035 (IDF, 2013) and 
there is an urgent need for new therapies to offer not only the glucose-lowering effects of 
existing drugs, but also the potential to delay disease progression and prevent secondary 
complications. Islet GPCRs are drawing strong interests for their therapeutic potentials due to 
the possibility of modulating GPCR activities via extracellular ligands. This has led to the 
launch of GLP-1R agonists for clinical treatment of T2DM since 2005 and ongoing clinical 
trials on other GPCR ligands, such as free fatty acid receptor 1 agonist, TAK-875 (Araki et al., 
2012).  
 
The search for novel T2DM therapeutic targets continues and, as summarised in Section 1.3, 
recent studies in islet biology have identified the roles of two GPCRs, CB1 and CB2, in 
regulating islet hormone secretion. However, there is currently a lack of consensus in terms of 
the expression and function of CB1 and CB2 in islets (Di Marzo, 2008; Li et al., 2010), 
possibly due to different experimental settings (Anderson et al., 2013) or off-target effects of 
some cannabinoid ligands (Curran et al., 2005; Derocq et al., 1998; Kaplan et al., 2005; Nieri 
et al., 2003). Reports published since 2007 have suggested that GPR55 may be a third 
cannabinoid receptor as it can be activated by a range of endogenous and pharmacological 
cannabinoids (Ross, 2009; Sharir and Abood, 2010). It has been shown that activation of 
GPR55 resulted in elevations in [Ca
2+
]i in GPR55-HEK293 cells, cancer cell lines, primary 
endothelial cells, presynaptic cells and cardiomyocytes (Henstridge et al., 2010; Kargl et al., 
2013; Oka et al., 2007; Pineiro et al., 2011; Sylantyev et al., 2013; Waldeck-Weiermair et al., 
2008; Yu et al., 2013), suggesting the possibility that it may also be coupled to Ca
2+
 
mobilisation and insulin secretion in β-cells. In addition, GPR55 has been shown to activate 
transcription factors such as CREB and NFAT (Henstridge et al., 2010; Henstridge et al., 
2009b; Oka et al., 2010) and to promote proliferation in cancer cells (Andradas et al., 2011; 
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Perez-Gomez et al., 2013; Pineiro et al., 2011). This implies that activation of GPR55 could 
help to maintain or increase β-cell mass, if similar pathways exist in the endocrine pancreas. In 
order to investigate whether GPR55 is a potential therapeutic target for providing glycaemic 
control and β-cell protection for T2DM patients, the experiments described in this thesis 
examined the expression and functional roles of GPR55 in islets of Langerhans.  
 
As described in Chapter 3, expression of GPR55 mRNA and protein was initially examined 
and data from these experiments indicated that GPR55 was expressed in MIN6 β-cells, and 
also in mouse and human islets. Experiments presented in Chapter 4 were then performed to 
investigate whether GPR55 is coupled to second messenger generation in β-cells. The single-
cell calcium microfluorimetry experiments revealed that pharmacological activation of GPR55 
led to elevations in [Ca
2+
]i in MIN6 cells, as well as in dispersed mouse and human islet cells. 
On the other hand, GPR55 was shown not to be coupled to RhoA, a member of Rho GTPase 
family, in MIN6 cells. Although we cannot rule out that GPR55 may be linked to other Rho 
GTPases, evidence presented here strongly suggests that GPR55 is coupled to the Gq subunit 
to stimulate Ca
2+
 mobilisation in β-cells. This led us to test whether activation of GPR55 is 
associated with increased insulin secretion from β-cells. Dynamic insulin secretion from 
mouse and human islets was thus measured in the perifusion experiments described in Chapter 
5, and the data obtained demonstrated that activation of GPR55 stimulated basal insulin 
secretion and potentiated glucose-induced insulin secretion from both mouse and human islets. 
The stimulatory effects of GPR55 agonist were lost in islets isolated from GPR55 KO mice. 
Taken together, the data presented in Chapters 4 and 5 suggest that GPR55 plays an important 
role in regulating insulin secretion from β-cells. In Chapter 6, the capacity of GPR55 to 
maintain functional islet mass was examined. It was found that GPR55 deletion resulted in 
higher caspase activity in mouse islets and activation of GPR55 protected them from 
undergoing apoptosis, consistent with GPR55 also playing a role in regulating β-cell mass. 
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The data generated during this thesis are consistent with those reported in two recent 
publications investigating the role of GPR55 in rodent islets (McKillop et al., 2013; Romero-
Zerbo et al., 2011). Data from the perifusion experiments described here provide robust 
measurements of dynamic, minute to minute changes in insulin release in response to GPR55 
agonists, which further extend our understanding of their effects on insulin secretion obtained 
from the static incubation experiments performed by others (McKillop et al., 2013; Romero-
Zerbo et al., 2011). Immunofluorescence staining data presented in those studies suggested that 
GPR55 was only expressed by insulin-expressing β-cells, consisting with a functional role of 
GPR55 in regulating β-cell functions. It was also shown that activation of GPR55 by O-1602 
and other GPR55 agonists stimulated increases in [Ca
2+
]i and insulin secretion from β-cell lines 
and rodent islets. The in vivo studies reported in those papers also demonstrated that O-1602 
administration increased plasma insulin levels and improved glucose handling in rodents 
(McKillop et al., 2013; Romero-Zerbo et al., 2011). Thus, all studies to date, including the 
research described in this thesis, indicate that GPR55 is expressed by islet β-cells and it is 
coupled to Ca
2+
 mobilisation and insulin secretion.  
 
The signalling pathways downstream of GPR55 in β-cells have not been defined, although 
experiments in other cell types have shown that GPR55 is coupled to either Gq or G12/13 
subunits (Henstridge et al., 2009b; Lauckner et al., 2008; Ryberg et al., 2007). Data presented 
in this thesis and in other studies indicate that GPR55 activation leads to Ca
2+
 mobilisation in 
β-cells, implying that GPR55 is coupled Gq. G12/13 is coupled to RhoA and its effector 
protein ROCK (Obara et al., 2011; Ryberg et al., 2007; Whyte et al., 2009), and both RhoA 
and ROCK have been shown to play a negative role in insulin secretion (Hammar et al., 2009). 
The RhoA assay described in Chapter 4 demonstrated that although glucose stimulated RhoA 
activation after 10 minutes of incubation, activation of GPR55 with O-1602 was without effect, 
suggesting that the receptor is not linked to the RhoA-ROCK cascade in islets. However, it 
would be useful in future experiments to determine whether RhoA is activated by O-1602 in -
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cells over an extended time-course by performing the activation assay over 1-30 minutes. Only 
RhoA activation was measured in these experiments and the relationship between GPR55 and 
other Rho small GTPases was not tested, so the possibility that GPR55 is coupled to G12/13 in 
β-cells cannot be ruled out. In addition, activation of GPR55 is also reported to induce cAMP 
generation in β-cells (McKillop et al., 2013). Since there is no evidence that GPR55 is coupled 
to Gs, it is possible that GPR55 can regulate cAMP through modulating Ca
2+
-sensitive AC 




Experiments described here investigated, for the first time, the expression and function of 
GPR55 in human islets and obtained findings consistent with observations from rodent studies. 
Thus, data from Chapter 3 demonstrated that GPR55 is expressed by human islets and 
experiments in Chapters 4 and 5 have shown that activation of GPR55 stimulated elevations in 
[Ca
2+
]i in dispersed human islet cells and insulin secretion from human islets at both sub-
stimulatory and stimulatory concentrations of glucose. It is worth noting that insulin secretion 
profiles recorded from human islets following GPR55 ligand administration were different 
from those obtained using mouse islets, perhaps highlighting species variability in islet biology 
(Cabrera et al., 2006).  
 
O-1602 is reported to be a potent and selective GPR55 agonist that lacks significant binding 
affinity for either CB1 or CB2 (Johns et al., 2007; Ryberg et al., 2007; Waldeck-Weiermair et 
al., 2008). By using islets isolated from WT and GPR55 KO mice, experiments in this thesis 
confirmed that the effects of O-1602 in islets are dependent on GPR55 expression and that O-
1602 is a selective agonist for stimulating GPR55 activity in islets, as had been reported earlier 
in static incubation studies. (Romero-Zerbo et al., 2011). The bioactive lipid, LPI has also been 
suggested by some studies to be a specific endogenous ligand for the receptor in various cell 
lines (Henstridge et al., 2009b; Lauckner et al., 2008; Oka et al., 2007; Oka et al., 2009; 
Waldeck-Weiermair et al., 2008) and in primary cells (Kargl et al., 2013; Pineiro et al., 2011; 
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Sylantyev et al., 2013). However, the stimulatory effects of LPI on Ca
2+
 mobilisation and 
insulin secretion were observed in islets from both WT and GPR55 KO mice, as shown in 
Chapter 4 and 5, respectively. This suggests that LPI does not depend on GPR55 to mediate its 




 channels instead (Bondarenko 
et al., 2010; Bondarenko et al., 2011a, b). Furthermore, the phytocannabinoid CBD is 
generally considered to be a GPR55 antagonist (Lauckner et al., 2008; Ryberg et al., 2007; 
Whyte et al., 2009) and it has been reported that CBD was able to attenuate GPR55 ligand-
induced insulin secretion from BRIN-BD11 cells and mouse islets (McKillop et al., 2013). In 
contrast to these findings, data presented in Chapters 4 and 5 demonstrated that CBD exerted 
similar stimulatory effects to O-1602 in islets, in both the presence and absence of GPR55 
gene expression. The exact mechanism of action of CBD in islets remains unknown, but 
studies in other cell types have suggested that it may activate TRPV2 cation channels (Qin et 
al., 2008) or PPARγ (Shimomura et al., 2004). There are studies currently developing novel, 
selective GPR55 agonists and antagonists and promising candidates have recently been 
identified using -arrestin recruitment assays for high-throughput screening of compound 
libraries (Kotsikorou et al., 2011; Kotsikorou et al., 2013) or of coumarin derivatives (Rempel 
et al., 2013). These competitive GPR55 ligands, which have negligible pharmacological effects 
on CB1 and CB2 receptors, have much potential for investigating whether GPR55 may be a 
suitable drug target, but their effects on biological functions are largely untested. However, 
promising data have been obtained with a novel antagonist, CID16020046, which effectively 
reduced GPR55 agonist-mediated physiological responses in primary human platelets and 
endothelial cells (Kargl et al., 2013). These agents are likely to be useful tools for future 
studies in the role of GPR55 in islet function (see Section 7.2).  
 
The experiments described in Chapter 6 were the first measurements of the effects of GPR55 
on islet cell apoptosis. A luminescence caspase assay optimised by our group for measuring 
islet cell apotosis was employed to assess the capase-3 and -7 activities of islets in the absence 
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and presence of a cytokine cocktail, which was used to induce apoptosis in islets. Data 
presented in Chapter 6 have shown that islets from GPR55 KO mice had higher basal and 
cytokine-induced caspase activities compared to those from WT mice. In addition, 48 hours 
exposure to O-1602 protected mouse islets from undergoing apoptosis. These observations are 
consistent with an anti-apoptotic signalling cascade downstream of GPR55 in islet cells and 
with publications indicating GPR55 is coupled to the MAPK cell survival pathway and the 
transcription factors NFAT and CREB (Henstridge et al., 2010; Henstridge et al., 2009b; Kargl 
et al., 2013; Oka et al., 2010; Waldeck-Weiermair et al., 2008). As described in Chapter 1, 
MAPK, NFAT and CREB play important roles in the regulation of β-cell survival. GPR55 
may therefore play a role in promoting β-cell survival, which is an area where further research 
is required (see Section 7.2). In addition, both LPI and CBD were also able to protect islets 
from undergoing apoptosis, but time constraints meant that it was not possible to determine 
whether these effects were via GPR55 activation or occurred independently of GPR55. Further 
studies could measure insulin secretion from these islets after treatment with cytokines in the 
absence and presence of GPR55 agonists to determine whether their insulin secretory 
capacities are improved after GPR55 activation. Further work aimed at defining their 
mechanisms of action opens up the possibility of identifying novel therapeutic targets to 
maintain functional β-cell mass in T2DM patients. 
 
Thus, the main observations of this thesis are illustrated schematically in Figure 7.1.1 and can 
be summarised as follows: the novel cannabinoid receptor GPR55 is expressed by MIN6 -
cells and by mouse and human islets at both mRNA and protein levels. GPR55 is coupled to 
elevations in β-cell [Ca2+]i, but not to RhoA activation. In addition, activation of GPR55 leads 
to enhanced insulin secretion and promotes -cell survival in islets. Unlike CB1 and CB2, all 
studies to date indicate that activation of GPR55 stimulates insulin secretion, and the 
observations here, of reduced apoptosis following GPR55 activation, suggest that GPR55 may 
be a target for the development of novel treatments for improving glycaemic control in 
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individuals with T2DM. However, since activation of GPR55 stimulates insulin secretion at 
both basal and stimulatory glucose concentrations exposure to GPR55 agonists in vivo may 
have the side effect of hypoglycaemia, as may occur with sulphonylurea therapy. On the other 
hand, GPR55 may also be a target to maintain and/or increase β-cell mass to delay the 
progression of T1DM and T2DM, but a potential side effect of this is increased cancer risk in 
GPR55-expressing tissues, such as bone, GI tract, adrenal and spleen. Further studies in tissues 
in addition to islets will further help us design and develop safe and effective therapeutic 
approaches targeting GPR55 for treating diabetes. 
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Figure 7.1.1 Schematic summary of the signalling pathways downstream of GPR55 in the 
regulation of β-cell function. 
Activation of -cell GPR55 causes elevations in [Ca2+]i, possibly via PLC-induced Ca
2+
 release 
from the ER. PKC is also activated following PLC-induced DAG generation and together with 
increases in [Ca
2+
]i activated PKC stimulates insulin secretion. In addition, PKC can also 
modulate -cell mass by regulating MAPK and transcription factors (such as CREB and 
NFAT). Furthermore, GPR55 is not coupled to RhoA in islets and it is currently unknown if it 
is coupled to G12/13 and other Rho small GTPases to regulate β-cell function.  
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7.2 Further studies 
Experiments described in this thesis provide a firm foundation on the role of GPR55 in the 
regulation of insulin secretion and cell survival in islets of Langerhans. However, due to time 
constraints it was not possible to fully define the role of this receptor in islets. Future work 
should first aim to improve the robustness of the current findings from this thesis. This will 
include performing further perifusion experiments to investigate how islets isolated from WT 
and GPR55 KO mice respond to 20mM glucose over time-courses longer than 30 minutes, to 
help us confirm that the potentiation of glucose-induced insulin secretion observed in Section 
5.3 is due to the action of the test compounds. In addition, understanding of how O-1602 
regulates the activity of RhoA at other time points and the acitivities of other Rho small 
GTPases (e.g. Cdc42 and Rac1) will clarify if GPR55 is coupled to G12/13 in -cells. 
Furthermore, further work is required to investigate whether the anti-apoptotic effects of O-
1602, LPI and CBD are abolished in islets from GPR55 KO mice. It will also be interesting to 
measure insulin secretion from islets under the conditions tested in the caspase-3/7 apoptosis 
assays to determine if insulin secretory responses are improved under conditions where 
apoptosis is decreased. In order to gain a full picture of the role of GPR55 in islet function 
experiments should also be performed to investigate the effects of GPR55 agonists and 
antagonists on glucagon and somatostatin secretion. 
 
Studies so far have mainly focused on understanding the roles of GPR55 in rodent islets, but it 
will be more clinically relevant to translate these findings, where possible, to human islets. 
Therefore, further studies should be performed using human islets to address which endocrine 
cells express GPR55, to examine whether O-1602 protects human islets from undergoing 
apoptosis and to investigate the effects of selective GPR55 agonists and antagonists on 
glucagon and somatostatin secretion from human islets. 
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Further studies should also address the relationship between GPR55 and CB1 and CB2 
receptors in islets to gain understanding of the possible crosstalk between GPR55 and the ECS. 
One study in endothelial cells has demonstrated that the CB1 and GPR55 signalling cascades 
exhibit negative feedback on the other, a process that depends on the status of integrin 
configuration (Waldeck-Weiermair et al., 2008). Another recent publication has indicated that 
GPR55 and CB1 receptors alter each other’s signalling properties at the levels of MAPKs and 
downstream transcription factor activation (Kargl et al., 2013). GPR55 was also shown to 
regulate CB2-mediated responses in human neutrophils through Rac1 and Cdc42 (Balenga et 
al., 2011). Potential cross-regulation between the three receptor systems in islets would have to 
be taken into consideration when exploring the therapeutic potential of targeting GPR55. 
 
Research into the roles of GPR55 in glucose homeostasis can further benefit from in vivo 
studies. The most logical experiments are studying the effects of administration of GPR55 
agonists and antagonists on plasma insulin, glucagon and glucose levels in WT and GPR55 
KO mice. Further studies may also examine the effects of GPR55 receptor stimulation and 
antagonism on β-cell proliferation and apoptosis in WT and GPR55 KO mice in vivo. These 
studies will help us to determine the therapeutic potential of targeting GPR55 for regulating 
glucose homeostasis and maintaining β-cell mass. 
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